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ABSTRACT 
 
TRIGGERED RELEASE OF SMALL MOLECULES  
FROM SOLID SUPPORTS USING HEAT OR AN  
APPLIED MAGNETIC FIELD 
Ralph Jacob Knipp
November 19, 2014 
 
 The reaction of an aminooxy moiety (RONH2) with an aldehyde or ketone carbonyl, 
an oximation reaction, results in the formation of robust oxime ether linkages.  Oximation 
is a form of click chemistry and is chemoselective, occurs in a variety of solvents 
including water, and produces high yields with little to no purification.   
 We were inspired to exploit the advantages of oximation reactions by attaching 
aminooxy-functionalized molecules to solid supports, thus allowing us to employ 
aminooxy chemistry in ways that cannot be achieved using solution phase.  Chapter 1 
provides a review of aminooxy chemistry, its advantages over similar reactions and its 
multitude of applications.  Chapter 2 describes the use of aminium aminooxy salts fixed 
to a silicon microreactor to enable the capture of volatile aldehydes and ketones from 
exhaled breath for early detection of lung cancer.  Since only carbonyl compounds were
 
 viii 
 retained and thereby concentrated, the accurate measurements of scarce metabolite 
cancer markers were realized.  Use of an acid-scavenging polymer transformed the 
aminium salt adducts into a volatile adducts, thus enabling analyses by both high-
resolution mass spectrometry and gas chromatography. 
 Chapter 3 details our investigation into the use of thermally-induced intramolecular 
cyclization as a release mechanism.  A kinetic study on the cyclization rates of a panel of 
thermally-labile linkers led to a demonstration involving such an aminooxy-
functionalized linker covalently bonded within a poly(dimethylsiloxane) microchannel.  
After capture of an aldehyde-functionalized fluorophore that had been passed through the 
microchannel, the intramolecular cyclization release mechanism was induced by gentle 
warming to liberate the fluorescent oxime ether adduct.  In Chapter 4 we applied our 
thermally-labile linkers to iron oxide nanoparticles in an effort to design an externally 
controlled drug delivery system.  Fe3O4 nanoparticles generate heat when subjected to an 
alternating magnetic field (AMF), thus eliminating the need for an in vivo conventional 
heat source.  During our investigation of AMF-induced release we discovered the 
unprecedented hydrolysis of robust chemical functionalities that occurs only at the 
nanoparticle-liquid interface.  This discovery was exploited in the development of a 
delivery system capable of releasing oxime ether adducts.   
 In conclusion, this thesis describes novel innovations that can be immediately 
applied in a multitude of disciplines, from analytics to diagnoses and to drug delivery. 
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CHAPTER 1 
 
ADVANCEMENTS IN OXIMATION:  APPLICATION OF AMINOOXY 
CHEMISTRY AND ATTACHMENT TO SOLID SUPPORTS 
 
 
1.1. INTRODUCTION 
1.2. CHEMOSELECTIVE LIGATION 
1.3. SOLID-SUPPORTED AMINOOXY CHEMISTRY 
1.4. USE OF AMINOOXY CHEMISTRY IN NANOTECHNOLOGY 
1.5. IRON OXIDE NANOPARTICLES 
1.6. USE OF IRON OXIDE NANOPARTICLES TO GENERATE HEAT 
1.7. CONCLUSION 
 
 
 2 
1.1. INTRODUCTION 
 Aminooxy chemistry is one of the true forms of click chemistry as described by 
Nobel laureate K. Barry Sharpless in 2001.1  Sharpless recommended to follow Nature’s 
lead, namely to synthesize substances by joining small segments together through 
heteroatom linkages (C–X–C) as opposed to focusing on carbon-carbon bond generation 
as the key assembly process.  In order for a reaction to be considered click chemistry, it 
must be modular, wide in scope, have high yields, generate only inoffensive byproducts 
that can be removed without chromatography, use only readily available starting 
materials and reagents and be carried out either without solvents or with solvents such as 
water. 
 With such stringent specifications, only a handful of reactions can be labeled as 
click chemistry.  Click chemistry reactions can be divided into four different classes:  1) 
cycloadditions of unsaturated species, especially 1,3-dipolar cycloaddition reactions, but 
also the Diels–Alder family of transformations; 2) additions to carbon–carbon multiple 
bonds, particularly oxidative cases such as epoxidation and aziridination; 3) carbonyl 
chemistry of the “non-aldol” type, such as formation of oxime ethers, hydrazones and 
amides; and 4) nucleophilic substitution chemistry of the SN2 type, such as ring-opening 
reactions of strained heterocyclic electrophiles (i.e., epoxides and aziridines).1  Examples 
of these reactions can be seen in Figure 1.1. 
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1.   Cycloadditions of unsaturated species 
 Azide-Alkyne Cycloadditions 
 
  
2. Additions to carbon–carbon multiple bonds 
 Olefin Epoxidation 
 
   
3.   Carbonyl chemistry of the “non-aldol” type 
 Aminooxy-Carbonyl Oximation 
 
  
4.   Ring opening reaction of strained hetercycles 
 Epoxide ring-opening 
 
  
Figure 1.1.  Generic examples of the four click chemistry classes of 
chemical transformations. 
  
 Though the azide-alkyne cycloaddition is one of the most popular forms of click 
chemistry, our lab has focused on the development of carbonyl chemistry of the “non-
aldol” type, specifically aminooxy chemistry.  Aminooxy chemistry involves the reaction 
of an aminooxy group with an aldehyde or ketone to form an oxime ether derivative 
R N3 + R'
N
N
N N
N
N
R'
R
R'
R1) Cu(l)      or
2) Ru complex
or
1 2
R
R'CO3H
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R'-OOH, B- O
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(H)R'
O
R'' (H)R'
N
R''
O R
(H)R'
N
R''
ORand
R NH2
O
R"(H)
R'
+
R
H
N
R"(H)
OH
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(Scheme 1.1).  The aminooxy nitrogen exhibits very different properties from the 
nitrogen of an amine moiety.  Table 1.1 highlights a few of these major differences. 
 
 
Scheme 1.1.  Reaction of an aminooxy with an aldehyde or ketone to form 
an oxime ether. 
 
Table 1.1.  Comparison of the aminooxy functionality with a primary amine. 
Aminooxy Primary Amine 
  
 
At room temperature and neutral pH, the 
aminooxy group reacts chemoselectively 
with aldehydes and ketones to form the E/Z 
isomeric oxime ethers. 
 
At room temperature and neutral pH, a 
primary amine reacts with aldehydes, 
ketones to form imines and with esters to 
form secondary amides. 
 
Hydrolysis of the oxime ether linkage 
cannot be achieved by water alone and 
results in the restoration of the active 
aminooxy group. 
 
Hydrolysis of the imine linkage is readily 
achieved under aqueous conditions and 
results in the restoration of the active 
primary amine.  
 
 The stark difference between the aminooxy group and the primary amine stems 
from the presence of the oxygen adjacent to the nitrogen (i.e., in an α-position), a 
phenomenon termed the α-effect.2  Edwards and Pearson3 first introduced the α-effect in 
1962 to explain the enhanced nucleophilicity of a certain group of nucleophiles.  The 
presence of an electronegative atom with one or more unshared pairs of electrons in an α-
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position to the nucleophilic atom was the one common feature among this class of 
nucleophiles.  Edwards and Pearson postulated that the unshared electrons in the α-
position help to stabilize a positive charge on the nucleophilic atom, thus allowing the 
nucleophilic atom to more freely bond to electrophiles.   
 A major contributing factor to the chemoselectivity of the aminooxy nitrogen is the 
electronegativity of the α-oxygen.  This is most evident by observing the pKa difference 
between a protonated aminooxy (RONH3+) having a pKa of 5-64 and a primary aminium 
(RNH3+) having a pKa of 9-10.  Hydrazine, another molecule/functional group subject to 
the α-effect, has a pKa of 8 when protonated.  Similar to an aminooxy group, hydrazine 
reacts with aldehydes and ketones to form stable hydrazones, but it is not chemoselective 
like the aminooxy group in that it will react with esters, phthalimides and anhydrides.  
The hydrolytic stability of oximes and hydrazones, in contrast with imines, is also due to 
the α-effect.  As can be seen in Figure 1.2, the lone pair of electrons α to the sp2-
hybridized nitrogen allow for resonance stabilization by increasing the negative charge 
density at C1, thus reducing its electrophilicity.5  When the resonance forms of an oxime 
or hydrazone are compared to the resonance forms of an imine it is easy to understand 
why imines are susceptible to hydrolysis.  Imine electron density is primarily located at 
the nitrogen atom, making C1 electrophilic and prone to nucleophilic attack by water.  In 
addition, Wiberg and Glaser6 proposed another explanation for the hydrolytic stability of 
oximes ethers and hydrazones.  They predict that the reduction in lone-pair repulsion 
achieved by going from an aminooxy and hydrazine to respective oxime ether and 
hydrazone leads to this stability.   
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Figure 1.2.  Resonance forms of oximes, hydrazones and imines.  
Resonance in oximes or hydrazones increases the negative charge 
density at C1 and imparts hydrolytic stability.  
 
 Though oximes and hydrazones are hydrolytically stable in an aqueous 
environment, hydrolysis can still be achieved.  Figure 1.3 shows the mechanism of the 
acidic hydrolysis of oximes and hydrazones to restore the aminooxy and hydrazine along 
with the starting aldehyde.  It is well known that the hydrazone bond is more susceptible 
to acidic hydrolysis than its oxime counterpart.  As was noted by Kalia and Raines,5 the 
difference in hydrolytic stability is due to the electronegativity of the atom α to the 
nucleophilic atom in the preceding aminooxy or hydrazine (atom X, Figure 1.3).  For the 
oxime, the increased electronegativity of an oxygen atom (χO = 3.57) in the X position 
(Figure 1.3), α to the nitrogen, reduces the probability of the formation of III and 
increases the likelihood of forming II.  This resonance makes the convenient hydrolysis 
of oxime ethers require heat with HCl or HClO4 at pH 0-4.  Hydrazones, due to the 
reduced electronegativity of a nitrogen atom (χN = 3.0) in the X position (Figure 1.3), can 
undergo hydrolysis under more mildly acidic conditions.  The hydrazone functionality 
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makes the formation of III much more likely, thus perpetuating the acidic hydrolysis to 
give the hydrazine and starting aldehyde.  
 
 
Figure 1.3.  Mechanistic considerations for acid-induced 
hydrolysis of oximes and hydrazones. 
 
 The ability of the aminooxy functionality to chemoselectively bond to aldehydes 
and ketones to form oxime ethers makes it attractive for a variety of applications.  
Though aminooxy groups are usually quite reactive and can react to completion very 
rapidly, there are some oximation reactions that occur very slowly.  Numerous different 
catalysts have been studied to hasten this process.  Crisalli and Kool8 report a panel of 
anthranilic acids for the nucleophilic catalysis of oximation and hydrazonation (Table 
1.2).  Aniline is the central focal point of the majority of nucleophilic catalysts for 
oximation and hydrazonation.9  Aniline catalyzes the reaction by first forming an 
iminium ion, then the nucleophilic amine of an aminooxy or hydrazine functionality can 
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Table 1.2.  Yields of hydrazone formation of nitrobenzoxadiazole hydrazine 
and 4-nitrobenzaldehyde with varied anthranilic acid catalysts at pH 7.4.8  
Entry Catalyst Structure Conversion  (2 h) 
Relative 
Yield 
1 no catalyst - 0.7 ± 0.2% 1.0 
2 aniline  10.4 ± 1.3% 14 
3 anthranilic acid 
 
21.5 ± 0.8% 29 
4 4-methylanthranilic acid 
 
28.4 ± 4.4% 38 
5 5-methylanthranilic acid 
 
32.6 ± 0.5% 44 
6 3-amino-2-naphthoic acid 
 
31.5 ± 1.5% 43 
7 4-methoxyanthranilic acid 
 
21.7 ± 2.2% 29 
8 4,5-dimethoxyanthranilic acid 
 
37.1 ± 2.5% 50 
9 5-methoxyanthranilic acid 
 
55.2 ± 1.1% 75 
10 4,6’-bianthranilic acid 
 
57.8 ± 7.3% 78 
 
attack the unstable iminium ion in aqueous conditions to form the stable oxime or 
hydrazone, respectively (Scheme 1.2).10  This process, the attack of a nucleophilic  
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Scheme 1.2.  Intermediates in the nucleophilic catalysis of 
oximation (X = O) and hydrazonation (X = NR”) by aniline at pH 
4-5 as proposed by Thygesen et al.10  
 
primary amine on an aldehyde or ketone under acidic conditions to form the susceptible 
iminium ion, can be compared to a reductive amination reaction.11  The enhancement of 
oximation and hydrazonation reactions under acidic conditions was displayed in Crisalli 
and Kool’s8 catalytic studies, as can be seen in Table 1.3.  It should also be emphasized 
that all reported catalysts for oximation and hydrazonation reactions are water-soluble 
and the water solubility of the catalyst is oftentimes a deciding factor for its promise.12 
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Table 1.3.  Yields of hydrazone formation of nitrobenzoxadiazole 
hydrazine and 4-nitrobenzaldehyde with varied arylamine/acid 
catalysts at pH 7.4.8  
Entry Catalyst Conversion (2 h) Relative Yield 
1 no catalyst 0.7 ± 0.2% 1.0 
2 aniline 10.4 ± 1.3% 14 
3 anthranilic acid 21.5 ± 0.8% 29 
4 anthranilonitrile 0.8 ± 0.1% 1.0 
5 anthranilamide 1.6 ± 0.1% 2.1 
6 ethyl anthranilate 1.5 ± 0.3% 2.1 
7 benzoic acid 1.8 ± 0.4 % 2.4 
8 benzoic acid + aniline 1:1 18.1 ± 1.9% 25 
9 3-aminobenzoic acid 14.3 ± 1.2 % 19 
10 4-aminobenzoic acid 7.4 ± 0.4% 10 
11 3,5-diaminobenzoic acid 34.7 ± 2.4% 47 
 
 
1.2.  CHEMOSELECTIVE LIGATION 
 Most organic chemistry transformations cannot be performed in aqueous 
conditions, thus making the application of organic chemistry techniques to biological 
systems, such as cells, challenging.  Due to this difficulty, researchers interested in 
common biological processes, such as ligation, are constrained and forced to work with a 
limited number of reactions.13  Figure 1.4 shows the limited catalog of chemoselective 
reactions available for ligation or other modifications of cells. The hydrolytic stability, 
chemoselectivity and overall robustness of the aminooxy linkage make it an excellent 
candidate for such biological applications.   
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Figure 1.4.    Chemoselective ligation reactions used in the convergent assembly of 
biopolymers and their mimetics, and in the modification of biopolymers and cells. 
The products of the reactions are (A) N-acylhydrazones, (B) oxime ethers, (C) 
thiosemicarbazones, (D) thioethers, (E) native amide bonds, (F) simple amide 
bonds, (G) pseudoproline linkages, (H) tetrahydro-β-carbolines, (I) native amide 
bonds after reduction of disulfide bonds, and (J) amide phosphine oxide.14  
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 Pascal Dumy’s lab has developed a tetrameric cRGD containing nano-probe by 
covalently linking four peptides to the cyclic decapeptide scaffold regioselectively 
addressable functionalized template (RAFT).15  Dumy et al. used aminooxy ligation to 
ensure chemoselectivity, versatility and allow for covalent attachment without the use of 
coupling agents.  But the most influential reason that oximation was the chosen ligation 
technique was that the oxime bond afforded robust and stable linkages for both in vitro 
and in vivo applications.  This technology, now commercially available under the name 
AngioLoneTM, can be linked with a fluorescent dye or with radioactive contrast agents for 
use in the surgical removal of tumors.  The αvβ3 integrin is overexpressed on the surface 
of endothelial cells16 and several tumor cell types.17  RGD is a known recognition motif 
and thus allows the AngioLoneTM to have a high tumor-targeting efficacy.18  As a proof 
of concept for upcoming human clinical trials, Coll et al. applied AngioLoneTM for the 
removal of a mesenchymal tumor, a feline fibrosarcoma, where it was found to be 
effective in the accurate, safe and complete removal of the tumors in real surgical 
conditions.  As can be seen in Figure 1.5, the cluster of αvβ3 ligands are bound to the 
decapeptide RAFT through oxime ether bonds. 
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Figure 1.5.  Chemical structure of the tetravalent RGD ligand RAFT 
conjugated to a fluorescent or radioactive label.19 
 
 Zeng et al. 20  used oxime ether and thioether linkages to build a synthetic 
lipopeptide-based self-adjuvanting vaccine that can elicit neutralizing antibodies against 
heat-stable enterotoxin from enterotoxigenic Escherichia coli.  They found that the 
thioether vaccine showed residual toxicity in suckling mice while the oxime ether 
versions expressed no cytotoxicity.  Though both the thioether and oxime ether vaccine 
produced specific anti-ST antibodies, only the oxime ether vaccine, specifically the STN-
oxime-P2C-TH vaccine, generated antibodies capable of neutralizing the virus when 
administered by the mucosal (intranasal) route.  This finding suggests that the chemical 
linkage affects the efficacy of the antibodies.  Figure 1.6 shows the three different 
vaccines that Zeng and coworkers synthesized. 
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Figure 1.6.  Schematic representation of the structures of the ST-based 
lipopeptide vaccines with oxime ether and thioether linkages.  TH refers to the 
helper T cell epitope, C and N refer to the N-terminus and C-terminus, 
respectively, of peptide sequences and P2C refers to S-[2,3-
bis(palmitoyloxy)propyl]cysteine.20  
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1.3.  SOLID-SUPPORTED AMINOOXY CHEMISTRY 
 Oxime bonds are also used extensively for solid support surface modification.  
Lepens et al.21 modified surface plasmon resonance (SPR) chips with aminooxy groups 
using a newly developed bifunctional linker.  After the carboxylic acid groups on the 
SPR chip surface were activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS), a solution of a Boc-protected aminooxy 
derivative was injected.  To quench the unreacted activated esters on the SPR chip a 
solution of ethanolamine was injected.  Following cleavage of the Boc protecting group, 
N-terminal aldehyde or ketone functionality was introduced either by oxidation of N-
terminal amino acids with pyridoxal 5’-phosphate (R = R’ = amino acid side chain) or by 
oxidation of N-terminal serine (R’ = H, R” = CH2OH) or threonine (R’ = H, R” = 
CH(CH3)OH) residues using NaIO4.  These functional groups allowed for the covalent 
retention of the modified proteins on the SPR chip (Scheme 1.3).  The process was 
catalyzed with aniline and, consistent with previously discussed findings, Lepens et al. 
found that the oximation reaction occurred most rapidly under acidic conditions at pH 
4.5. 
 
 
 16 
 
Scheme 1.3.  Site-specific immobilization of peptides and proteins on a 
biosensor chip surface using aniline-catalyzed oximation.21  
 
 Another example of solid-supported aminooxy chemistry was shown by Chan et 
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substrates derivatized with aldehyde groups were dipped into a solution of aminooxy 
substituted poly(phenylenevinylene) (PPV) in methylene chloride and were allowed to sit 
for 4 hours.  Sonication was used to remove unbound polymer.  The coated plates could 
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multilayer films (Figure 1.7).  This technology provided nanostructured thin films with 
potential in a range of applications from light-emitting diodes to the coating for 
biomedical devices.23 
 
 
Figure 1.7.  Multilayer deposition of PPV supported aldehyde and 
aminooxy substrates on derivatized glass via chemoselective ligation.22  
 
1.4. USE OF AMINOOXY CHEMISTRY IN NANOTECHNOLOGY 
 The click assembly of aminooxy compounds with aldehyde and ketone substrates 
has also been employed in the popular field of nanotechnology.  Using gold nanoparticles 
(NPs), Thygesen et al. 24  synthesized glyconanoparticles from unprotected reducing 
glycans and glycopeptide aldehydes.  To do this, a protected aminooxy-thiol linker was 
bound to a gold NP through a gold-thiol bond.  Following deprotection, the active 
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Aldehyde functionalized
glass substrate
O O O
Aminooxy PPV
solution
Aldehyde functionalized
glass substrate
N N N
O O O
ONH2 ONH2 ONH2
PPV backbone N N N
O O O
O O O
N N N
O O O
Aldehyde PPV
solution
Aminooxy PPV
solution
Repeated solution
dipping process
 
 18 
reaction to attach them through an oxime ether bond to the surface of the gold NPs (Table 
1.4).  The oximation was performed in phosphate buffer solution (PBS) without catalysis 
and all of the glycans contained a fluorenylmethyloxycarbonyl (Fmoc) protecting group 
to allow for spectrophotometric quantification of the aminooxy NP capture efficiency 
(Scheme 1.4). 
 
Scheme 1.4.  Synthesis of aminooxy-terminated core-shell gold NPs via Trim 
deprotection and oximation of a peptide, glycopeptide and glycan.  Trim 
quantification gave an aminooxy loading of ~435 reactive linkers/gold NP.24  
 
Table 1.4.  Oxime coupling with Fmoc-Glu-Glu-Gly-Gly-H on aminooxy-
terminated core-shell gold NPs.24  
Entry Conditions Ligand density (peptides/Au NP) 
Surface coverage 
(peptides/nm2) Yield (%)
a 
1 25 °C, 16 h 157 0.32 36 
2 60 °Cb, 1 h 162 0.33 37 
3 40 °C, 16 h 427 0.86 98 
     
a  Calculated from Fmoc quantification relative to trimellitoyl (Trim)  
   quantification. 
b  By microwave heating. 
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 Biswas and coworkers25 used iron oxide, specifically Fe3O4, NPs as a solid support 
for quaternary ammonium lipids to serve as a magnetic transfection vector (Scheme 1.5).  
The ammonium salt allowed for electrostatic attraction between the negatively charged 
surface for the NPs and a cationic polar head group of the lipid.  By using click ligation 
to attach the hydrophobic chain a variety of lipids could be easily bound to the NPs to aid 
in finding the most efficient lipid for transfection.  In addition, the magnetic NPs allow 
for in vivo direction and collection of the coated NPs at the treatment site. 
 
 
Scheme 1.5.  Preparation of lipid-coated Fe3O4 NPs using oximation to 
attach hydrophobic chains.25  
 
 Zhang et al.26 used core-shell Fe3O4-SiO2 NPs to covalently attach an aminooxy 
linker to the NP surface.  Using alkoxysilane chemistry, a Boc-protected was bound to 
the NP surface followed by deprotection using trifluoroacetic acid (TFA) to unmask the 
reactive aminooxy (Scheme 1.6).  Zhang and coworkers used the functionalized NPs to 
chemoselectively capture glycopeptides via oximation in the presence of non-oxidized 
peptides.  This method is particularly attractive due to the magnetic properties of the iron 
oxide NPs.  After the glycopeptides are covalently bound to the NPs, the loaded iron NPs 
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can be rapidly magnetically separated from the mixture.   
 
 
Scheme 1.6.  Installation of an aminooxy moiety onto core-shell Fe3O4-SiO2 
NPs for subsequent chemoselective reaction with glycopeptides.26  
 
1.5. IRON OXIDE NANOPARTICLES 
 As is apparent from the aforementioned examples, iron oxide NPs can readily serve 
as an advantageous solid support.  Iron oxide NPs are ferromagnetic in both the form of 
Fe3O4 or the more oxidized version Fe2O3.27  This magnetism allows the NPs to be easily 
removed from suspensions with the use of a magnet.  The magnetism of the NPs also 
allows enables applications as magnetic resonance imaging (MRI) contrast agents.28  In 
this capacity, the magnetic NPs greatly enhance the sensitivity of MRI, a technique that is 
often coupled with another imaging method, such as positron emission tomography 
(PET), to account for its low sensitivity.  Huang et al.29 have reported such a coupling of 
MRI using NPs with PET for increased sensitivity.   
 Localization within the body of the iron oxide NPs in the area of interest is an 
important part of effectively utilizing the magnetic NPs as a contrast agent.  To achieve 
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Yang et al.30 synthesized receptor-targeted NPs for in vivo imaging of breast cancer.  The 
NP surface was functionalized with a peptide containing a fragment of a urokinase-type 
plasminogen activator (uPA) (Figure 1.8).  The bound uPA ligand directed the NPs to  
uPA receptors that were overexpressed in breast cancer tissues.  The benefit of using a 
magnetic NP-based contrast agent over a small molecule contrast agent is that the small 
molecule agents have a relatively short lifespan (< 30 minutes), thus resulting in 
degradation prior to accumulation at the tumor site.31  Polymer-coated iron oxide NP-
based contrast agents have been shown to have over eight hours of plasma retention 
time.32  This helps to ensure that the NPs reach and bind to the tumor cells.  Yang and 
coworkers30 report that the NPs remained stable in vivo and in intracellular environments 
for over forty-eight hours during the imaging experiments.  The Food and Drug 
Administration (FDA) have already approved use of iron oxide NPs as an MRI contrast 
agent due to biological compatibility and an agreeable toxicity profile. 
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Figure 1.8.  Final functionalization of polymer-coated iron oxide NPs 
with an amine terminated fragment of urokinase-type plasminogen 
activator to enable binding of the NP to breast cancer cells, and cyanine 
5.5 dye to aid in fluorescent imaging of the NP location.30, 33 
 
1.6. USE OF IRON OXIDE NANOPARTICLES TO GENERATE HEAT 
 One of the more novel ways to exploit the magnetic properties of iron oxide NPs is 
to use them as a source of heat.  When the magnetic NPs are subjected to an alternating 
magnetic field (AMF) the NPs generate heat as they attempt to realign their magnetic 
pole with that of the AMF.  The NPs transform the energy from the AMF into heat via 
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two mechanisms: 1) through internal dipole rotation or Néel relaxation, and 2) by 
physical particle rotation called Brownian relaxation as can be seen in Figure 1.9.27  In 
either case, there are internal and external factors that prevent the magnetic dipole of the 
NP from realigning with the AMF, thus resulting in the production and release of heat.  
The dominant form of relaxation is largely thought to follow the mechanism with the 
shortest relaxation time.  Small nanoparticles tend to be dominated by Néel relaxation 
while in larger particles the Brownian relaxation prevails.   
 
 
Figure 1.9.  Magnetic NPs respond to AMF through either internal 
dipole rotation, Néel relaxation, or through physical particle rotation 
called Brownian relaxation.  The straight arrow shows the alignment 
of the internal magnetic dipole and the arched arrows show whether 
the dipole or the NP is rotating.27  
 
 When the iron oxide NPs are < 20 nm in diameter they can begin to be 
superparamagnetic. 34   Superparamagnetism is a form of magnetism where the 
magnetization can randomly flip direction under the influence of temperature.35  The time 
between the reorientation of the magnetic dipole is the Néel relaxation.  In the absence of 
Néel relaxation Brownian relaxation
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an external magnetic field the superparamagnetic particles appear to show no magnetism.  
This phenomenon is due to the time used to measure the reorientation of the 
magnetization being much longer than the Néel relaxation.  The aforementioned 
attributes, in addition to other variations such as alteration of size, 36  shape37  and 
functionality,38 make iron oxide NPs an attractive solid support with tunable magnetic 
properties. 
 One application of AMF-induced iron oxide NP heating is localized hyperthermia 
for cancer abolition.  Hyperthermia treatment first involves localization of iron oxide NPs 
(Fe3O4 or  γ-Fe2O3) in a tumor and then AMF exposure to elevate the local, cellular 
temperature to at least 40-47 °C.39  These elevated temperatures result in cell death.  
Alternate methods for inducing hyperthermia are based on the application of 
microwaves.40  But the use of microwaves has been limited due to the inability to control 
temperatures and the ineptitude to minimize collateral damage such as exposure to 
radiation and a lack of selectiveness that causes extensive damage to the surrounding 
healthy tissue.  Treatment of iron oxide NPs with an AMF also has the advantage of 
using an alternating current (AC) magnetic field with a significantly lower frequency (105 
Hz) than its microwave counterpart at nearly 1015 Hz.  Operation at a frequency of 105 Hz 
results in negligible damage to the living tissue.  Figure 1.10 shows an MFH 300F AMF 
applicator instrument (MagForce Nanotechnologies, AG, Berlin, Germany) that is 
currently being used to treat patients via hyperthermia.39  
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Figure 1.10.  Thermotherapy treatment of the pelvic region after 
intratumoral injection of magnetic NPs using the AMF applicator MFH 
300F.39  
 
 AMF-induced hyperthermia is also frequently used in conjunction with 
chemotherapy to increase the efficacy of an administered drug.  This multimodal 
approach circumvents many of the limitations of conventional chemotherapy and 
hyperthermia.  In chemotherapy, aggressive cytotoxic drugs kill both cancerous and 
healthy cells without discrimination and can cause systemic toxicity and decreased drug 
concentrations in the tumor. 41   Hyperthermia suffers from insufficient temperature 
increase in the tumor, poor temperature distribution and risk of damage to surrounding 
organs due to overheating.42  Aoki et al.43 reported a significant increase in drug efficacy 
when malignant gliomas were treated with liposomal adriamycin, a chemotherapeutic 
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drug, in addition to mild hyperthermia at 40 – 43 °C.  Purushotham and Ramanujan44 
found that when doxorubicin (Dox) was loaded into poly-n-isopropylacrylamide coated 
iron oxide (12 nm diameter Fe3O4 or  23 nm diameter γ-Fe2O3) NPs the in vitro tumor 
cells were far more responsive to treatment when compared to in vitro tumor cells treated 
with only Dox or hyperthermia.  The efficacy of Dox was increased enough that the 
therapeutic effect obtained with a normal dosing could be matched by using 
Dox/magnetic NPs with doses as low as 20% – 50% of the standard dosing.  Using the 
combination of Dox and AMF-induced hyperthermia with magnetic NPs, Alexiou et al.45 
found that the same chemotherapeutic result could be obtained using a dose of as low as 
to 20% - 50% of the standard dosing of Dox. 
 
1.7. CONCLUSION 
 It is clear from the above examples that aminooxy chemistry, and the resultant 
oxime ethers formed on chemoselective reaction of an aminooxy moiety with an 
aldehyde or ketone carbonyl, are of great value for biological applications.  The 
aminooxy groups also provide the versatility to react readily in a variety of solvents, 
importantly water, while either in solution or bound to a solid support.  Chapter 2 
presents a solid-support application of a new aminooxy-based reagent, 4-(2-
aminooxyethyl)-morpholin-4-ium chloride (AMAH).  Relying on both electrostatic and 
hydrogen-bonding interations, a silicon microreactor can be loaded with AMAH for 
chemoselective, covalent capture and concentration of volatile aldehydes and ketones in 
exhaled breath (Scheme 1.7).  This application has great potential in the early diagnosis 
of lung cancer.  AMAH-adducts can be analyzed via Fourier transform-ion cyclotron 
 
 27 
resonance (FT-ICR) mass spectrometry (MS) as well as gas chromatography (GC) MS.  
By utilizing both forms of analysis, volatile organic compounds (VOCs) can be 
quantified and the conformational isomers, indistinguishable by FT-ICR-MS, can be 
accurately assigned.  We developed a novel method to benefit from the cationic aminium 
salt using FT-ICR-MS while being able to neutralize the salt and directly inject the VOC 
adduct solution for GC-MS analysis without the use of salts or a liquid-liquid extraction. 
 
 
Scheme 1.7.  Chapter 2 Summary:  AMAH 
oximation covalently traps aldehydes and 
ketones in the microreactor. 
 
 Chapter 3 describes the synthesis of a panel of thermally labile linkers engineered to 
undergo intramolecular cyclization on heating.  One goal of this work is application to a 
polydimethylsiloxane microchannel (Figure 1.11) for use in combination with aminooxy 
chemistry to capture aldehyde and ketone metabolites passing through the microchannel.  
After preparing the linker panel, each substrate was analyzed to determine any thermal 
responsiveness.  By design, heating is intended to promote addition of a nucleophilic 
amine, positioned along a connecting chain, to an electrophilic carbonyl to form various-
sized heterocyclic rings.  To tune the thermal responsiveness of the linker different 
functional groups including esters, amides, carbonates and carbamates were inserted 
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around the electrophilic carbonyl.  We also tuned the cyclization rate by altering the ring 
size from five to seven and employing gem-dimethylation.  After an optimal linker was 
established, we installed an aminooxy group and then bound the assembly to the interior 
walls of a microchannel for carbonyl capture applications. 
 
 
Figure 1.11.  Chapter 3 Summary:  Heat-
induced cyclization via (a) lactamization or (b) 
carbamate formation. 
 
 Chapter 4 describes our efforts to engineer an AMF-induced iron oxide NP drug 
delivery system, one that involves a covalently NP-bound drug as opposed to a NP-
associated drug (Figure 1.12).  This work possessed many hurdles including formation of 
a covalent bond between the iron oxide NP and the organic linker, modification of the 
surface properties of the NPs, reduction of NP agglomeration as well as the discovery of 
a phenomenon that had not yet been reported.  Though originally expecting to utilize our 
thermally labile linkers for drug delivery, we discovered a not-yet-reported release 
mechanism that appears to be the result of an AMF-induced hydrolysis.  We were able to 
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hydrolyze robust, i.e. carbonate and carbamate, functionalities at room temperature, 
neutral pH and in less than 45 minutes. 
 
 
Figure 1.12.  Chapter 4 Summary:  AMF-triggered 
hydrolysis of pendant functionality (FL = 
fluorophore, •; carbamate moiety, n; terminal amine 
residue, n). 
 
 Chapter 5 presents the experimental procedures for all of the chemistry described in 
Chapters 2, 3 and 4.  Select 1H and 13C NMR spectra as well as other select spectroscopic 
data of synthesized molecules and NPs are provided in Appendix A. 
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2.1. INTRODUCTION 
 In 2011, there were 98,000 men and 77,000 women who developed lung cancer.1  
Only ~18% of these people will survive beyond five years.1  However, if the spread of 
the lung cancer can be minimized at the time of diagnosis and quickly treated, the five-
year survival rate increases to 54%.1  Thus, the early detection of lung cancer is of critical 
importance.  Currently, the common methods of diagnosing lung cancer include, but are 
not limited to, bronchoscopy, PET scan or needle biopsy, all of which are after having 
completed a CT scan.  All of these methods are either invasive or subject the patient to a 
substantial dose of radiation.  Due to the aforementioned side effects, these methods of 
diagnosis are usually used only when the cancer has become symptomatic.  Lung cancer 
is largely asymptomatic in its early stages.  Screening is the only systematic means of 
finding tumors at the surgically curable stage.2  Therefore, it is easy to appreciate the 
need for a non-invasive method to accurately diagnosis lung cancer in its early stages. 
 There are many minimally or non-invasive methods being designed and tested for 
clinical application in the early detection of lung cancer.  Some of these methods include 
the cytology of the sputum,3,4 detection of circulating cancer biomarkers,5, 6 determination 
of blood proteomic patterns,7,8 chest tomography,9,10 and whole body magnetic resonance 
imaging (wbMRI). 11   But all of these techniques suffer from serious drawbacks.  
Specifically, sputum cytology regularly provides false negatives and, therefore, fails to 
detect numerous early-stage cases of lung cancer.12  Circulating cancer biomarkers, when 
used alone, have not shown promise as a screening test and it is not yet clear which panel 
of tests will afford the necessary sensitivity and specificity.13, 14  Blood proteomic 
patterns are difficult to establish, though FT-ICR has aided in the advancement of this 
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technology.5, 6  Computed tomography (CT) scans, despite subjecting the patient to high 
doses of X-ray radiation, can accurately detect nodules as small as 1 mm in diameter, but 
they also show many false positives if not confirmed by positron emission tomography 
(PET), that lead to unnecessary biopsies.15  Table 2.1 outlines the different methods of 
analysis, the procedure for the collection of a sample, the invasiveness and the method of 
diagnosis of lung cancer. 
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Table 2.1.  Analytical procedures for the diagnosis of lung cancer. 
Method of 
Analysis Collection of Sample 
Invasive/ 
Non-Invasive Method of Diagnosis 
Cytology of 
the sputum 
- Subject coughs up   
   mucus 
- Subject inhales  
   saline followed by  
   coughing 
- Bronchoscopy 
Non-Invasive 
(coughing) 
 
 
Invasive 
(bronchoscopy) 
Cells are observed 
under microscope to 
determine if 
abnormalities are 
carcinogenic 
Circulating 
tumor 
biomarkers 
- Tissue collection 
- Draw blood Invasive 
Tissue biopsy/blood 
analysis looking for 
known cancer derived 
metabolites 
Blood 
proteomic 
patterns 
- Draw blood 
- Lung cancer tissue 
- Serum 
- Plasma 
- Pleural effusions 
Invasive 
MALDI-TOF or FT-
ICR-MS used to scan 
for known proteins 
derived from cancer 
Chest 
tomography 
Spiral CT scan of 
chest Non-Invasive 
CT image shows 
visible nodules in 
lung 
Whole body 
magnetic 
resonance 
imaging 
(wbMRI) 
wbMRI Non-Invasive 
Used in partnership 
with diffusion 
weighted imaging 
(DWI) and apparent 
diffusion coefficient 
(ADC) to determine 
metabolic and 
morphological 
deviations 
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 The analysis of volatile organic compounds (VOCs) in exhaled human breath is 
another area of focus for non-invasive early diagnosis of lung cancer.  In 1971, Pauling et 
al.16 reported that human breath is comprised of over 1000 VOCs.  Beginning in 1985, 
O’Neill and coworkers17, 18 identified 28 VOCs from exhaled breath as candidate markers 
of lung cancer, including hexane, methylpentane, o-toluidine, and aniline.  In addition, 
altered lipid-peroxidation activity in patients with lung cancer was observed in the form 
of over-oxidized VOC metabolites.19, 20  But since most VOCs occur at picomolar 
concentrations, advanced techniques must be employed to effectively capture and 
concentrate the VOCs prior to analysis.21 
 The development of devices to perform the capture and subsequent concentration of 
the VOCs in exhaled breath has received much attention.  One of the most simplistic (and 
sensational) methods of diagnosing lung cancer from exhaled breath involves the use of 
canines for scent detection.  First proposed by Williams and Pembroke in 1989,22 the 
hypothesis for this method of detection is based on the idea that dogs are known to 
possess superior olfactory systems capable of detecting VOCs at parts-per-trillion levels 
from complex mixtures.23  Application of five dogs (both genders) for canine scent 
detection in a double-blinded testing of 28 lung cancer patients and 6 breast cancer 
patients against 17 controls found that the dogs had an overall sensitivity of 0.99 (95% 
confidence) and overall specificity of 0.99 (95% confidence) when compared to biopsy-
confirmed conventional diagnosis.2  Despite the tremendous sensitivity and specificity of 
the dogs, there are significant drawbacks to this idea, largely due to the variables 
involved with a living species.       
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 Other, more conventional, forms of non-invasive lung cancer diagnoses include the 
aforementioned induced sputum, exhaled nitric oxide, exhaled breath condensate and the 
electronic nose.  The advantages and disadvantages of each non-invasive diagnostic 
method are summarized in Table 2.2.  In particular, the electronic nose possesses great 
potential in its ability to accurately identify specific VOC profiles in exhaled breath.  But 
the electronic nose is comprised of a series of electronic sensors of different composition 
and relies heavily on complex algorithms to give rise to the so-called “breathprint.”24 
 Analysis of VOCs that are a direct result of the oxidative stress inherent in lung 
cancer, usually in the form of aldehydes and ketones, is another area that has great 
potential.  Table 2.3 shows common targeted VOC metabolites along with the method of 
detection, concentration threshold and whether the technology has been tested with 
humans.  
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Table 2.2.  Mean advantages and disadvantages of non-invasive diagnostic tools 
detecting biomarkers of pulmonary inflammation in smoking subjects.24 
Diagnostic 
Tools Biomarkers Advantages Disadvantages Conclusions 
Induced 
Sputum 
Airway 
cellularity 
Inflammatory 
mediators in 
supernatants 
Easier and more 
comfortable 
than 
bronchoalveolar 
lavage or 
bronchial 
biopsy 
Not completely 
non-invasive; 
may induce 
bronchospasm 
Partially 
conflicting 
data; need large 
longitudinal 
studies 
Exhaled  
Nitric Oxide 
Nitric oxide in 
exhaled air 
Completely 
non-invasive; 
repeatable 
Many 
confounding 
factors such as 
meals, asthma, 
respiratory 
infections 
May play an 
important role 
in smoking 
cessation 
programs 
Exhaled 
Breath 
Condensate 
Many 
inflammatory 
markers in 
exhaled air 
Completely 
non-invasive; 
repeatable 
Not 
standardized 
Smokers show 
an increased 
oxidative stress 
and a lower pH 
than non-
smokers 
Electronic 
Nose 
Able to identify 
specific VOC 
profiles in 
exhaled breath 
Completely 
non-invasive; 
repeatable 
Not 
standardized 
Discriminate 
between 
healthy non-
smokers and 
healthy 
smokers 
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Table 2.3.  Current technology for the diagnosis of lung cancer using VOCs.25 
Primary 
Target 
Sensor 
Technology 
Sensing Materials Human 
Tests 
Limit Of 
Detection 
Sample 
Treatment 
Reference 
Volatile 
thiols 
Colorimetry Iodine Yes 0.05 µg L-1 of 
H2S 
No 26 
Volatile 
thiols 
Chemiresistor Au nanoparticles 
decorated with 
polyaniline 
No 1 mM of H2S 
and CH3SH 
No 27 
Volatile 
thiols 
Fiber optic Monoamine oxidase 
A & optical O sensor 
Yes 200 ppb No 28 
Acetone Chemiresistor Si:WO3 Yes 20 ppb No 29 
Acetone Chemiresistor Chitosan No 0.1 ppm No 30 
Acetone Chemiresistor In2O3 & Pt-In2O3 No <1 ppm No 31 
Acetone Chemiresistor Hemitubes of Pt-
WO3 
No 120 ppb No 32 
Acetone Direct optical 
spectroscopy 
Cavity ringdown 
spectroscopy 
Yes 130 ppb Yes 33 
Hydrogen 
peroxide 
ChemFET Os-PVP containing 
peroxidase 
No 0.8 µM Breath 
condensate 
34 
Hydrogen 
peroxide 
Amperometric Pt electrode with 
agarose membrane 
Yes 50 ppb No 35 
Hydrogen 
peroxide 
Potentiometric Prussian blue solid 
state salt 
Yes 0.1 µM in 
aerosol 
No 36 
Nitric 
oxide 
Potentiometric YSZ Yes 5 ppb Water 
removal 
37 
Nitric 
oxide 
Chemiresistor PEDOT:PSS coated 
nanofibrous TiO2 
No 6 ppb No 38 
Nitric 
oxide 
Direct optical 
spectroscopy 
Tunable diode laser 
absorption 
spectroscopy 
Yes 11 ppb No 39 
Nitric 
oxide 
Direct optical 
spectroscopy 
Quantum cascade 
laser and cavity 
spectroscopy 
Yes 4 ppb No 40 
Nitric 
Acid 
Chemiresistor Chemically 
functionalized 
carbon nanotubes 
No 5 ppb CO2 
removal 
41 
Sleep 
apnea 
Chemiresistor Multi-wall carbon 
nanotubes 
Yes Less than 6 
breaths/minute 
No 42 
Ammonia Chemiresistor H2SO4 solution Yes <18 ppb No 43 
Ammonia Chemiresistor MoO3 No <1 ppm No 44 
Ammonia Optical TFE membrane and 
pH dye 
Yes 50 ppb No 45 
Carbon 
dioxide 
Optical [CH3(CH2)7]4N(OH) 
and pH dyes  
No 0.25% No 46 
Carbon 
dioxide 
Optical [CH3(CH2)7]4N(OH) 
and pH dyes 
No <5% No 47 
Influenza 
virus 
Chemiresistor Antibody coated 
silicon nanowire 
Yes <1 pg mL-1 Dilution of 
condensed 
breath 
48 
Influenza 
virus 
Dynamic light 
scattering 
Antibody coated 
gold nanoparticles 
No 8.6 TCID50 
mL-1 
No 49 
Drink test Potentiometry Alcohol oxidase and 
aldehyde 
dehydrogenase 
Yes Ethanol  
<1 ppm 
Acetaldehyde 
<0.1 ppm 
No 50 
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2.2. AMAH: A VERSATILE REAGENT FOR ANALYSIS OF VOCS 
 Our attempt to develop a non-invasive method for early detection of lung cancer 
also focuses on the capture and identification of carbonyl metabolites.  My group 
colleague, Dr. Souvik Biswas, 51  had developed the reagent N-(2-(aminooxy)ethyl)-
N,N,N-trimethylammonium iodide (ATM) to chemoselectively capture volatile aldehydes 
and ketones from exhaled human breath and ambient air.52, 53, 54, 55  Several carbonyl 
compounds in exhaled breath previously had been identified as lung cancer markers.52, 56, 
57, 58, 59, 60, 61  Reaction of ATM with VOCs was achieved by first coating ATM on the 
surface of micropillars within a silicon microreactor.  The microreactor (or, more 
precisely, a preconcentrator) contains thousands of micropillars that function to distribute 
gas flow through channels to provide surface area for efficient capture of the VOCs by 
the reactive coating.  Aldehydes and ketones from exhaled breath are selectively and 
covalently preconcentrated in the microreactor using a click chemistry reaction 
(oximation).  The resultant ATM-carbonyl adducts are eluted from the microreactor using 
a small volume (ca. 50 µL) of methanol, and analysis of the breath analytes then is 
performed using rapid direct-infusion Fourier transform-ion cyclotron resonance (FT-
ICR) mass spectrometry (MS) to determine the concentrations of exhaled carbonyl 
VOCs.   
 Though convenient for rapid identification of biomarkers, FT-ICR-MS is often 
incapable of distinguishing structural isomers (e.g., constitutional isomers), especially as 
compound molecular weights increase.  One method for confirming an isomer 
assignment is to use gas chromatography-mass spectrometry (GC-MS) in conjunction 
with a reference standard of the compound.  Unfortunately, the adducts of ATM are not 
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suitable for analysis by GC-MS since ATM is non-volatile as a consequence of its 
quaternary ammonium moiety.  The use of ammonium ions to enhance the MS signal 
intensity at low concentrations is a well-established technique,62 but since such ions 
typically are non-volatile a new strategy is required to conjunctively use the speed and 
accuracy of FT-ICR-MS with the isomeric differentiation afforded by GC-MS.  We 
developed an approach to address this challenge by introducing a versatile aminooxy 
reagent, 4-(2-aminooxyethyl)-morpholin-4-ium chloride (AMAH, Scheme 2.1).  AMAH 
functions as a chemoselective probe as a consequence of the aminooxy reactivity, and  it 
contains a titratable ammonium salt for enhancing [+]-ion electrospray MS analysis.  
Moreover, AMAH-carbonyl adducts can be made volatile for analysis by GC using a 
straightforward basification procedure.  By applying AMAH onto the micropillars of the 
silicon microreactor, the dual capability of AMAH can be exploited through detection 
and structural assignment of carbonyl VOC adducts from exhaled breath using both FT-
ICR-MS and GC-MS.   
 
!
Scheme 2.1.  AMAH oximation covalently traps 
aldehydes and ketones in the microreactor.!
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2.3. RESULTS AND DISCUSSION 
 ATM was specifically designed with several features that would optimize analyses 
of its adducts by FT-ICR-MS.  The quaternary ammonium salt allowed for electrostatic 
interaction between ATM and the negatively charged silica surface of the micropillars 
(Scheme 2.1).  Secondly, the aminooxy moiety allowed for the rapid, chemoselective 
capture of gaseous aldehyde and ketone metabolites in exhaled breath samples with 
>90% capture efficiency.55  Finally, the permanent positive charge of the quaternary 
ammonium salt enhanced the signal intensity of the metabolite adducts at low 
concentrations when analyzed by FT-ICR-MS.62  In addition to cost considerations, a 
limitation of analyzing ATM-adducts using FT-ICR-MS is the inability to differentiate 
constitutional isomers for a given molecular mass.  MS-MS techniques can be applied to 
address this issue; however, use of a more widely available and affordable analytical 
platform, such as GC-MS, would improve the accessibility of the microreactor approach 
for identifying metabolites.  Unfortunately, GC-MS cannot be used to analyze ATM-
carbonyl metabolite adducts since these are non-volatile.  To address this issue, we 
developed a second-generation reagent that allows for both FT-ICR-MS and GC-MS 
identification with isomeric accuracy. 
 
 
Figure 2.1.  Structures of ATM, AMAH and AMA. 
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 By slightly expanding the structural framework of ATM, we engineered second-
generation reagent, AMAH (Figure 2.1), that features a titratable aminium nitrogen 
instead of a quaternary ammonium salt.  The morpholino bridge, as opposed to N,N-
dimethyl, imparts an order of magnitude greater acidity for ease of basification, a 
subsequent key step, to generate neutral species, such as AMA or neutral AMA-carbonyl 
adducts. 63   Upon introduction to the microreactor, the aminium salt of AMAH 
electrostatically bonds to the silica surface of the micropillars while the morpholino 
oxygen and aminic proton also provide hydrogen bonding opportunities with surface 
silanols to improve the availability of the aminooxy moiety for carbonyl capture.  Finally, 
the tertiary ammonium ion also enhances the MS signal intensity for analyses using FT-
ICR-MS so that high mass accuracy can be determined for even low abundance carbonyl 
metabolites.   
 The key advantage in using AMAH over ATM for metabolite identification is its 
ability to be volatilized through a basification procedure, thus making it applicable for 
both FT-ICR-MS and GC-MS analyses.  To ensure that the basification of AMAH-
carbonyl adducts proceeds to give an analyte mixture that can be injected directly into a 
GC instrument, we developed a salt-free neutralization procedure that does not require 
liquid-liquid extraction or other lengthy handling processes (Scheme 2.2).  First, the 
eluted methanolic AMAH-carbonyl adduct mixture can be directly analyzed by FT-ICR-
MS.  An aliquot can then be prepared for GC-MS analysis by reaction with poly(4-
vinylpyridine) (PVP), an acid scavenging polymer (Figure 2.2).  We were gratified to 
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Figure 2.2.  Structure of poly(4-
vinylpyridine) (PVP). 
 
 find that when a 40 µL sample of AMAH-adducts in methanol was added to 2 mg of 
PVP followed by shaking for 30 seconds, complete neutralization of the adducts was 
achieved.  Efficient neutralization using this procedure was confirmed by NMR 
spectroscopy (Figure 2.3).  When the acetone-d6 adduct of AMAH is treated with PVP, 
the chemical shifts of the morpholino methylene protons coalesce into broad singlets, at δ 
3.95 and δ 3.37 ppm for the methylene signals adjacent to oxygen and nitrogen, 
respectively, as a result of the greater conformational flexibility of the AMA-adduct.  
This procedure is particularly appealing in that after basification using PVP the polymer 
quickly sediments to allow convenient aliquot sampling for direct GC injection.     
 
 
Scheme 2.2.  Use of AMAH for both FT-ICR-MS 
and GC-MS analyses.  PVP = poly(4-vinylpyridine) 
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Figure 2.3.  400 MHz 1H NMR (CD3OD) of (a) 
AMAH–acetone-d6 adduct and (b) AMA–acetone-
d6 after treatment with PVP.    
 
 To examine the reactivity of AMAH with volatile carbonyl compounds, we 
performed a calibration experiment with acetaldehyde, acetone and 2-butanone in a 
closed chip.  Each carbonyl (7.67 × 10−7 to 7.67 × 10−10 mol) was injected into a 1 liter 
Tedlar bag and connected to the preconcentration setup (Figure 2.4).  A vacuum pump 
 
 
Figure 2.4.  Schematic flow diagram of the preconcentration set-up. 
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 pulled the gaseous contents of the bag through the AMAH-functionalized, closed 
microreactor (Figure 2.5) at a rate of 3.5 mL/min.  After the Tedlar bag had been fully 
evacuated, the microreactor was removed from the preconcentration assembly and the 
analytes were washed free from the chip using methanol.  A solution of AMAH– 
 
 
Figure 2.5.  Silicon microreactor for the capture of 
carbonyl VOCs in exhaled breath.  (a) Optical 
micrograph of the microreactor before bonding with 
a glass wafer.  (b) SEM micrograph of the 
micropillar array within the microreactor. 
 
acetone-d6 adduct was added to the analyte solution to serve as an internal standard.  For 
both aldehydes and ketones, the linear capture efficiency of AMAH peaks at a ~91 % 
capture rate at a 103 AMAH/analytes molar ratio (Figure 2.6, Table 2.4).  The reason that 
the highest capture efficiency occurred at higher AMAH/analyte molar ratios is due to the 
elevated reaction probability for the capture of aldehyde and ketone VOCs.  Due to the 
low concentrations of carbonyl VOCs in exhaled breath, 180-800 ppbv for acetone, 
AMAH should capture nearly all of VOCs of interest and provide an accurate 
concentration of each metabolite.64, 65  Having confirmed that AMAH was highly reactive 
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Figure 2.6.  Graphical relationship 
between VOC capture efficiency and 
AMAH/VOC molar ratio. 
 
Table 2.4.  Tabulated relationship between VOC capture efficiency 
and AMAH/VOC molar ratio. 
AMAH/VOC 
molar ratio 
log(AMAH/ 
VOC molar 
ratio) 
Capture Efficiency (% ± standard error) 
Acetaldehyde     Acetone    2-Butanone 
1 0 41.5 ± 1.7 45.8 ± 1.8 44.7 ± 3.8 
10 1 59.3 ± 3.9 67.4 ± 4.8 65.5 ± 4.9 
100 2 73.3 ± 1.6 80.3 ± 3.8 78.0 ± 1.8 
500 2.7 84.1 ± 4.3 87.9 ± 1.7 86.4 ± 2.2 
1000 3 89.3 ± 3.6 92.4 ± 2.9 91.1 ± 1.6 
 
and applicable for both FT-ICR-MS and GC-MS, we analyzed a panel of AMA–C1-C5 
aldehyde and ketone adducts (Figure 2.7, Table 2.5) on GC-MS to establish reference 
retention times for the adducts. 
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Figure 2.7.  GC-MS chromatogram of reference 
AMA–carbonyl adducts; TBSO = t-
butyldimethylsilyloxy. 
 
 Table 2.5.  Retention times of AMA–C1-C7 adducts. 
Adduct tR (min) Adduct tR (min) 
AMA–
formaldehyde  7.92 AMA–n-butanal 11.61 
AMA 8.18 AMA–2-pentanone  12.44 
AMA–
acetaldehyde 9.55 
AMA–n-pentanal 12.64 
AMA–acetone 10.46 AMA–TBSO-acetaldehydea 15.80 
AMA–n-propanal 10.71 AMA–3-TBSO-2-butanonea 
18.27 
AMA–2-butanone  11.35   
 a TBSO = t-butyldimethylsilyloxy 
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 Following calibration, the closed chip was replaced by an open chip to allow a 
patient to blow directly onto the AMAH-functionalized microreactor through a straw.  
Subjects blew into a vial containing the microreactor for 15 minutes.  Upon completion, 
methanol was used to elute the AMAH–adducts from the microreactor, and the collected 
eluent then was directly analyzed by FT-ICR-MS.  Figure 2.8 shows a FT-ICR-MS 
spectrum of a healthy non-smoking subject.   An aliquot (ca. 35 µL) of the methanol 
AMAH–adduct mixture also was added to PVP.  After neutralization, the PVP was 
  
 
 
Figure 2.8.  Qualitative comparison of (a) FT-ICR-
MS spectrum and (b) GC-MS chromatogram of 
VOCs from a healthy, non-smoking subject. 
11_07_12_1_open #60-98 RT: 1.39-6.90 AV: 39 NL: 2.00E7
T: FTMS + p ESI Full ms [50.00-500.00]
140 150 160 170 180 190 200 210 220 230 240 250 260 270 280
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Re
lat
ive
 A
bu
nd
an
ce
147.11292
258.18201
187.14453
233.15026
201.16025
215.17601
159.11312
173.12884
273.18183245.15037219.13457
204.13482
169.09509 177.12378 261.18176191.10297156.73518
252.17882
x5
AMAH-C2H4O 
AMAH-C3H6O 
AMAH-C4H8O 
AMAH-C5H10O 
AMAH 
FT-ICR-MS Spectrum  
AMAH-C1H2O 
m/z 
R
el
at
iv
e 
In
te
ns
ity
 
AMA-C2H4O2 
(m/z = 189) 
AMA-C4H8O2 
(m/z = 217) 
A
M
A
-form
aldehyde 
A
M
A
 
A
M
A
-acetaldehyde 
A
M
A
-acetone 
A
M
A
-2-butanone 
A
M
A
--2-pentanone 
A
M
A
-n-pentanal 
A
M
A
-3-TB
SO
-2-butanone 
A
M
A
-TB
SO
-acetaldehyde 
GC-MS Chromatogram  
R
el
at
iv
e 
in
te
ns
ity
 
Retention time (min) 
(b) 
(a) 
 
 48 
filtered and the methanol filtrate was evaporated.  To the residue was added a 1:1 mixture 
of acetonitrile:N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) (v/v) 
(30 µL).  MTBSTFA was used to produce volatile and stable tert-butyldimethylsilyl 
(TBS) derivatives of hydroxyl groups for GC analysis.  MTBSTFA was used over TBSCl 
because its reaction byproducts are volatile and neutral, thus minimizing the risk of 
degrading other VOCs.  The resultant silylated AMA-adduct mixture was analyzed by 
GC-MS.   With results from both the FT-ICR-MS and GC-MS analyses in hand, we 
compared the abundance of captured carbonyls by calculating the ratio of the abundance 
of an analyte to the sum of the abundance of all analytes (Table 2.6).  The results indicate 
that the carbonyl ratios based on GC-MS analysis were consistent with the ratios 
calculated using the FT-ICR-MS results with a 2.6% variance as the largest difference 
(entry 1). 
 
Table 2.6.  Quantitative comparison of FT-ICR-MS 
and GC-MS analyses of a breath sample.a 
Entry Carbonyl VOC GC-MS b FT-ICR-MS b 
1 CH2O (formaldehyde) 0.128 0.154 
2 C2H4O (acetaldehyde) 0.109 0.099 
3 C3H6O (acetone) 0.281 0.290 
4 C4H8O (2-butanone) 0.260 0.254 
5 C5H10O (2-pentanone, 
n-pentanal) 0.193 0.173 
6 C2H4O2 (hydroxyl-
acetaldehyde) 
0.015 0.017 
7 C4H8O2 (3-hydroxy-
2-butanone) 
0.011 0.013 
    
a Breath sample from a healthy, non-smoker;  
bAnalyte contribution to total (ratio of analyte 
abundance/sum of the abundance of all analytes). 
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 With the knowledge that AMAH can be used in conjunction with either GC-MS or 
FT-ICR-MS to analyze these high abundance carbonyl compounds in exhaled breath, Dr 
Fu working with Dr. Michael Bousamra, University of Louisville, Brown Cancer Center, 
examined samples from more than 30 non-smoker controls, 30 smoker controls and 50 
patients diagnosed with lung cancer to determine differences in their exhaled breath.  
Each subject blew into a vial containing an AMAH-functionalized open chip for 15 
minutes.  Then, the AMAH-adducts were washed from the microreactor with methanol 
and injected for FT-ICR MS analysis (Figure 2.9a).  Finally, an aliquot was neutralized, 
silylated and then analyzed by GC-MS.  Figure 2.9a shows typical FT-ICR-MS spectra of 
a non-smoker control, a smoker control and a lung cancer patient.  Figure 2.9b shows 
typical GC-MS chromatograms of a non-smoker control, a smoker control and a lung 
cancer patient. 
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Figure 2.9.  Analyses of a healthy non-smoker 
control, smoker control and lung cancer subject 
via (a) FT-ICR-MS and (b) GC-MS. 
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 The FT-ICR-MS and GC-MS spectra both show that the smoker control and the 
lung cancer subject have considerably more carbonyl VOCs than the non-smoker control.  
For example, n-propanal and 2-pentanone are conspicuous in the lung cancer subject.  
Figure 2.8a and 2.8b also show a higher abundance of 2-butanone and n-pentanal in the 
exhaled breath of the lung cancer patient.  These compounds have been reported as lung 
cancer markers.52, 57, 58, 60  Hydroxyacetaldehyde and 3-hydroxy-2-butanone also have 
been identified as lung cancer markers in our previous work on closed chip 
microreactors.52  Whereas breath analysis for detection of lung cancer using GC-MS has 
great potential, these results are only a preliminary indication of the potential of AMAH.   
In this regard, a major advantage in using AMAH/AMA is the ability to accurately 
determine marker molecular formulae as well as to detect the isomeric differences by 
GC-MS that FT-ICR-MS does not provide. For example, 2-pentanone and pentanal are 
constitutional isomers that would register as a single m/z on FT-ICR-MS, but the AMA 
adducts of these VOCs are readily separated by GC-MS to reveal an abundance of one 
over the other.  In addition, due to the chemoselectivity of aminooxy compounds for 
reacting with aldehydes and ketones,66 interference of other abundant volatiles in exhaled 
human breath, such as O2, CO2, H2O and numerous VOCs, is avoided and this greatly 
facilitates carbonyl compound calibration as well as peak identification.  
 
2.4. CONCLUSION 
 This thesis research resulted in the development of a second-generation ammonium 
aminooxy probe, AMAH, to efficiently capture trace aldehyde and ketone VOCs from 
exhaled breath when applied to a silicon microreactor containing thousands of 
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micropillars.  The AMAH-coated microreactor chemoselectively and covalently 
concentrates carbonyl VOCs through an oximation reaction.  The resultant AMAH-
adducts can be readily rinsed from the microreactor by elution with cold methanol and 
then directly analyzed by FT-ICR-MS.  The positive charge of the AMAH-VOC adducts 
enhances sensitivity for the high mass accuracy and ultra-high resolution of FT-ICR-MS 
to enable determination of molecular formulae.  Also developed was a protocol whereby 
the AMAH-VOC adduct solution is added to a small amount of the acid-scavenging 
polymer PVP to produce volatile AMA-VOC adducts that can be analyzed by GC-MS.  
This versatile attribute of AMAH enables the identification and quantification of isomeric 
metabolites using GC-MS.  The combination of a titratable aminium reagent with the 
PVP neutralization protocol constitutes a general approach that may be applicable for the 
development of other chemoselective probes. 
 
2.5. FUTURE DIRECTIONS 
 To expand the use of this technology, I have also synthesized ADMH, an aminium 
version of ATM, as can be seen in Figure 2.10.  The synthesis of ADMH was similar to 
that of ATM.  A Mitsunobu reaction with N,N-dimethylethanolamine was performed to 
afford the phthalimide protected aminooxy.   The phthalimide was cleaved via  
hydrazinolysis with methylhydrazine and the resulting ADM was distilled using a 
 
 
Figure 2.10.  Structures of ATM and ADMH. 
N ONH2
I
ATM
H N ONH2
Cl
ADMH
 
 53 
 Kügelrohr apparatus.  Due to the reactive nature of the aminooxy terminus, the 1H NMR 
spectrum revealed that ca. 48% of the product had reacted and formed an oxime ether 
adduct.  To circumvent this problem, the partially reacted material was hydrolyzed under 
acidic conditions (6 M HCl, reflux, 22 h) to unmask the aminooxy moiety and to provide 
the ADMH amminic proton needed to reduce volatility.  The reactivity of ADMH and its 
application to both FT-ICR-MS and GC-MS analyses are currently being investigated by 
Dr. Xiao-An Fu and collaborators. 
 In addition, I  have pursued initial efforts to prepare an aminooxy reagent that could 
be used for the analysis and detection of VOC adducts via HPLC-MS.  Our goal in 
designing this molecule was to have a non-volatile aminooxy molecule that was 
sufficiently reactive to efficiently capture and covalently retain VOCs from exhaled 
breath while also providing a convenient and sensitive method of detection, such as by 
HPLC.  We chose to use a fluorescent detector with the HPLC to ensure that we would be 
able to quantify the VOC oxime ether adducts at nanomolar concentrations.  When 
searching for a fluorophore, we found a paper by Goto et al.67 that specifically addressed 
the formation of sensitive fluorescence labeling reagents for HPLC of carbonyl 
compounds.  Figure 2.11 shows a time course to exemplify the oximation of 2 with a 
ketone (ca. 12α-hydroxy-3-oxo-5β-chloanoic acid).  Though Goto only reported the 
reactivity of 2, he noted that there was no difference in the reactivity between the 
anthracene-aminooxy molecules.   
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Figure 2.11.  Time course for derivatization of 12α-hydroxy-3-oxo-5β-
chloanoic acid with O-(2-anthrylmethyl)hydroxylamine (2).67  
 
 With this information in-hand, we synthesized AAn (Figure 2.11) from 9-
anthracenemethanol.  Briefly, the alcohol was reacted with N-hydroxyphthalimide under 
Mitsunobu conditions to afford the phthalimide-protected aminooxy that was deprotected 
with hydrazine monohydrate to give AAn.  Though initial results are encouraging, the Fu 
lab is still in the early stages of testing AAn and comparing its reactivity with ATM and 
AMAH. 
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CHAPTER 3 
 
THERMALLY-INDUCED INTRAMOLECULAR CYCLIZATION  
AS A MECHANISM FOR SUBSTRATE RELEASE 
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3.4. CYCLIZATION STUDY 
3.5. MICROCHANNEL APPLICATION 
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3.1. INTRODUCTION 
 Intramolecular cyclization is a well known chemical process often exploited in 
synthesis, not only for target molecule synthesis but also for diverse applications in many 
fields, such as materials science and biochemistry.  Examples include carbon-carbon 
bond formation via intramolecular Diels-Alder reactions 1  as well as catalyzed 
cyclizations 2  and formation of heterocyclic rings such as lactones, 3  lactams, 4  and 
oxazolidinones.5  Though intramolecular cyclization is usually utilized as a means to ring 
formation, it can also be used as a mode of substrate release.   The intramolecular 
cyclizations that focused more so on substrate release typically were engineered in this 
manner to function as mechanisms for drug delivery.6, 7, 8, 9  In these cases, the released 
substrate is either a phenol (R’ = Ar) or an aniline derivative (Figure 3.1b) so that the 
intramolecular cyclization occurs rapidly at physiological temperature,10 generally with a 
half-life from minutes to one hour.11  Intramolecular cyclizations of this type also have 
been used to unmask aromatic hydroxyl,12 amine13 or thiol14 moieties as mechanisms to 
initiate electron cascade reactions or for release of polymer-bound drugs (Figure 3.1).15  
Again the focus was to use the intramolecular cyclization for rapid drug release at 
physiological temperature, and this required R’ to be aromatic.  Few examples have used 
this approach to release non-aromatic alcohols,16, 17 the most common being for the 
delivery of 5-halo deoxyuridine analogs.18, 19, 20 
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Figure 3.1.  General structure of drug or prodrug delivery systems involving (a) 
electron cascade reactions, (b)  rapid intramolecular cyclizations or (c) a hybrid of 
intramolecular cyclization and electron cascade reactions.11  
 
 Our interest in control over heat-induced intramolecular cyclization as a mechanism 
for substrate release led us to investigate linkers that would expel HO-R’ (Figure 3.2) at 
temperatures above 37 °C, such as in response to an externally triggered local 
hyperthermia.  In addition to the release of alcoholic substrates, thermally induced 
intramolecular cyclization could also be used to release any carbonyl agent by fitting R’ 
with an aminooxy group.   
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Figure 3.2.  Heat-induced cyclization 
via (a) lactamization or (b) carbamate 
formation. 
 
3.2. FIRST GENERATION 
 My first generation attempts at developing this strategy were motivated by a report 
published in Organometallics by Ojima and Vidal21 that described the synthesis and 
reactivity of amine 1 (Figure 3.3).  We envisioned that the hydroxyl group could readily 
be transformed into the requisite, electrophilic carbonyl needed for the cyclization 
trigger, as in 2 (Figure 3.3).  Aside from this attribute, 2 would also afford an 
alkoxysilane group that could allow the linker to be covalently bound to a variety of solid 
supports containing surface hydroxyl groups.22, 23  Finally, the intramolecular cyclization 
could occur in response to heat.  Thermal induction was desired because the cyclization 
rate could be tuned to occur at a range of temperatures, allowing for the technology to be 
adjusted for the application.  In order to tune the thermal responsiveness of 2, the butyl 
group could be modified to increase or decrease steric bulk.  In addition, the primary 
alcohol of 1 would allow the subsequent carbonyl to be an ester or a carbonate.  This 
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functional group variation from ester to carbonate would allow for accelerated or retarded 
cyclization, respectively. 
 
 
Figure 3.3.  Proposed alterations to molecule published by Ojima and Vidal.21  The 
target molecule would cyclize when heated to form the lactam. 
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Scheme 3.1.  Synthesis of 2.  Conditions:  a. Phthalimide, DIAD, 
PPh3, THF, 0 °C, 87%; b. N2H4•H2O, CH2Cl2, 56%; c. n-BuLi, 
chlorodimethylsilane, THF, -78 °C, 73%; d. cat. Rh4(CO)12, CO (10 
atm), toluene, 60 °C; e. NaBH4, MeOH, toluene, 66% over 2 steps; f. 
[O]; g. Substrate–OH; h. cat. Pd/C, H2, MeOH. 
 
 Starting with 3-octyn-1-ol (Scheme 3.1), a two-step functional group transformation 
using Mitsunobu conditions to add a phthalimide followed by hydrazinolysis yielded oct-
3-yn-1-amine in 49% overall yield.  The primary amine was then bis-silylated by reaction 
with chlorodimethylsilane.  Subsequent Rh4(CO)12-catalyzed intramolecular 
silylformylation of the resident alkyne moiety under 10 atm CO followed by immediate 
reaction with methanolic NaBH4 afforded the stable azasilacyclopentane 5 in good yield.  
The results of the reaction were supported by the downfield position of the methylene 
protons and carbon of 1 (Figure 3.4) that was added in the reaction of CO with the alkyne 
bond.  Further verification was found in the 13C NMR spectrum with carbon 2 and 3 
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(Figure 3.4) in the olefinic region.  The presence of the exo-alkylene group of 5 is 
postulated to stabilize the Si–N bond against hydrolysis.  This unique stability would 
allow for further modification of 5 while affording the ability to restore the characteristic 
hydrolytic susceptibility of Si–N bonds by subsequent hydrogenation.  On hydrogenation 
of the exomethylene (and thus removal of its stabilizing influence) in dry methanol, the 
Si–N bond would be expected to immediately hydrolyze and form the target 
methoxysilane (e.g., as in 2, Figure 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 62 
 
 
Figure 3.4.  1H and 13C NMR spectra (CDCl3) confirming the 
synthesis of 5 (Scheme 3.1). 
 
 Despite our synthetic success, we ceased our pursuits of 2 after obtaining 5 due to 
concerns about the synthetic pathway.  The first challenge was the hydrolytic 
susceptibility of 4 and the second concern was the safety of using CO gas at 10 atm of 
pressure at elevated temperatures.  Throughout this process the scalability of our 
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syntheses was always a goal; therefore, a new target molecule was deemed necessary due 
to the finesse and potential dangers associated with the aforementioned concerns. 
 
3.3. SECOND GENERATION 
 To create a less cumbersome synthetic approach while still maintaining the goal for 
development of a thermally induced intramolecular cyclization we reflected on the 
positive and negative aspects of the route involving 2.  On doing so, the linearity of the 
amine with the carbonyl became evident and made us realize that an ω-amino acid could 
be used as a readily available starting material (Figure 3.5).   
 
 
Figure 3.5.  Retrosynthetic analysis of 2 reveals a path for 
simplification involving  an ω-amino acid starting material. 
 
 In addition to availability, there were other advantages to modifying the synthetic 
procedure to start with an ω-amino acid.  First, the distance between the nucleophilic 
amine and electrophilic carbonyl was no longer fixed at four carbons.  This is of great 
importance because it allows for tuning the thermal responsiveness by adjusting the size 
of the heterocyclic ring that would be formed, from an expected rapid 5-membered ring 
formation to a slower forming 7-membered ring.  Second, an oxidation step to form the 
carbonyl was no longer necessary.   
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 But there were also new synthetic challenges in using an ω-amino acid starting 
material.  First, we would have to devise a way to incorporate an alkoxysilane into the 
linker.  The second challenge was that the preexisting carbonyl was only advantageous 
for esterification.  In order to modify the functionality around the carbonyl we would 
have to reduce the esterified or acidic carboxyl group to form a primary alcohol.  The 
alcohol could then be used in the formation of a carbonate or undergo a functional group 
transformation to an amine for eventual carbamate formation (Scheme 3.2). 
 
 
Scheme 3.2.  Modification of carbonyl functionality from 
carboxylic acid to a carbonate or carbamate. 
 
 The first issue that we addressed was the incorporation of an alkoxysilane into the 
linker motif.  A convenient location for attachment of an alkoxysilane group is to use the 
amine.  In doing so, we gain nucleophilicity by forming a secondary amine.  Furthermore, 
this approach would not be expected to deter the desired intramolecular cyclization — 
steric hindrance issues are minimal.  We therefore decided to alkylate the primary amine 
with an allyl group to subsequently use the unsaturation as a means for incorporating the 
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al.24 we used PtO2 as a catalyst to add triethoxysilane in the γ position.  As can be seen 
from the 1H NMR spectrum in Figure 3.6, the disappearance of the olefinic peaks (red), 
the collapse of the methylenes surrounding the Boc-protected nitrogen into one broad 
peak (blue) and the appearance of an upfield peak at 0.57 ppm (green) all support the 
effectiveness of the hydrosilylation.  Despite the option of other hydrosilylation catalysts 
(Table 3.1), PtO2 was an affordable option that would enable us to use a minimal amount 
due to its high w/w percentage of Pt.  In addition, the catalyst could be recovered and 
reused, thus making PtO2 applicable for industrial reactions. 
 
 
Figure 3.6.  1H NMR spectrum (CDCl3) of the hydrosilylated ester 14.3. 
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Table 3.1.  Hydrosilylation of allylamine with methyldiethoxysilane in the 
presence of various catalysts.24  
Entry Catalyst Reaction time (h) 
Ratioa 
(γ/β) 
Yielda 
(%) 
1 H2PtCl6 • 6H2O in i-PrOH 48 > 95/5 20 – 55 
2 
(Karstedt catalyst) 
24 > 95/5 50 
3 Pt/C (10% Pt w/w) 24 > 95/5 > 95 
4 PtO2 (83.69% Pt w/w) 24 > 95/5 > 95 
        a Calculated on the basis of 1H NMR spectrum. 
 
  
 We now turned our attention to studying how the functionality around the carbonyl 
and the heterocyclic ring size affected the rate of cyclization.  To do this, we prepared a 
panel of amino carbonyl substrates to determine factors that would minimize the rate of 
cyclization at 37 °C while allowing cyclization to proceed at higher temperature (Figure 
3.6).   
 
3.3.1. Cyclization Panel (Figure 3.7)   
 All substrates were prepared to contain an N-allyl moiety for convenient 
functionalization, such as hydrosilylation or thiol incorporation, for eventual covalent 
attachment to various supports.  To quantify release of the ‘payload’ (e.g., HO-R’ in 6-8 
and 10-11, H2N-R’ in 9) on heating, R’ was selected as a 9-substituted anthracene for 
ease of UV and fluorescent measurements.  When using the commercially available 9-
anthracenemethanol, we found that the acidic Boc-deprotection step would also 
Si O Si 3Pt2
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hydrolyze the fluorophore.  This issue was circumvented by synthesizing the homologous 
2-(9-anthracenyl)ethanol.  In addition to the cyclization ring size (italics, Figure 3.6), we  
 
 
Figure 3.7.  Cyclization precursors (R = 2-
(9-anthracenyl)ethyl).  Ring size after 
intramolecular cyclization given in 
parentheses. 
 
varied the carbonyl functionality to include ester, carbonate, carbamate and amide 
examples.   The influence of gem-dimethylation, as in seven-membered ring precursors 
ester 10 and carbonate 11, also was examined as a means to enhance intramolecular 
cyclization via the Thorpe-Ingold effect.25 
 
3.3.2. Syntheses (Schemes 3.3-3.7)   
 N-allylation 26  of commercial Boc-protected amino acids 12 followed by 
carbodiimide-mediated esterification with 2-(9-anthracenyl)ethanol 27  and Boc-
deprotection furnished amino esters 6.1-3 (Figure 3.8, Scheme 3.3). 
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Figure 3.8.  1H NMR (CDCl3) of ester 14.3 showing successful Boc-
protection, N-allylation and esterification with 2-(9-anthracenyl)ethanol. 
 
 Condensation of amino acid 13.1 with 2-(9-anthracenyl)ethanamine28 gave the 
amino amide substrate 9.  In similar fashion, N-allylation of Boc-protected alcohols 15 
(Scheme 3.4), after necessary silylation and desilylation steps, gave alcohols 16.  The 
carbonate moiety was installed by first forming the corresponding acyl imidazole 
intermediates 17.  Reaction with anthracenyl ethanol under basic conditions21 then gave 
amino carbonates 7.1-2.  Though the 1H NMR spectra were similar for these compounds, 
the 13C NMR spectra allowed for confirmation of the functionality around the carbonyl 
(Figure 3.9). 
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Scheme 3.3.  Synthesis of amino esters 6 and amide 9.  
Conditions: a. allyl bromide, NaH, THF, 0 °C to rt, 81-
98%; b. 2-(9-anthracenyl)ethanol (or 2-(9-
anthracenyl)ethanamine), DIC, cat. DMAP, CH2Cl2, 12h, 
59-97%; c. TFA, CH2Cl2, 0 °C, 1h, 72-100% 
 
 
Scheme 3.4.  Synthesis of amino carbonates 7.  Conditions: 
a. TBSCl, Et3N, imidazole, CH2Cl2, 0 °C to rt, 95-98%; b. 
allyl bromide, NaH, THF, 0 °C to rt, 77-84%; c. TBAF, 
THF, 0 °C to rt, 90-95%; d. (imid)2C=O, (i-Pr)2NEt, 
CH2Cl2, 0 oC to rt, 93-95%; e. 2-(9-anthracenyl)ethanol, 
KOH, toluene, 60 °C, 34-45%; f. TFA, CH2Cl2, 0 °C, 1h, 
96-100%. 
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Figure 3.9.  13C NMR (CDCl3) spectra of ester 14.3 (155.7 and 173.9 ppm), 
amide 14.4 (156.3 and 173.1) and Boc-protected carbonate 7.2 (155.5 and 155.6 
ppm) emphasizing the effects of carbonyl functionality on 13C chemical shift 
and confirming molecular structure. 
 
 Chloroformate acylation of N-allyl-N-Boc-ethanediamine provided a convenient 
route for synthesis of the amino carbamate substrate 8 (Scheme 3.5). 
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Scheme 3.5.  Synthesis of amino carbamate 8.  Conditions: 
a. phthalic anhydride, toluene, reflux, 77%; b. allyl 
bromide, NaH, THF, 0 °C to rt, 58%; c. hydrazine 
monohydrate, 2:1 CH2Cl2:EtOH, 0 °C to rt, 92%; d.  
ArCH2CH2OC(O)Cl, Et3N, CH2Cl2, 0 °C to rt, 12h, 41%; e. 
TFA, CH2Cl2, 0 °C, 1h, 88%. 
 
 The gem-dimethyl amino ester 10 was prepared by applying the above-described 
three-step sequence of N-allylation, esterification and Boc-deprotection to commercially 
available amino acid 20 (Scheme 3.6).  Synthesis of gem-dimethyl amino carbonate 11 
followed from bis-α-methylation15 of the ester derived from amino acid 16.1 (Scheme 
3.7).  Mono-methylation could be identified by thin layer chromatography (TLC) since 
the Rf of bis-α-methylated product was 0.53 and the mono-α-methylated product had an 
Rf of 0.50.  Incomplete α-methylation could also be confirmed by the integration of the 
1H NMR spectrum (Figure 3.10).  Subsequent chemoselective ester reduction29 and 
carbonate formation using the established method gave desired substrate 11.  
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Scheme 3.6.  Synthesis of gem-dimethylated ester 10.  
Conditions: a. allyl bromide, NaH, THF, 0 °C to rt, 68%; b. 
2-(9-anthracenyl)ethanol, DIC, cat. DMAP, CH2Cl2, 12h, 
87%; c. TFA, CH2Cl2, 0 °C, 1h, 85%. 
 
 
 
Scheme 3.7.  Synthesis of gem-dimethylated carbonate 11.  
Conditions: a. MeOH, DIC, cat. DMAP, rt, 80%; b. 
LiHMDS, MeI, THF, –78 °C to rt, 67%; c. LiBH4, THF, 0 
°C to rt, 73%; d. (imid)2C=O, (i-Pr)2NEt, CH2Cl2, 0 °C to 
rt, 92%; e. 2-(9-anthracenyl)ethanol, NaH, THF, –5 °C to 
rt, 48%;  f. TFA, CH2Cl2, 0 °C, 1h, 92%. 
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Figure 3.10.  1H NMR spectrum (CDCl3) of ester 22 after complete bis-α-
methylation. 
 
3.4. CYCLIZATION STUDY 
 To determine the release rates of the 9-substituted anthracenes (e.g., 25, Scheme 
3.8) from the panel of amino-carbonyl substrates, dilute methanol solutions of each 
compound were heated at 55 °C.  Aliquots taken at various times were analyzed by 
normal phase HPLC for the appearance of 25 or 26.  Amino-carbamate 8 and amino-
amide 9 were unreactive under the conditions and did not release detectable 25 or 26, 
respectively (Scheme 3.8).  As could be expected, anthracene alcohol 25 was released 
from the amino-ester and amino-carbonate progenitors of the 5- and 6-membered lactams 
(24, Y = CH2, n = 0, 1) and oxazolidinones (24, Y = O, n = 0, 1) at rates faster than from 
the progenitors of corresponding 7-membered rings (Figure 3.11 and Table 3.2).  Control 
experiments indicated that ester or carbonate methanolysis did not occur under the 
conditions to yield 25.  Whereas dilute conditions were used to reduce the incidence of 
N
Boc
O
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intermolecular reactions, these cannot be ruled out as a possible source of 25 particularly 
with the substrates that lead to 7-membered rings.  In regards to potential heat-triggered 
release applications, the high thermal responsiveness of esters 6.1-2 and carbonates 7.1-2 
make these constructs ideal for applications involving thermally sensitive substrates, such 
as in cell studies involving triggered release at or below 37 °C. 
 
 
Scheme 3.8.  Heat-induced release of 
anthracene probes. 
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Figure 3.11.  Percent release of 25 from indicated substrates in MeOH at 
55 °C.  Shown are the standard deviations from the mean (n = 3).30 
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Table 3.2.  Heat-induced release of alcohol 25 (Scheme 3.8 and Figure 
3.7).30  
Entry Substrate (ring size) 
% release after heating (55 °C) at time (h) % release 
at rt, 3.5h 0.25 0.5 0.75 1 2 3 24h 
1  ester 6.1 (5) 
24.6 
±3.1 
29.2 
±1.7 
33.4 
±2.5 
36.6 
±2.6 
44.4 
±3.7 
50.2 
±4.2 
94.0 
±1.8 20.2 ±3.1 
2 ester 6.2 (6) 
20.9 
±1.9 
21.6 
±3.5 
23.0 
±3.0 
25.0 
±2.1 
30.5 
±1.3 
36.5 
±1.2 
75.7 
±3.2 17.0 ±4.5 
3 ester 6.3 (7) 
2.1 
±1.6 
1.8 
±1.9 
2.1 
±2.2 
2.1 
±1.8 
3.1 
±2.9 
3.6 
±3.0 
10.4 
±3.8 1.7 ±2.0 
4 gem-ester 10 (7) 
2.0 
±0.1 
2.2 
±0.1 
2.7 
±0.1 
3.3 
±0.4 
4.1 
±0.3 
5.2 
±0.8 
24.7 
±3.9 1.8 ±0.2 
5 carbonate 7.1 (5) 
23.5 
±1.9 
28.9 
±1.7 
32.4 
±4.0 
36.7 
±4.8 
48.3 
±5.7 
57.0 
±6.9 
68.9 
±3.0 18.8 ±2.3 
6 carbonate 7.2 (6) 
12.0 
±0.8 
14.1 
±0.7 
16.4 
±1.0 
18.0 
±0.7 
24.8 
±1.1 
29.0 
±1.0 
62.1 
±5.6 9.6 ±1.1 
7 
gem-
carbonate 
11 (7) 
1.8 
±0.4 
2.3 
± 0.5 
2.9 
±0.1 
4.0 
±0.3 
5.7 
±1.0 
7.6 
±0.3 
36.6 
±0.3 0.7 ±0.1 
8 amide  9 (5) no reaction 
9 carbamate 8 (5) no reaction 
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 In contrast, the resistance to cyclization of the 7-ring progenitor ester 6.3 is 
promising for higher temperature applications (Figure 3.11 and Table 3.2), although the 
overall release of 25 from 6.3 on heating at 55 °C was low.  Comparison of amino-esters 
6.3 and 10 shows that gem-dimethylation more than doubled the heat-induced release of 
anthracene 25 after heating 24 h.  The gem-dimethyl amino-carbonate 11 provided an 
even higher thermal response than gem-dimethyl ester 10 with a nearly 40% release of 
payload at 55 °C over 24 h.  Furthermore, the gem-dimethyl 7-ring carbonate motif 
resists cyclization at lower temperatures.  Incubation of 11 at 37 °C for 24 h resulted in 
only 5.7% ± 0.7% release of 25. 
 We also performed an NMR experiment to prove that the release 25 was due to 
intramolecular cyclization and not intermolecular polymerization.  1H NMR spectra 
allowed us to not only see 25, but also the subsequent lactam or oxazolidinone.  Samples 
of 6.1 and 7.1 were placed into NMR tubes with toluene-d8 and heated.  The resulting 1H 
NMR spectra (Figure 3.12) showed the formation of cyclized rings that were in 
agreement with literature while also showing the liberated alcohol 25. 31   No 
polymerization was observed in the spectra.   
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Figure 3.12.  1H NMR (toluene-d6) spectra of ester 6.1 before heating (top 
spectrum) and after thermally-induced intramolecular cyclization (bottom 
spectrum). 
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3.5. MICROCHANNEL APPLICATION 
 With these cyclization trends established, we set out to incorporate an aminooxy 
group into the linker chain.  We felt that the addition of an aminooxy group would allow 
us to design a pre-concentrator for the chemoselective capture of carbonyl metabolites 
from an aqueous solution.  After concentration of the aldehydes and ketones, the oxime 
ether adducts would be released from the linker with mild heating.   
 We chose to use a poly(dimethylsiloxane) (PDMS) microchannel (Figure 3.13) as a 
substrate from which we could covalently attach our linker and release its cargo upon 
heating.  Microchannels fabricated using PDMS have shown great utility for molecular 
and cellular separations due to their extremely high surface to volume ratio. 32  
 
 
 
Figure 3.13.  Schematic of poly(dimethylsiloxane) 
microchannel.  
 
Further, small PDMS channel heights and incorporation of features, such as 
microfabricated grooves, enhance fluid mixing within the channel to increase interactions 
of functionalized surfaces with target molecules flowing through the channel.33   
 The N-allyl moiety of ammonium aminooxy ester 27 (Scheme 3.9), based on the 
ester motif of 6.2, was hydrosilylated24 to attach a terminal triethoxysilane group.  The 
ammonium aminooxy substructure of ester 27 follows from our previously published 
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work on ammonium aminooxy reagents for capture of aldehyde and ketone metabolites 
from aqueous cell extracts. 34 , 35   Subsequent condensation 36 , 37  with the PDMS 
microchannel (Figure 3.13) covalently attached 28 to afford an aminooxy-functionalized 
microchannel specific for reaction with aldehydes and ketones.  Injection of an  
 
 
Scheme 3.9.  Poly(dimethylsiloxane) microchannel functionalization and 
heat-induced release study (FL = fluorescein, X– = CF3CO2–). 
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acetonitrile solution containing a fluorescent aldehyde probe, FITC (fluorescein 
isothiocyanate) reacted with a 4-aminobutanal equivalent (Scheme 3.10),38 anchored the 
fluorophore to the surfaces of the microchannel via oxime ether formation.  The  
  
 
Scheme 3.10.  Preparation of the aldehydic FITC moiety.  Conditions:  
a. H2N–(CH2)3–CH(OEt)2, 94%; b. 30% aq. AcOH, 50%.38  
 
quaternary ammonium salt of 28 ensures availability of the aminooxy moiety for reaction 
with aldehydes since charged polar groups are repelled by the hydrophobic PDMS 
matrix.  The capture and covalent attachment of the FITC-derived fluorophore to the 
microchannel was verified using fluorescent microscopy (Figure 3.14a).  Boc-
deprotection using trifluoroacetic acid afforded trifluoroacetate salt 30.  Concerned that 
loss of captured aldehyde probe may occur at this stage, we verified that no fluorescent 
probe was released prior to neutralization and thermal triggering.  Indeed, no 
fluorescence was observed in the microchannel effluent after heating 30 at 60 °C for 30 
min.  Injection of a dilute solution of triethanolamine into the microchannel neutralized 
the linker.  After subsequent rinsing (CH3CN) of the microchannel, we were gratified to 
observe that mild heating (60 °C, 30 min) promoted the intramolecular cyclization to 
release alcohol 32.  As can be seen in Figure 3.14b, nearly complete release of the bound 
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fluorophore was achieved.  Further utilization of this release mechanism in microchannel 
studies of cell metabolites requiring hydroxide-free cleavage conditions are ongoing. 
 
 
 
 
Figure 3.14. Fluorescence microscopy image of (a) FITC-
derived substrate 17 within the microchannel and (b) same 
field of view showing microchannel fluorescence after 
heating neutralized 18. 
 
3.6. CONCLUSION 
 In summary, a brief study on the cyclization of amino esters and amino carbonates 
as a mode for substrate release revealed that both ring size and carbonyl functionality 
significantly influence the release rate.  The process is facile at mild temperatures in 
cases where 5- and 6-membered rings are formed, even for non-phenolic alcohols as 
illustrated in a PDMS microchannel application.  In contrast, an amino carbonate motif 
leading to a seven-membered ring appears well suited for applications requiring thermal 
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stability at 37 °C while still releasing the alcohol substrate at slightly elevated 
temperatures.  This particular secondary amine–carbonate structural combination may be 
a promising linker for drug delivery vehicles relying on the generation of local 
hyperthermia.    
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CHAPTER 4 
 
ALTERNATING MAGNETIC FIELD-INDUCED  
SUBSTRATE RELEASE FROM IRON OXIDE NANOPARTICLES 
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4.1. INTRODUCTION 
 An important attribute of a drug delivery system is regulated spatial and temporal 
drug release to minimize side effects as well as to improve the therapeutic efficacy of 
conventional pharmaceuticals.  Iron oxide nanoparticles (NPs) possess many appropriate 
qualities that make them a viable choice for drug delivery formulations.  Magnetite 
(Fe3O4) NPs are biocompatible,1 have low cytotoxicity,2 and provide multiple means for 
surface modification.  Fe3O4 NPs are set apart from other forms of iron oxide due to 
inherent paramagnetic or superparamagnetic properties.3 As a result of the magnetism, 
one highly-studied feature of Fe3O4 NPs is their ability to heat a surrounding environment 
when exposed to an alternating magnetic field (AMF).  Indeed, irradiation of Fe3O4 NPs 
with an AMF to cause local hyperthermia (i.e., to raise target body tissue to 40-45 °C) is 
an emerging alternative treatment for several cancers, 4  such as melanoma, 5 , 6 
glioblastoma,7, 8 liver,9, 10 or prostate11, 12 cancer.  Furthermore, when the Fe3O4 NPs are 
fitted with a drug, attached either through ionic interactions or via entrapment in a 
polymer gel coating, the drug may be guided to tumors using a magnet, a property first 
demonstrated by Meyers in 1963.13 Consequently, many Fe3O4 NP-based systems now 
are extensively functionalized for drug delivery applications.14, 15 
 Some of the most common approaches for association of drug payloads with Fe3O4 
NPs include encapsulation of Fe3O4 NPs within drug-loaded liposomal formulations,16, 17 
addition and subsequent functionalization of mesoporous silica shells18, 19, 20 and the use 
of polymer coatings to surround the Fe3O4 NPs (Figure 4.1).21, 22  As the NPs reach  
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Figure 4.1.  (a) Liposomal, (b) mesoporous silica and (c) polymeric iron 
oxide drug delivery platforms that use AMF-induced heat as a mechanism 
for controlled drug relesase. 
 
 a target (e.g., cancerous) tissue, a release mechanism is initiated so that the drug 
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include the use of pH-sensitive — typically acid-labile — triggers (Figure 4.2a),23 
photolabile linkers (Figure 4.2b)24 and AMF irradiation (Figure 4.1).25, 26  
 
 
Figure 4.2.  Drug release mechanism for (a) acid-labile hydrazone 
linkages and (b) photolabile o-nitrobenzyl linkages. 
 
 AMF-induced drug release has a distinct advantage over the pH-mediated 
approaches in that the former exploits advantages associated with using a controllable, 
external stimulus whereas the later requires contact with an internal stimulus that cannot 
be easily controlled.  AMF induction stimulates controlled release at a specific region and 
at a specific time without the need for a precise, and often unpredictable, internal 
environment.27, 28  Despite the advantage of controlled release using an AMF trigger, 
many such NP drug delivery systems still have a problem with premature drug release 
(i.e., payload leaching).  In these instances, drugs are continuously released prior to 
application of the external stimulus.29, 30  This problem is generally due to the inability of 
the payload to be covalently retained until the stimulus is applied.  For example, Brule et 
al. 31  have used AMF-induction to increase the porosity of drug-loaded, alginate 
microbeads containing Fe3O4 NPs.  Whereas this elegant approach is quite functional for 
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drug release, undesired diffusion of loaded drug from the microbeads is noted prior to 
AMF irradiation.  Thus, the development of an AMF-responsive delivery system that 
covalently retains its payload until stimulated would constitute a desirable next-step and 
advance the evolution of nano-delivery systems.   
  
4.2. NANOPARTICLE FUNCTIONALIZATION AND RELEASE 
4.2.1. Initial Loading 
 Our initial concept was to covalently tether a drug to an Fe3O4 NP via a thermally 
labile functionality using a linking chain that contains a secondary amine, such as shown 
by NP assembly 1 (Figure 4.3).  With judicious choice in linker length, we expected that 
application of an AMF to raise the surrounding temperature would power an 
intramolecular cyclization via reaction of the amine with the carbonyl moiety, as in [2].  
We aimed to achieve this goal using one of our thermally labile linkers (Figure 4.4) 
discussed in Chapter 3. 
 
 
Figure 4.3.  AMF-mediated intramolecular cyclization 
results in release of ROH.  X = CH2, O, NH, or NR’. 
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Figure 4.4.  Cyclization precursors (R = 2-(9-
anthracenyl)ethyl).  Ring size after intramolecular 
cyclization given in parentheses. 
 
 The first issue that we addressed was the formation of a covalent bond between 
Fe3O4 NPs and an organic linker.  Despite the plethora of options for non-covalent 
bonding of Fe3O4 NPs, including but not limited to catechols,32 polysaccharides,33 
liposomal,34 polymers35 and cationic molecules,36 there are limited options to effectively 
form a covalent bond to iron oxides.  The three avenues to the formation of a covalent 
bond to Fe3O4 NPs (Figure 4.5) are 1) phosphonic acids/phosphonates 37  2) 
trichlorosilanes38 and 3) alkoxysilanes.39, 40  Out of these three, only the trichlorosilanes 
and the alkoxysilanes form a true covalent bond.  It has been suggested that the 
phosphonic acids and phosphonates, similar to carboxylic acids, bind to the iron oxide 
surface through an interaction with a trivalent iron atom.41  The resulting interaction 
between the Fe3O4 and the carboxylic acid is relatively weak while the phosphonic acids 
and phosphonates form stronger interactions.42  The chlorosilanes, though quite effective 
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at forming bonds to the Fe3O4 NP surface, are quite hydrolytically unstable and are more 
difficult to handle when compared to the alkoxysilane.  Due to the aforementioned 
reasons, the alkoxysilane is currently the primary method used to form a covalent bond to 
iron oxides.  But formation of the Fe–O–Si bond is not as straightforward as the 
formation of the Si–O–Si bonds described in Chapter 3 between the linker and the PDMS 
microchannel.  In Figure 4.6 Gelest, an industry leader in silanes and silicones, reports 
that the bonding effectiveness of an alkoxysilane with iron oxides is moderate.  All 
Metal–O–Si bonds are inferior to the robust and hydrolytically stable Si–O–Si bonds.43 
 
 
Figure 4.5.  Phosphonic acid/phosphonate, chlorosilane and 
alkoxysilane functionalities used to form moderate to strong bonds to 
Fe3O4 NPs. 
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Figure 4.6.  Effectiveness of silane bonding to various substrates.44 
 
 Using the same hydrosilylation protocol as described by Sabourault,75 we added a 
triethoxysilane to linker 4.3 to allow for loading onto Fe3O4 NPs.  The NP loading was 
achieved following a procedure by Ma et al.45 to afford the functionalized iron oxide 
NPs.  There were two different means of loading alkoxysilylated molecules onto iron 
oxide NPs in literature.  The two routes differ only after magnetically separating the NPs 
with the first route calling to dry the fuctionalized NPs under vacuum and the second 
route calling for the NPs to be dried by heating at ~100 °C (Figure 4.7, final bond 
formation/condensation step).  The route described by Ma and coworkers called for the 
use of vacuum without heating.  Abstaining from heating the NPs was attractive to us 
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since our NPs were functionalized with a thermally labile linker.  Since we wanted to 
induce the intramolecular cyclization using AMF, not conventional heat, using vacuum to 
induce the final condensation reaction was desirable.   
 
 
Figure 4.7.  Hydrolytic deposition of silanes.46 
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NPs were synthesized by combining FeCl2 • 4 H2O and FeCl3 • 6 H2O in a 1:2 molar ratio 
in a 0.1 M solution of NaOH with rapid stirring.  As the solution of the iron salts is added 
to the basic solution the black Fe3O4 NPs form.   
 To functionalize the magnetic NPs, they were suspended by sonication in ethanol 
with a small amount of water added to aid in hydrolysis of the alkoxysilane to form the 
silanol.  The alkoxysilane linker was added to the NP suspension and was mechanically 
stirred for 24 h at room temperature.  The functionalized NPs were magnetically 
separated and washed with EtOH until there was no activity to ultraviolet (UV) light 
observed in the supernatant as determined using thin layer chromatography (TLC).  
Finally, the NPs were dried under vacuum for 12 hours to afford a tan powder.  Using the 
weight difference between the starting, black Fe3O4 NPs and the final, tan functionalized 
NPs, we had obtained a loading of 1.75 µmol/mg.  To verify that the linker was loaded 
onto the NPs and was still capable of undergoing an intramolecular cyclization to release, 
a portion of the NPs were suspended in toluene and heated to reflux for 22 hours.  After 
magnetic separation, the supernatant was analyzed by TLC.  TLC analysis (developed 
using UV and p-anisaldehyde stain) revealed the presence of 2-(9-anthracenyl)ethanol.  
This result confirmed that our linker was covalently bound to the Fe3O4 NP and was still 
capable of undergoing an intramolecular cyclization for the release of an alcohol.   
 When we began to characterize the functionalized NPs by attenuated total 
reflectance (ATR) Fourier Transform (FT) infrared (IR) spectrometry we noticed that our 
signal intensity was high and that we had an intense signal at 1060 cm-1.  This signal is 
attributed to Si–O, Si–O–Si and Fe–O–Si vibrations. 48   In addition, Galeotti and 
coworkers report that the signal intensity of the Fe–O bonds (580-635 cm-1) in a 
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monolayer of silane should be stronger than the Si–O, Si–O–Si and Fe–O–Si vibration 
signal.  As can be seen in Figure 4.8 our peak at 1060 cm-1 is very intense and the peak at 
632 cm-1 is much weaker.   
 
 
Figure 4.8.  FT-IR spectrum of Fe3O4 NPs functionalized via an 
EtOH:H2O route with linker 4.3 obtained using ATR. 
 
 These results were indicative of a thick silica-linker shell around the iron oxide NP.  
These results were not desired despite the advantages provided by the silica shell 
including the robust Si–O–Si linkages between the linkers.  We were targeting a silane 
monolayer for two main reasons, 1) to maximize the percent released when compared to 
the loading and 2) to increase the magnetism and thus the potential thermal response with 
the application of an AMF.  Larumbe et al.49 reported that as the thickness of the SiO2 
layer increases there is a sharp reduction in the magnetic response of the Fe3O4 NPs when 
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compared to analogous uncoated Fe3O4 NPs.  After running the kinetic experiment, we 
knew that the 7-membered ring formation required temperatures above 55 °C and, 
therefore, were trying to maximize the AMF-induced release of thermal energy. 
 Before we could correct the thickness of the alkoxysilane coating we had to 
understand why the alkoxysilane was polymerizing instead of only binding to the surface 
of the NP.  In order to form a SiO2 shell on an Fe3O4 NP it is common to use the Stöber 
process, which is also performed in a solution of EtOH and water.50  But this process 
utilizes basic conditions to catalyze the hydrolysis of the alkoxysilane and the 
condensation of the silanols.  Following the LaMer model, the nucleation is the fast 
process and the particle growth follows without further nucleation and can also be 
thought of as the addition of monomers.51  In our case, the base was likely from excess 
NaOH that had not been removed the synthesized Fe3O4 NPs.  The presence of the base, 
in conjunction with the solvent conditions, had mimicked the Stöber process.  Even if we 
were to eliminate the base from the prepared NPs, there was still worry that the water 
would eliminate our ability to positively obtain only a monolayer due to the inability to 
control the self-polymerization of the silanols in the presence of water as depicted in 
Figure 4.9. 
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Figure 4.9.  Examples of hydrolysis and condensation of alkoxysilanes with 
surface hydroxyl groups in the presence of water to afford A) a monolayer, 
B) a bilayer and C) an uncontrolled and disorderly polymeric shell.  
 
 For greater reliability, we switched from using in-house prepared Fe3O4 NPs to 
commercial Fe3O4 NPs with a diameter of 20-30 nm (US Research Nanomaterials, 
98+%).  This change reduced the risk of any problems arising from having used more 
basic NPs — commercial NPs are acid-washed.  We also averted the unpredictability of 
aqueous loading by shifting to an anhydrous variation.  Galeotti et al.48 reported a route 
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that would consistently provide a monolayer by performing the loading in chloroform 
instead of aqueous EtOH.  The loading procedure involved suspending the Fe3O4 NPs in 
chloroform via sonication, then adding a solution of the alkoxysilane linker in chloroform 
to the suspension with sonication.  Upon completion of the addition, the reaction was 
moved to an overhead stirrer and heated to 65 °C for at least 24 hours.  Heat can be used 
instead of water to induce the hydrolysis of the alkoxysilane.44 The work-up was 
consistent with Ma et al.45 except the EtOH washes were replaced with chloroform 
washes.  When the NPs functionalized via the procedure described by Galeotti and 
coworkers48 were characterized by FT-IR, the spectra were similar to published data 
(Figure 4.10).   
 
 
Figure 4.10.  FT-IR spectrum of Fe3O4 NPs functionalized via an 
anhydrous route with linker 4.3 obtained using ATR. 
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4.2.2. Formation of Covalent Bond to NP 
 Now, with functionalized NPs similar to those published in the literature, we were 
able to begin experimenting with the exposure of the NPs to an AMF.  We placed ~4 mg 
of the magnetic NPs functionalized with linker 4.3 in 0.75 mL of 2:1 phosphate buffer 
solution (PBS) : acetonitrile.  The pH was adjusted to 7.4 with glacial acetic acid and the 
acetonitrile was used to keep the hydrophobic anthracene fluorophore in solution to 
enable fluorescence measurements to be taken.  As a control, one vial was allowed to sit 
on the bench at room temperature and a second vial was subjected to an AMF at 595 
amps and 204 kHz using a 5-turn coil.  After separating the NPs by magnetic 
sedimentation, the supernatant could be conveniently analyzed.  We were pleased to find 
that after 30 minutes of AMF exposure there was substantial fluorescence in the 
supernatant.  However, much to our surprise, a similar result was obtained when 
analyzing the non-AMF exposed control (Figure 4.11). 
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Figure 4.11.  595 Amp AMF and non-AMF induced release of fluorophore 
from ~4 mg of 20-30 nm Fe3O4 NPs functionalized with linker 4.3 in 2:1 
PBS:MeCN at pH 7.4. 
 
 There were two possibilities to explain the minimal difference between non-AMF 
and AMF-induced release.  The first possibility was that the intramolecular cyclization 
was occurring at a faster than expected rate when attached to the iron oxide NP.  The 
second explanation was that we were not actually forming a covalent bond to the 
magnetic NPs.  This would be the case if we had not successfully initiated the final 
condensation in the NP loading (Figure 4.12).   
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Figure 4.12.  Possible explanations for non-AMF induced 
release of fluorophore.  A) accelerated intramolecular 
cyclization or B) linker anchored to NPs through a non-
covalent, hydrogen bond. 
  
 To discriminate these theories, I synthesized linker 10 (Figure 4.13) wherein the 
secondary amine involved in the intramolecular cyclization is replaced with a non-
reactive methylene group.  Also, the anthracenyl fluorophore was slightly modified to use 
the commercially available 9-anthracenemethanol instead of the 2-(9-anthracenyl)ethanol 
since no Boc-deprotection step is required for synthesis of 10.  Having eliminated the 
possibility of an intramolecular cyclization for release of fluorophore, we expected it 
would be straightforward to differentiate this mechanism from the hypothesis that 
fluorophore release occurs via mere detachment of a hydrogen bound linker. 
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Figure 4.13.  Linker 4.3, capable of intramolecular cyclization, 
and 10 with a methylene instead of a nucleophilic amine, 
rendering it incapable of intramolecular cyclization.  Linker 10 
was used to probe the origin of the observed non-AMF induced 
release. 
 
 Using the procedure described by Galeotti et al.48 the Fe3O4 NPs were 
functionalized with 10 in the same manner as the NPs were loaded with 4.3.  The AMF 
experiment was repeated with ~3 mg of Fe3O4 NPs coated with 10 and the addition of a 
30 second sonication step to ensure that we would see fluorescence from any non-
covalently bound fluorophore.  The results of this experiment are shown in Figure 4.14.  
Though the non-AMF induced release without sonication has been reduced, sonication 
and AMF exposure resulted in substantial release of the fluorphore.  These results led us 
to understand that we were not successfully initiating the final condensation step using 
vacuum in the absence of heat. 
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Figure 4.14.  595 Amp AMF and non-AMF induced release of fluorophore 
from ~3 mg of 20-30 nm Fe3O4 NPs functionalized with linker 10 in 2:1 
PBS:MeCN at pH 7.4. 
 
 Dr. Jerry Larson, senior research fellow at Gelest Inc., Morrisville, PA, advised us 
that, despite what literature reports claim, Fe–O–Si bonds are difficult to form and that 
high temperatures (≥100 °C) are required to induce the final condensation reaction for 
covalent attachment of the linker to the iron oxide NP.  Armed with this knowledge, the 
NPs that were functionalized with 10 were heated to 110 °C for 24 hours at atmospheric 
pressure and the previous experiment was repeated, the results of which are combined 
with the results from Figure 4.14 and shown in Figure 4.15.  When compared with the 
results obtained using conditions 1a-3a, conditions 1b-3b showed almost no release of the 
fluorophore; a vast improvement in the minimization of undesired fluorophore release.  
These results also show that the use of heat to initiate the final condensation reaction and 
covalently bond the linker to the NP surface (Figure 4.7) is necessary and that vacuum 
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alone cannot form the Fe–O–Si bond.  Without the use of heat, the hydrolyzed 
alkoxysilane is only hydrogen bound to the Fe–OH surface of the NP, thus explaining the 
high release rate when the functionalized NPs are subjected to sonication (condition 2a). 
 
 
Figure 4.15.  595 Amp AMF and non-AMF induced release of fluorophore 
from ~3 mg of 20-30 nm Fe3O4 NPs functionalized with linker 10 in 2:1 
PBS:MeCN at pH 7.4.  With and without heat refers to the curing process of 
the functionalized NPs.  Without heat NPs were cured under vacuum and 
with heat NPs were cured at 110 °C for 24 hour at atmospheric pressure. 
 
 Though the results presented in Figure 4.15 were promising, it was necessary to 
confirm that the anthracene fluorophore was still attached to the Fe3O4 NPs.  The NPs 
loaded with 10 and cured at 110 °C (~3 mg) underwent saponification to liberate the 
esterified 9-anthracenemethanol.  Briefly, bare Fe3O4 NPs (as a control) and NPs 
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functionalized with 10 were suspended in a 2:1 solution of THF:MeOH.  Then, a 0.03 M 
aqueous solution of NaOH was added and the suspension was stirred overnight.  After 
centrifuging the NPs out of solution the fluorescence of the supernatant was measured to 
find a fluorescent signal released only from the functionalized NPs. 
 
4.2.3. Acidic Boc-deprotection on NPs 
 Since exposure of the NPs functionalized with the thermally labile linker to high 
temperatures were now required, we were no longer able to perform the acidic -C(O)Ot-
Bu (Boc) deprotection prior to loading the linker onto the NPs.  To test the acidic stability 
of the Fe3O4 NP and the Fe–O–Si bonds we synthesized a small linker, 11, and attached it 
to the Fe3O4 NPs to form 12 (Scheme 4.1).  We chose a secondary amine to best model 
our thermally responsive linkers. 
 
 
Scheme 4.1.  Boc-deprotection of a 2° amine bound to a 20-
30 nm Fe3O4 NP under acidic conditions.  Conditions:  a. 
(EtO)3SiH, cat. PtO2, 90 °C; b. Fe3O4, CHCl3, 65 °C; c.  i. 
CF3CO2H : CH2Cl2, 1:1, 0 °C, 1 h; ii. Et3N : CH2Cl2, 1:1, rt. 
 
 The Boc-deprotection of 12 was performed using 1:1 CF3COOH:CH2Cl2 at 0 °C for 
1 hour, the same as the Boc-deprotection performed to the linkers not bound to NPs.  
Upon completion the aminium functionalized NPs were magnetically separated, washed 
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with CH2Cl2 and dried under vacuum.  Thermogravimetric analysis (TGA) of 12 and 13i 
showed that ~50% of the loading had been cleaved during the Boc-deprotection.  As an 
affirmation of the successful deprotection and presence of nucleophilic 13, the NPs were 
neutralized with 1:1 Et3N:CH2Cl2 and fluorescein isothiocyanate (FITC) was added.  13, 
now functionalized with an FITC-thiourea fluorophore, was washed with methanol and 
ethyl ether, dried under vacuum and the fluorescent signal was observed using a 
Molecular Devices SpectraMax M5 fluorescent well plate reader.  A well plate reader 
was necessary singe the solid NPs prohibit the standard fluorescent emission at 90° to the 
excitation.  The fluorescent signal confirmed the successful Boc-deprotection as can be 
seen in Figure 4.16, though costing ~50% of the loading.  Since we were still aiming for 
proof of concept this was deemed acceptable. 
 
 
Figure 4.16.  Fluorescent signal of 13 functionalized with 
FITC via a thiourea linkage in MeCN.   
 
 We were now ready to load 14 (Scheme 4.2) onto the Fe3O4 NPs using the 
information we had learned.  This included the information that anhydrous loading 
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conditions decreased the uncontrolled polymerization and loading of the NPs, heat was 
necessary to initiate the final condensation reaction and acidic Boc-deprotection could 
effectively be performed on NP-bound linkers.  The release experiment was set-up 
similar to earlier experiments with 16 (~7 mg) being suspended in 2:1 PBS:acetonitrile 
(1.5 mL) at pH 7.4.  First, 16 was suspended and left on the bench for 30 minutes without 
exposure to sonication or an AMF.  Using magnetic separation 16 was removed and the 
supernatant was collected and retained for fluorescent measurements.  Then, the samples 
of 16 were again suspended in 1.5 mL 2:1 PBS:acetonitrile and were subjected to an 
AMF at 595 amps and 204 kHz with a 5-turn coil for 30 minutes.  The NPs were then 
magnetically separated and the supernatant was collected.  Both samples of the 
supernatant were then analyzed using fluorescent spectrometry, the results of which are 
displayed in Figure 4.17.  The only mystery that remained was an explanation for the 
continued release in the absence of an AMF. 
 
 
Scheme 4.2.  Loading of 14 onto 20-30 nm Fe3O4 NPs and 
Boc-deprotection of 15 under acidic conditions to afford a 
thermally labile linker.  Conditions:  a. (EtO)3SiH, cat. PtO2, 
90 °C; b. Fe3O4, CHCl3, 65 °C; c. i. CF3CO2H : CH2Cl2, 1:1, 
0 °C, 1 h; ii. Et3N : CH2Cl2, 1:1, rt. 
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Figure 4.17.  595 Amp AMF and non-AMF induced release of fluorophore 
from ~7 mg of 16 in 1.5 mL 2:1 PBS:MeCN at pH 7.4.  The AMF-induced 
release is the result of what remained on the NPs following the incubation 
period of 30 minutes at room temperature in 1.5 mL 2:1 PBS:MeCN at pH 
7.4.   
 
4.2.4. AMF vs. Non-AMF Induced Release:  Hydrolysis 
 We began to suspect that the hydrolytic susceptibility of the ester functionality 
might be the culprit responsible for non-triggered release of fluorophore.  To test this 
theory we synthesized three short linkers, one with an ester functionality, one with a more 
hydrolytically stable carbonate functionality and one with an even more hydrolytically 
stable carbamate functionality (Scheme 4.3).  The chemical structure of 17.1-3 was 
confirmed by 13C NMR (Figure 4.18).  Aside from the differences in the carbonyl carbon 
peak, the methylenes α to the carbonyl functionality also distinctly different chemical 
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shifts.  The ester methylenes have a chemical shift of 64.3 ppm and 33.8 ppm with the 
methylene α to the carbonyl being upfield of the methylene adjacent to the ester oxygen.  
The allyl methylene of the carbonate was at 67.4 ppm, upfield of the methylene next to 
the oxygen on the anthracene side of the molecule that was at 68.7 ppm.  The methylene 
beside the carbamate nitrogen had an upfield chemical shift of 43.7 ppm compared to the 
methylene near the oxygen, which had a chemical shift of 64.9 ppm.  In addition to 
increasing the robustness of the carbonyl functionality, we also made several 
experimental adjustments:  (1) the AMF power amperage was reduced from 595 amps to 
200 amps (the frequency was kept at 204 kHz since the coil diameter and number of turns 
dictate this frequency); (2) to begin modeling physiological conditions, we changed the 
control conditions from NPs incubated at room temperature to NPs incubated at 37 °C; 
and (3) we also changed the AMF application protocol from 30 minutes of continuous 
exposure to a pulsed application of AMF consisting of consecutive 5 minute ‘on’ and 5 
minute ‘off’ cycles for a total of 30 minutes of AMF exposure.  The pulsed modification 
in the experimental design allowed for collection of multiple data points needed to 
establish a release profile and provided a procedure that would be more agreeable with a 
biological system.  Figure 4.19 shows the results of the AMF experiments. 
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Scheme 4.3.  Short chain linkers bound to Fe3O4 NPs to test hydrolytic 
stability of ester, carbonate and carbamate functionalities.  Conditions:  a. 
(EtO)3SiH, cat. PtO2, 90 °C; b. Fe3O4, CHCl3, 65 °C. 
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Figure 4.18.  13C NMR spectra (CDCl3) confirming the structures of 17.1-3. 
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Figure 4.19.  200 amp AMF induced release of fluorophore from ~6 
mg of 18.1-3 in 0.75 mL 2:1 PBS:MeCN at pH 7.4.  
 
 The release results from 18.1-3 were quite unexpected.  The ester, the most easily 
hydrolyzed functionality of the panel, showed the lowest rate of release while the more 
robust linkages, carbonate and carbamate, showed higher release rates with the carbonate 
releasing the fastest.  But the release patterns all appeared to be a stepwise release, 
indicating that it could be a result of AMF exposure.  To test this theory we performed 
another experiment, but instead of exposing the NPs 18.1-3 to an AMF we incubated 
them at 37 °C in the 2:1 PBS:acetonitrile solution at pH 7.4 for 20 hours.  This 
experiment would allow us to see if the release was AMF-induced.  Figure 4.20 depicts 
the incubation results. 
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Figure 4.20.  Release of fluorophore from ~6 mg of 18.1-3 in 0.75 mL 2:1 
PBS:MeCN at pH 7.4 incubated at 37 °C for 20 h. 
 
 Incubation of 18.1-3 at 37 °C for 20 hours resulted in a release profile that was 
similar to the one obtained using an AMF.  This result is remarkable — carbonate and 
carbamate functionalities undergoing hydrolysis at pH 7.4 at 37 °C.  This import of this 
finding is put into perspective on comparison with current hydrolytic examples from the 
literature (Scheme 4.4) that show the forcing conditions needed to cleave carbonate and 
carbamate functionalities.  It became obvious that the Fe3O4 NPs must be exerting some 
effect to accelerate the hydrolyses, even in the absence of an AMF. 
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Scheme 4.4.  Examples from current literature of the 
hydrolysis of A. an ester,52 B. a carbonate53 and C. a 
carbamate.54  Conditions:  a. H2O, DMSO, rt, 42 h, 58%; b. 
5 M NaOH, MeOH, rt, 3 d, 90%; c. KOH, N2H4, 
(CH2OMe)2, 200 °C, 80%. 
 
 To attempt to explain the iron oxide NP hydrolysis phenomenon we started to 
investigate the catalytic and physical attributes of iron.  The Fe3O4 NPs are comprised of 
a mixture of both Fe2+ and Fe3+ at a molar ratio of 1:2, respectively.47 Since Fe3O4 is 
readily oxidized to Fe2O3 (Fe3+) when exposed to air, changing the NP color from black 
to an orange/red color, it is not uncommon for the NPs to have an oxidized layer of Fe2O3 
or Fe3+.55  With this in mind, we researched the properties of iron(III) and found that 
iron(III) oxides are a known Lewis acid, thus making them capable of selectively binding 
to Lewis bases (e.g., heteroatoms, particularly carbonyl oxygens).56  The Lewis acid-
Lewis base concept could help explain why the carbonate and carbamate groups were 
hydrolyzed to a greater extent than the ester.  The attribute of both the carbonate and 
carbamate that adds to their hydrolytic stability is the increased electron density supplied 
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to the carbonyl, thus making it less susceptible to nucleophilic attack at the carbonyl 
carbon by water.  As can be seen from Scheme 4.4, the hydrolysis of carbonates and 
carbamates require highly basic reaction conditions and, in the case of the carbamate, 
high temperatures.  These conditions are all methods of enhancing the nucleophilicity of 
water/hydroxyl groups.  But this hydrolytic acceleration can also be achieved with Lewis 
acids that, instead of increasing nucleophilicity, enhance the electrophilicity of the 
carbonyl and allow a weaker nucleophile to attack an otherwise stable functional group.  
This knowledge led us to postulate a possible mechanism for the Fe3O4 NP accelerated 
hydrolysis that is shown in Figure 4.21.  
 
 
Figure 4.21.  Proposed mechanism for Fe3O4 NP accelerated hydrolysis of 
esters, carbonates and carbamates under mild conditions. 
 
4.2.5.  Suppression of Hydrolysis 
 Our attention was now turned to possibly masking the Lewis acidity at the surface 
of the magnetic NPs.  The first approach we tried was to coat the functionalized NPs with 
either the disaccharide D-lactose or the polysaccharide dextran.  The idea in using the 
these substrates was to effectively mask the unfunctionalized portions of magnetic NPs 
Fe3O4
O Si
O O
YO
O H
O
H
Fe3O4
O Si
O O
YO
O OH
Fe3O4
O Si
O O
OH
YCO2
 
 115 
(Scheme 4.5a).  The hydroxyl groups of the carbohydrate or polymer would hydrogen 
bond to the NP surface and prevent the Lewis basic carbonyl oxygen from coordinating 
with the NP surface.  We postulated that application of an AMF would aid in the release 
of the hydrogen bound carbohydrate or polymer, allowing the NP accelerated hydrolysis 
to occur.  The second method of preventing the rapid, non-triggered hydrolysis was to 
coat the unfunctionalized Fe3O4 NPs with a silica shell and then load the linkers onto the 
silica surface (Scheme 4.5b).  Though silica can still serve as a Lewis acid, its acidity, in 
comparison to iron oxides, is far less since its Lewis acid centers are developed only from 
silicon atoms in a strained siloxane bridge.57  In this case the strained covalent bond 
causes the formation of a dipole, thus causing the silicon atom to become electron 
deficient and Lewis acidic.  By using a silica shell around the iron oxide NP we would 
provide a permanent shield to prevent the linkers from interacting with the iron core.  The 
linker-NP bond would also be strengthened and easier to form since we would be seeking 
to form Si–O–Si bonds instead of Fe–O–Si bonds during linker loading.  As was 
previously stated, all Metal–O–Si bonds are inferior to the highly stable Si–O–Si bonds.43  
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Scheme 4.5.  Attempts to mask the iron oxide NP surface.  A: coating the 
functionalized NPs with polysaccharides; B: coating the iron oxide core 
with a silica shell.  Conditions:  a. D-lactose or dextran (6 kd); b. tetraethyl 
orthosilicate, NH4OH, EtOH, H2O; c. i. 17.2, (EtO)3SiH, cat. PtO2, 90 °C, 
ii. add alkoxysilane to NPs. 
 
 The 37 °C incubation experiment was repeated to compare the release rate of 18.2 
with that of 19.1-2 and 20 and to see if we were able to effectively minimize non-AMF 
induced hydrolysis.  As can be seen from Figure 4.22, the polysaccharides did slightly 
reduce the rate of hydrolysis with 19.2 being more effective.  Since the vast majority of 
the non-AMF induced hydrolysis occurred soon after the incubation began, Figure 4.22 
has focused only on the first 2 hours of incubation.  This was especially true at the 
beginning of the experiment but the lack of a covalent bond resulted in a large amount of 
the mask dissociating from the NP surface.  The silica shell of 20 greatly increased the 
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hydrolytic stability of the linker.  We continued all further experiments with SiO2@Fe3O4 
NPs. 
 
 
Figure 4.22.  Non-triggered (i.e., no AMF application) hydrolysis of ~7 
mg 18.2 compared with the suppressed hydrolysis of 19.1-2 and 20 at 37 
°C in 2:1 PBS:MeCN pH 7.4. 
 
4.2.6. Commencement of SiO2@Fe3O4 NPs 
 With non-AMF induced hydrolysis sufficiently minimized, we returned to the 
investigation of AMF-induced intramolecular cyclization.  Using the kinetic study 
discussed in Chapter 3 (Figure 3.11 and Table 3.2), we selected 9 as the optimal linker.  It 
afforded thermal stability over short periods of time at 55 °C while remaining thermally 
responsive over extended intervals.  Consequently, we set out to evaluate the feasibility 
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of AMF-mediated oxazolidinone formation as a mechanism for drug release by 
covalently attaching 9 to SiO2@Fe3O4 NPs (Scheme 4.6).    
 
 
Scheme 4.6.  Synthesis of NP-carbonate linker conjugates 
with anthracenyl fluorophore (Ar = 9-anthracenyl).  
Conditions: a. (EtO)3SiH, cat. PtO2, 90 °C; b. SiO2@Fe3O4, 
EtOH, H2O; c.  i. CF3CO2H : CH2Cl2, 1:1, 0 °C, 1 h; ii. 
Et3N : CH2Cl2, 1:1, rt. 
 
 After adding the alkoxysilane to 9 through the PtO2-catalyzed hydrosilylation 
described by Sabourault et al.58 the linker was bound to SiO2@Fe3O4 NPs.  The Boc 
group was once again cleaved by treatment with trifluoroacetic acid followed by 
neutralization with triethylamine to afford 22 with the unmasked nucleophilic amine 
needed for the AMF-induced intramolecular cyclization.59  The success of the Boc-
deprotection could be qualitatively observed by the formation of a white cloud when the 
1:1 triethylamine:CH2Cl2 solution was added to the coated NPs.  The basic solution was 
added after the removal of excess TFA with five washes of CH2Cl2.  
 A suspension of the free-amine NPs 22 in a 2:1 mixture of PBS:acetonitrile (pH 
adjusted to 7.4) at room temperature was sequentially pulsed with an AMF for six 5- 
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minute bursts with a delay time of 5 minutes between pulses.  Magnetic-assisted 
sedimentation of the NPs allowed facile measurement of supernatant fluorescence at the 
end of each pulse (Figure 4.23).  To confirm that we were releasing only the 2-(9-
anthracenyl)ethanol and not another fragment we analyzed the 2:1 PBS:acetonitrile 
supernatant that was used to suspend 22 during AMF exposure using matrix-assisted laser 
desorption ionization (MALDI) time of flight (TOF) mass spectrometry (MS) (Figure 
4.24).  The data show an AMF-promoted release of 2-(9-anthracenyl)ethanol (Figure 
4.25) presumably as a consequence of the expected amine addition to the proximal 
carbonate moiety.  
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Figure 4.23.  AMF-induced release of anthracene fluorophore from NPs 
21 (red) and 22 (blue).  NPs (6-8 mg) suspended in 2:1 PBS:acetonitrile 
(0.75 mL) at pH 7.4 were irradiated with an AMF (501.6 amps, 204 kHz) 
for 5-minute bursts followed by 5-minute intervals.  Vertical axis shows 
fluorescence intensity normalized to mmol of bound anthracene 
fluorophore as determined by thermogravimetric analysis. 
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Figure 4.24.  Procedure used to obtain sample for MALDI-TOF 
analysis and verification of released substrate.   
 
 
Figure 4.25.  MALDI-TOF spectrum using a 2,5-
dihydroxybenzoic acid matrix of the radical carbocation60 2-(9-
anthracenyl)ethanol released from 22.  The sample was acquired 
from the 2:1 PBS:acetonitrile supernatant used during the AMF 
treatment of 22. 
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 To test the proposed mechanism of substrate release, we examined the Boc-
protected NPs 21, which would be incapable of undergoing the postulated intramolecular 
cyclization, under identical conditions.  To our surprise, fluorophore release from 21 also 
occurred in response to AMF irradiation, albeit at a rate slower than the free amine 
formulation (Figure 4.23).  This result pointed toward enhanced hydrolysis as a function 
of the energy deposited by AMF irradiation.  Despite the reduced Lewis acidity of the 
SiO2@Fe3O4 NPs, the significant, rapid heating within nanometers of an iron oxide NP 
surface could still explain this phenomenon.61  On examination of the stability of NPs 21 
under the same conditions but without AMF irradiation, we noted the gradual release of 
2-(anthracen-9-yl)ethan-1-ol over an hour at 37 °C to ~50% of the cumulative level 
achieved by the six 5-minute bursts of AMF irradiation.  This finding, while precluding 
the use of 21 (or 22) as a drug delivery system, is noteworthy because dialkylcarbonates 
are stable to such mild conditions and generally require highly basic conditions for their 
hydrolysis (e.g., 5M NaOH, MeOH, rt, 3d53).  As a control, exposure of free carbonate 9 
(Scheme 4.6) to SiO2@Fe3O4 NPs in 2:1 phosphate buffer solution (PBS):acetonitrile at 
37 °C resulted in no reaction, even after 24 h exposure.  Consequently, we surmised that 
the close proximity and tethered relationship of the carbonate linkage in 21 to the iron 
oxide core and silica shell enhance, possibly through Lewis acid or hydrogen bonding 
interactions, respectively, the rate of hydrolysis of this linkage.  This reasoning supports 
the previously postulated mechanism (Figure 4.21). 
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4.2.7.  Monodispersed SiO2@Fe3O4 Nanoparticles 
 To gain a better understanding of 21, we had Dr. Jacek Jasinski (Conn Center for 
Renewable Energy, University of Louisville) obtain transmission electron microscopy 
(TEM) images.  As can be seen from the High Angle Annular Dark Field (HAADF) 
scanning transmission electron microscopy (STEM) images in Figure 4.26, the iron oxide 
NPs are largely aggregated and the silica shell is visible (a somewhat cloudy 
surrounding) at the outer perimeter of each iron cluster.  Iron oxide NPs are notorious for 
aggregating due to their anisotropic dipolar attraction.62  The most popular method of 
internalization of NPs into cells is through endocytosis. 63   For clathrin-mediated 
endocytosis, the NPs can be up to 100 nm in diameter and for caveolae mediated 
endocytosis the diameter can be no greater than 60-80 nm.64  As is evident, the mandates 
of endocytosis make NP aggregation an undesirable attribute for drug delivery.   
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Figure 4.26.  HAADF Z-contrast STEM image of 
aggregated Fe3O4 NPs with a thick silica shell surrounding 
them. 
 
 To prevent the aggregation the Fe3O4 NPs, a surfactant must immediately be 
applied to the surface of the NP.  One of the most common surfactants used in the 
synthesis of mondispersed Fe3O4 NPs is oleic acid or its sodiated derivative.  Following a 
two-step route described by Park et al.65 we synthesized oleate-coated Fe3O4 NPs via 
high-temperature (320 °C) decomposition of the organic precursor that was generated in 
situ.  Fe3O4-oleate NPs can also be prepared through a co-precipitation method as 
reported by Jiang et al.66  After obtaining the magnetic NPs we attempted to add the silica 
shell to the surface. Silica shells are usually added to iron oxide NPs using the Stöber 
process,50 but the presence of the oleate surfactant prevented the NPs from being 
dispersible in the standard ethanol/water mixture.  To circumvent this issue using 
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microemulsion, Ding and coworkers67 suspended the Fe3O4-oleate NPs in cyclohexane 
that was basified with NH4OH.  Using another surfactant, Igepal CO-520, the oleate 
surfactant is removed and replaced by the Igepal CO-520.  This surfactant exchange 
allows the ammonia, in the form a droplet containing the hydrolyzed tetraethyl 
orthosilicate (TEOS), to draw near to the NP and deposit the silica onto the NP surface 
(Scheme 4.7).  Though similar methods using Igepal CO-520 are frequently reported,68 
we found the collection of the SiO2@Fe3O4 NPs to be very difficult.  Magnetic separation 
cannot be used and centrifugation causes both the NPs and the surfactant to form a gelled 
pellet, resulting in an unusable paste.  When the Stöber process was attempted with the 
Fe3O4-oleate NPs there was rampant aggregation resulting in particles with a 
hydrodynamic diameter of 2065.2 ± 284.6 nm. 
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Scheme 4.7.  Illustration of the microemulsion coating mechanism of SiO2 
on the surface of Fe3O4-oleate NPs.67  
 
 We also investigated the use of hydrophilic surfactants.  Jing et al.69 used iron(II) 
sulfate in an oxidative coprecipitation synthesis of Fe3O4 NPs.  Briefly, FeSO4•7H2O and 
sodium citrate were co-added to an aqueous solution of sodium nitrate and potassium 
hydroxide.  The solution was heated to 90 °C for 5 h under an inert atmosphere before 
cooling to room temperature and precipitating the NPs from solution with acetone.  The 
NPs could then be easily collected by magnetic separation.  These NPs, though easy to 
suspend in water, still showed signs of aggregation with a hydrodynamic diameter of 
294.8 ± 11.7 nm.  When the silica shell was added to the Fe3O4-citrate NPs the 
hydrodynamic diameter increased to 453.8 ± 8.8 nm. 
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 We then looked into the use of commercial ferrofluid containing Fe3O4 NPs (EMG 
304, FerroTec).  We chose a procedure reported by Lu and coworkers62 due to its rapid 
application (3 hours) of a thin silica shell around Fe3O4 NPs.  As mentioned previously, 
as the thickness of the silica shell increases there is a sharp reduction in the magnetism of 
the NP.49  This reduction in magnetism decreases the AMF-induced energy and could 
potentially eliminate our ability to activate thermally-induced reactions.  The dynamic 
light scattering (DLS) measurements showed a hydrodynamic diameter of 310 ± 3.7 nm 
with a polydispersity of 0.23 ± 0.01 (Figure 4.27).  The ζ-Potential of the SiO2@Fe3O4 
NPs was -19.50 ± 9.12 mV with a mobility of -0.39 ± 0.18.  Though the DLS 
measurements still showed two distinct sizes of NPs with a larger than desired diameters 
we proceeded to obtain TEM images because Lu et al.62 had also used EMG 304 
ferrofluid to create their SiO2@Fe3O4 NPs.  The TEM (Figure 4.28) show a very thin 
silica shell but there is large-scale aggregation as well. 
 
 
Figure 4.27.  DLS of SiO2@Fe3O4 NPs in EtOH showing the 
hydrodynamic diameter at 310 nm with a polydispersity of 0.23. 
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Figure 4.28.  TEM image of SiO2@Fe3O4 NPs synthesized 
from EMG 304 showing excessive aggregation. 
 
 Because we were unable to reproduce the results of Lu et al.,62 we moved to a 
modified version of the Stöber process as reported by Pinho et al.70  This procedure was 
especially attractive as it included an equation, that allowed for the thickness of the silica 
shell to be adjusted by varying the amount of TEOS.  Using the volume of TEOS needed 
to afford a 4 nm thick silica shell, Fe3O4 NPs in the EMG 304 ferrofluid with a reported 
average diameter of 10 nm were silylated to form monodispersed superparamagnetic 
(Figure 4.29) SiO2@Fe3O4 NPs with a particle size distribution of 24 ± 6 nm and a silica 
shell thickness of 6-7 nm, as determined by TEM (Figure 4.30).  The monodispersed 
SiO2@Fe3O4 NPs had a ζ-Potential of -46.58 ± 0.47 mV and a mobility of -3.64 ± 0.04 in 
Millipore water.  The DLS measurements (Figure 4.31) showed a hydrodynamic diameter 
of 103 nm and a polydispersity of 0.17. 
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!!"#$ = !!"#$
!!"#!!!"#$
!!"#!!!"#$
4
3!((! + !!!!"")
! − !!)  
Equation 4.1.  Equation used to calculate the volume of TEOS 
required to obtain a silica shell of a desired thickness, where !!"#$ 
is the volume of TEOS required, !!"#$ is the number of Fe3O4 NPs 
to be coated, !!"#! is the density of silica, !!"#$ is the molecular 
weight of TEOS, !!"#! is the molecular weight of silica, !!"#$ is 
the density of TEOS, ! is the average radius of the Fe3O4 NPs, and 
!!!!"" is the desired thickness of the silica shell. 
 
 
 
Figure 4.29.  Superconducting quantum interference device (SQUID) 
measurement of SiO2@Fe3O4 NPs prepared from EMG 304.  
Measurements were taken at temperatures from 2 to 400 K and 
magnetization data was taken by cycling from -5 T to 5 T.  SQUID 
measurements were taken by Professor Lance DeLong, University of 
Kentucky. 
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Figure 4.30.  A. TEM image of SiO2@Fe3O4 NPs 
synthesized from EMG 304 with a B. particle size 
distribution of 24 ± 6 nm and a silica shell thickness of 6-7 
nm. 
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Figure 4.31.  DLS of SiO2@Fe3O4 NPs in Millipore water showing the 
hydrodynamic diameter at 103 nm with a polydispersity of 0.17. 
 
 When the monodispersed SiO2@Fe3O4 NPs with a 10 nm Fe3O4 core and a 6-7 nm 
thick silica shell were subjected to pulsed AMF irradiation at a concentration of 7 mg of 
NPs in 2:1 PBS:acetonitrile (0.75 mL), the temperature of the bulk suspension, as 
confirmed by measurements taken using a fiber optic temperature sensor, increased +16.4 
± 0.3 °C from the start of the AMF pulse to the end of the AMF pulse and increased +4 
°C from start of the first pulse to the start of the sixth pulse (Figure 4.32). 
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Figure 4.32.  AMF-induced heating/cooling of 2:1 
PBS:acetonitrile (0.75 mL) (blue), SiO2@Fe3O4 NPs (7 mg) in 
2:1 PBS:acetonitrile (0.75 mL) (red), AMF 5 min on/off 
sequence (green).  A. 5 minute pulse duration and B. 2 minute 
pulse duration.  AMF conditions:  500 amps, 204 kHz. 
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4.2.8. AMF-Induced Hydrolysis 
 
Figure 4.33.  AMF-triggered hydrolysis of pendant 
functionality (FL = anthracene fluorophore, •; carbamate 
moiety, n; terminal amine residue, n). 
 
 Since we were still observing significant AMF-induced hydrolysis (Figure 4.23, 21) 
and continuing to lose ~50% of the NP loading during Boc-deprotection, we decided to 
embrace the observed AMF-induced hydrolysis.  As depicted graphically in Figure 4.33, 
we engineered a new linker by first removing the nucleophilic element and, second, we 
replaced the carbonate moiety with an N-methyl carbamate linkage in order to effectively 
increase the hydrolytic stability of the carbonyl (Scheme 4.8).  Even unsubstituted 
carbamates are extremely resistant to hydrolysis and typically require treatment with base 
under forcing conditions for cleavage (e.g., KOH, diglyme, 200 °C).54  We also adopted a 
strategy for convenient attachment of substrate to the simplified carbamate-linked NPs, 
namely oximation (Schemes 4.8 and 4.9).  We71 and others72 have used the click 
chemistry reaction73 of NP-bound aminooxy groups with aldehydes to form oxime ethers 
as a convenient means for surface functionalization.  Any newly formed oxime ether 
linkage would be sufficiently resistant to hydrolysis and thereby decrease the risk of a 
non-AMF induced release.74  
RNH@SiO2@Fe3O4
Fe3O4 core
SiO2 shell
FL@SiO2@Fe3O4
(AMF)
H2O
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Scheme 4.8.  Synthesis of linkers for substrate release via AMF-induced 
hydrolysis.  Conditions: a. TBSCl, Et3N, CH2Cl2, 0 °C; b. 1,1’-
carbonyldiimidazole, (i-Pr)2NEt, CH2Cl2, 0 °C; c. DBU, MeCN, rt, 79% 
over 3 steps; d. TBAF, THF, 0 °C; e. MsCl, Et3N, CH2Cl2, 0 °C; f. N-
hydroxyphthalimide, K2CO3, DMSO, 75 °C, 71% over 3 steps; g. 
N2H4•H2O, CH2Cl2, 0 °C, 96%. 
 
 After preparing the SiO2@Fe3O4 NPs, the residual ammonia from the Stöber 
process was removed prior to NP functionalization by placing the ethanol/water 
suspension of SiO2@Fe3O4 NPs under mild vacuum and then heating at 60 °C for 8h.  
Removal of the ammonia in this way decreased the pH of the suspension from 11.7 to 
8.8.  The resultant SiO2@Fe3O4 NPs then were functionalized by adding an ethanolic 
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solution of the triethoxysilane-derived linker obtained from PtO2-catalyzed 75 
hydrosilylation of alkene 23 with (EtO)3SiH to obtain 24 (Scheme 4.9).  
 
 
Scheme 4.9.  Linkers designed for release via AMF-induced hydrolysis 
bound to SiO2@Fe3O4 NPs.  Conditions:  a. (EtO)3SiH, cat. PtO2, 90 °C; 
b. SiO2@Fe3O4, EtOH, H2O, rt, 12 h, c. 2-(9-anthryl)acetaldehyde,76 (26), 
EtOH, H2O, rt, 8 h. 
 
 The functionalization of the SiO2@Fe3O4 NPs with hydrosilylated 23 increased the 
shell thickness by ~3 nm to afford AO@SiO2@Fe3O4 NPs with a diameter of 30 ± 8 nm 
as determined by TEM (Figure 4.34).  The hydrodynamic diameter of aqueous 
AO@SiO2@Fe3O4 NPs was measured at 96 nm with a polydispersity of 0.16, roughly 
similar to the hydrodynamic diameter of the starting SiO2@Fe3O4 NPs at 103 nm with a 
polydispersity of 0.17 (Figure 4.35).  We also observed little change in ζ-potential, where 
both the SiO2@Fe3O4 and AO@SiO2@Fe3O4 NPs registered ca. – 45 mV as aqueous 
suspensions.  Simple mixing of AO@SiO2@Fe3O4 with anthracene aldehyde 26 (Scheme 
4.9) in aqueous ethanol gave NPs 25 (FL@SiO2@Fe3O4).  In an alternate approach, we 
conducted the oximation step first by reacting anthracene aldehyde 26 with 23 (Scheme 
4.9) followed by hydrosilylation of the oxime ether adduct and then loading onto 
SiO2@Fe3O4 NPs to obtain 25. 
24: Y = ONH2  (AO@SiO2@Fe3O4)
25: Y = ON=CHCH2Ar  (FL@SiO2@Fe3O4)
c
a, b
O SiN O
O
O NH2 N O
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Figure 4.34.  A. TEM image of AO@SiO2@Fe3O4 NPs 
with a B. particle size distribution (30.4 ± 0.8 nm) resulting 
in a ~3 nm increase in the NP radius. 
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Figure 4.35.  DLS of AO@SiO2@Fe3O4 NPs in Millipore water showing 
the hydrodynamic diameter at 96 nm with a polydispersity of 0.16. 
 
 With the FL@SiO2@Fe3O4 NPs in hand, we studied the AMF-induced hydrolysis 
of the carbamate linkage by measuring the release of anthracene oxime ether fragment 27 
(Scheme 4.10).  The AMF experiments were conducted as described above (2:1 
PBS:acetonitrile solution, pH 7.4).  As can be seen in Figure 4.36, AMF irradiation 
stimulated a rapid release of substrate from FL@SiO2@Fe3O4.  MALDI-TOF analysis 
confirmed that the oxime ether-anthracene fragment 27 was liberated from the NP 
formulation on AMF irradiation (Figure 4.37).  Based on fluorescent measurements, 40 
minutes of AMF exposure resulted in 67 ± 3% of payload release; longer exposure times 
did not release additional 27.   We also tested different currents by subjecting the NPs to 
100 amps and 300 amps and compared the release with the results from the previous 
experiment (Figure 4.38).  In addition, we also varied the duration of each AMF pulse 
from 5-minute on/off pulses to 2-minute on/off pulse with a total AMF exposure time of 
40 minutes for both samples.  As can be seen in Figure 4.39, the release of 27 is 
controlled by total AMF exposure time and not by the duration of the pulsing sequence. 
We were also gratified to find that the switch from carbonate to carbamate dramatically 
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reduced non-AMF release of substrate — less than 10% of the payload was released at 37 
°C after 40 minutes.  The rapid release of the fluorophore fragment on AMF application 
is quite remarkable in that N,N-dialkyl carbamates are not expected to cleave under these 
mild conditions (e.g., a previous kinetic study estimates a typical half-life of >550 years 
at 25 °C and pH 7).77 
  
 
 
Scheme 4.10.  AMF-induced carbamate hydrolysis. 
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Figure 4.36.  AMF-induced release of 27 from 
FL@SiO2@Fe3O4 (blue): NPs in PBS:acetonitrile were 
irradiated with an AMF (501.6 amps, 204 kHz) for 5-
minute bursts followed by 5-minute intervals; release of 27 
from FL@SiO2@Fe3O4 (red): NPs in PBS:acetonitrile were 
incubated at 37 °C for the indicated time.  Vertical axis 
shows the percent of 27 released as determined by 
fluorescent measurements; n = 3.  
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Figure 4.37.  MALDI-TOF spectra of the radical carbocation60 of the 
anthracynyl oxime ether of 23 (bottom, green) and 27 (top, blue) after AMF-
induced hydrolysis and release from FL@SiO2@Fe3O4 NPs (25).  The 
MALDI-TOF analysis of the anthracenyl oxime ether of 23 shows that the 
appearance of 27 is not a result of fragmentation during MS analysis.  
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Figure 4.38.  AMF-induced release, as determined by 
fluorescence measurements, of 27 from FL@SiO2@Fe3O4 
NPs in 2:1 PBS:acetonitrile at AMF amperages of 100.7 
(n=1), 300.2 (n=1) or 501.6 (n=3).  The control, incubated at 
37 °C for the indicated time, received no AMF pulses.   
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Figure 4.39.  AMF-induced release of 27 from 
FL@SiO2@Fe3O4 NPs during 2 minute (n=1) or 5 minute 
(n=3) AMF pulses at 501.6 amps versus incubation at 37 °C.   
  
4.3. CONCLUSION. 
 The use of a thermally susceptible bond, such as in the azo system recently 
disclosed by Riedinger et al.,61 enables several possibilities for controlled drug delivery 
from iron oxide NPs when using an AMF as an external stimulus.  In the present study, 
we have observed the AMF-stimulated release of fluorescent substrates from short-chain 
carbonate- and carbamate-based linkers covalently attached to magnetic iron oxide–silica, 
core–shell NPs.  Although the mode of catalysis for the cleavage of the carbonate and 
carbamate functional groups is unclear at this time, AMF-induction, likely through 
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accompanying local hyperthermia, dramatically enhances hydrolyses of these otherwise 
highly stable chemical linkages.  This first example of an AMF-induced hydrolysis of a 
carbamate linkage may find utility in the development of externally triggerable delivery 
systems.  In particular, the ease of carbamate synthesis, especially in the context of 
conjugating substrates to NPs, and the lower hydrolytic susceptibility of the N,N-dialkyl 
carbamate linkage in the absence of AMF exposure combine to make AMF-mediated 
functional group hydrolysis a promising strategy for regulated nanoparticle delivery of 
substrates. 
 
4.4. FUTURE DIRECTIONS. 
 It is still unclear why the release of the fluorophore always stops at approximately 
65%.  As was stated by Riedinger et al.,61 the energy produced by the iron oxide NPs in 
the presence of an AMF dissipates rapidly as the distance from the NP core is increased.  
We suspect that the remaining ~35% of the loading that does not release is too far away 
from the iron oxide core to induce the accelerated hydrolysis.  This hypothesis is quite 
reasonable in that the alkoxysilane can undergo self-condensation, or polymerization, 
prior to being attached to the NP surface.  This theory could be tested by incorporating 
poly(ethyleneglycol) (PEG) chains of varying length into the linker between the NP and 
the carbonyl functionality.  Modification of the linker with PEG would increase the 
distance of the carbonyl from the NP and help to determine at what distance the 
hydrolytic phenomenon ceases.  Elucidation of the reaction mechanism of the enhanced 
hydrolysis would also supply much needed information to further explain this surprising 
reaction. 
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 To advance this research to the next level, i.e., in vivo studies, we have partnered 
with Dr. Ralf Schirrmacher, a research scientist in Oncology at the University of Alberta 
Medical Isotope & Cyclotron facility.  Together with his post doctoral student Dr. Jun 
Zhu, they obtained gold coated Fe3O4 NPs using a procedure outlined in Scheme 4.11.  
Figure 4.40 shows the TEM image of the Au@Fe3O4 NPs and Figure 4.41 are the SQUID 
measurements showing superparamagnetism. 
 
 
Scheme 4.11.  Synthesis of Au@Fe3O4 NPs. 
 
 
Figure 4.40.  TEM image of Au@Fe3O4 NPs. 
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Figure 4.41.  SQUID measuments of Au@Fe3O4 NPs 
showing superparamagnetism. 
 
 To allow for covalent binding of our linkers to the surface of the Au@Fe3O4 NPs 
we replaced the unsaturation with a protected thiol (Scheme 4.12).  Gold is a very 
attractive surface because it allows for easy covalent attachment of the linker to the NP 
through the Au–S bond and is known to have very good biocompatibility.78  
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Scheme 4.12.  Synthesis of carbonate linker 28 for attachment to 
Au@Fe3O4 NPs.  Conditions:  a. TBSCl, Et3N, CH2Cl2, 0 °C, 17 h; b. 
MsCl, Et3N, CH2Cl2, 0 °C, 1.5 h; c. phthalimide, K2CO3, DMSO, 75 °C, 
18 h; d. N2H4•H2O, 1:2 EtOH:CH2Cl2, 20 h; e. 1,2-dibromoethane, 
K2CO3,THF, reflux, 24 h, 98%; f. MeCN, 55 °C, 24 h, 82%; g. Boc2O, 
Et3N, CH2Cl2, 0 °C, 2 h; h. 1 M TBAF in THF, THF, 0 °C, 20 h, 62%; i. 
1,1-carbonyldiimidazole, (i-Pr)NEt, CH2Cl2, 0 °C, j. 2-bromoethanol, 
AcONa, DMSO, 70 °C, 67%; k. DBU, MeCN, 18 h, 55%; l. N2H4•H2O, 
CH2Cl2, 0 °C, 92%. 
 
 By transitioning from SiO2@Fe3O4 NPs to Au@Fe3O4 NPs we suspect that 
hydrolysis will no longer occur.  This hypothesis is based on the elimination of the Lewis 
acidic iron oxide surface.  In the absence of hydrolysis we have resorted back to 
intramolecular cyclization as a release mechanism.  Another problem that we had 
previously faced was the loss of ~50% of the NP loading during the acidic Boc-
deprotection when performed on the functionalized NPs.  By using a thiol attachment and 
careful choice of protecting groups we have circumvented this issue.  Standard Boc-
deprotection usually involves a reaction with trifluoroacetic acid.  These acidic conditions 
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will also cleave the trityl thiol-protecting group.  After performing the dual acidic 
deprotection, the Au@Fe3O4 NPs can be loaded without the risk of premature 
intramolecular cyclization.  Leaving the linker in the form of an aminium salt prevents 
nucleophilic attack of the carbonyl by the amine.  After the Au@Fe3O4 NPs are 
functionalized, a base wash restores the nucleophilic amine, thus enabling intramolecular 
cyclization. 
 My laboratory co-worker, Ms. Sara Biladeau, is currently attaching the aldehyde 
functionalized fluorophore 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) 79 
through the oximation reaction and loading the linkers onto the Au@Fe3O4 NPs.   
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5.1. GENERAL STATEMENT 
All solvents and reagents used in this thesis were reagent grade and were used as received 
unless otherwise indicated.  Dry THF and CH2Cl2 were obtained from SPBT-101 Bench 
Top Solvent Purification System (LC Technology Solutions, Inc., USA).  Anhydrous 
DMF was purchased from Sigma-Aldrich.  Dry acetonitrile was obtained by distillation 
from CaH2.  Unless otherwise noted, all reagents were purchased from commercial 
suppliers and were used without further purification. The progress of reactions was 
monitored by thin-layer chromatography (TLC) using pre-coated silica plates (EMD 
Silica Gel 60 F254). Visualization was accomplished by staining the plates with iodine, 
PMA (3% phosphomolybdic acid/ethanol solution), PAA stain (2.5% p-anisaldehyde 
acid/ethanol solution) or ninhydrin stain (10 g ninhydrin in 100mL of n-butanol and add 3 
mL AcOH).  UV active compounds were visualized by UV light (254 nm).  Silica gel 60 
(230-400 mesh) was used for flash column chromatography.  1H NMR spectra were 
recorded at 400, 500 or 700 MHz, and 13C spectra were recorded at 100, 125 or 175 
MHz, respectively, in the indicated solvents. The chemical shifts are reported in ppm 
values relative to the solvent residual peak CDCl3 (7.26 ppm for 1H NMR and 77.23 ppm 
for 13C NMR), DMSO-d6 (2.50 ppm for 1H NMR and 39.52 ppm for 13C NMR), CD3OD 
(3.31 ppm for 1H NMR and 49.00 ppm for 13C NMR) or toluene-d8 (2.08 ppm for 1H 
NMR and 20.43 ppm for 13C NMR).  Coupling constants are reported in hertz (Hz).  High 
resolution ESI-MS were obtained using a FT-ICR-MS system (LTQ FT, Thermo Electron 
Corp.) at the Center for Regulatory and Environmental Analytical Metabolomics 
(CREAM) Mass Spectrometry Facility, University of Louisville, Kentucky.  Fluorescent 
measurements were taken on a Molecular Devices SpectraMax M5 in fluorescent mode at 
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an excitation of 366 nm and emission wavelength of 408 nm.  The fluorescent 
measurements were taken using a quartz semi-micro VWR Spectrosil spectrophotometer 
cell with a 10 mm light path.  Transmission electron microscopy (TEM) was used to 
analyze size distribution and morphology of fabricated nanoparticles, including 
uniformity and thickness of silica coating.  For this, ethanol-based nanoparticle 
dispersions were prepared and drop-casted on commercially available 300 mesh TEM 
support Cu grids coated with ultra thin carbon films.  After ethanol evaporation, samples 
were transferred to and analyzed using a field emission gun FEI Tecnaci F20 
transmission electron microscope operating at the accelerating voltage of 200 kV.  TGA 
measurements were made on a TA Insruments Hi-Res TGA 2950 Thermogravi-metric 
Analyzer using a Pt basket and maintaining a flow of N2 gas through the oven.  Each 
TGA experiment was run from 35 °C to 800 °C at a ramp rate of 20 °C/min.  DLS and ζ-
potential measurements were taken using a Brookhaven Instruments 90Plus Particle Size 
Analyzer.  All measurements were taken using aqueous colloids of the nanoparticles in 
Millipore water.  The alternating magnetic field (AMF) was generated with an Ambrell 
EasyHeat L1 set at 501.6 amps and 204 kHz using a 5-turn coil.  MALDI-TOF analysis 
was done on a Voyager DE-Pro MALDI-TOF instrument (PE Biosystems).  Spectra were 
acquired in positive reflectron mode and calibration was achieved by using known peaks 
from the 2,5-dihydroxybenzoic acid (2,5-DHB) matrix.  Data was analyzed with mMASS 
data analysis software.     
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5.2. EXPERIMENTAL PROCEDURES FROM CHAPTER 2 
5.2.1. Open- and Closed-Chip Microreactor Fabrication     
 Dr. Xiao-An Fu’s research group designed and fabricated the open-chip 
microreactor in a way that mirrored the microelectromechanical system procedures 
described previously. 1 , 2 , 3   Deep reactive ion etching (DRIE) was used to create 
microfluidic channels and micropillars with a height of roughly 250 µm on a silicon 
wafer.  The microreactor channels and micropillars were thermally oxidized to form a 50 
nm SiO2 thin film in an O2 and H2O atmosphere.  The silicon microreactors have a 7 x 5 
mm microfluidic channel consisting of over 2500 micropillars with a surface area of 
about 130 mm2.  
 The open-chip microreactors were completed by directly dicing the silicon wafer 
after the thermal oxidation process.  The microreactors were functionalized with AMAH 
by placing the chip into a 20 mL clean-air sampling vial.  Then, a solution of AMAH 
(140 µg, 7.67 × 10-7 mol) dissolved in methanol (20 µL) was added into the microfluidic 
channel of the chip.  The vial was put into an oven and dried for 5 minutes at 85 °C.  
 Closed-chip microreactors were prepared by bonding the wafer-supported 
microreactors with a Pyrex glass wafer using an anodic wafer bonding process.  Each 
wafer was subsequently diced, and the connection ports were opened for connecting 
fused silica tubes to the microreactors.  The surface of the micropillars in the closed-chip 
was functionalized with AMAH by infusing a solution of AMAH (67 µg, 3.65 × 10−7 
mol) in methanol (15 µL) into the microreactors followed by evaporation of the solvent 
under vacuum.  Finally, fused silica tubes with 190 µm o.d. and 100 µm i.d. were 
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connected to the inlet and outlet ports of the microreactor, respectfully, with a silica-
based bonding agent. 
 
5.2.2. Open-Chip Sample Collection 
 To test the open chip for capture of trace carbonyl compounds, exhaled breath 
samples were collected.  After approval by the Internal Review Board of the institution 
and after having obtained written informed consent, exhaled breath samples were 
collected from healthy never-smokers, current smokers and lung cancer patients.  To 
collect a breath sample, the subject used a straw to blow into the sampling vial containing 
the open-chip for 15 minutes.  During this process, the carbonyl compounds in the 
exhaled breath react with the AMAH coating and are retained in the microreactor while 
the rest of the breath sample moves freely away and out of the sampling vial.  After the 
subject had finished blowing, methanol (10 µL) was added into the microfluidic channel 
to dissolve the analytes.  The methanol solution was then removed from the microreactor 
using a pipette.  This process was repeated four more times to collect an approximate 
total of 50 µL of a methanol-analyte mixture for analysis.  
 
5.2.3. Determination of AMAH Capture Efficiency   
 To test the microreactor for capturing trace levels of carbonyl compounds, a 
solution of acetaldehyde, acetone or 2-butanone in methanol (7.67 × 10−7 to 7.67 × 10−10 
mol) was injected to a 1 liter air Tedlar bag.  The vapor-filled Tedlar bag then was 
connected to the preconcentration setup as shown in Figure 2.2 before a vacuum pump 
was used to pull the gaseous vapor from the Tedlar bag through the closed microreactor 
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at a flow rate of 3.5 mL/min.  The microreactor then was disconnected from the system 
after the air sample in the bag had been completely evacuated. 
 The reacted AMAH adduct and unreacted AMAH were eluted from the closed 
microreactor by flowing 100 µL methanol from one slightly pressurized vial through the 
microreactor, and into an empty collecting sample vial.  An internal reference for FT-
ICR-MS analysis was established by adding a solution of 1.53 × 10−8 mol of AMAH-
acetone-d6 adduct in methanol to each sample of eluent.  The resulting solutions were 
directly injected into the FT-ICR-MS for analysis without any further process. 
 
5.2.4. FT-ICR-MS Instrumentation  
 The methanol-eluted mixtures of AMAH–VOC adducts were analyzed on a hybrid 
linear ion trap- FT-ICR-MS instrument (Finnigan LTQ-FT, Thermo Electron, Bremen, 
Germany) equipped with a TriVersa NanoMate ion source (Advion BioSciences, Ithaca, 
NY) with an electrospray chip (nozzle inner diameter 5.5 µm).  The TriVersa NanoMate 
was operated in positive ion mode by applying 2.0 kV with no head pressure.  Initially, 
low-resolution MS scans were acquired for 1 min to ensure the stability of ionization, 
after which high mass accuracy data were collected using the FT-ICR analyzer where MS 
scans were acquired for 8.5 min and at the target mass resolution of 100,000 at 800 m/z.  
AMAH and AMAH-adduct species were assigned on the basis of their accurate mass by 
first applying a small (typically <0.0005) linear correction based on the observed mass of 
the internal standard. 
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5.2.5. GC-MS Instrumentation 
 A Thermo Scientific GC/MS instrument equipped with an AI 1310 automatic 
sampler, a TRACE 1310 GC with a split/splitless injector and an ITQ 1100 series iron 
trap MS was used for analysis.  The GC was fitted with an Agilent J&W DB-17ms 
column (30 m × 0.25 mm × 0.25µm film thickness).  The carrier helium flow rate was set 
to 1.5 mL/min.  The injection port temperature was set to 280 °C and the initial column 
temperature was 50 °C for 1 minute, with a 12 °C/min ramp up to 290 °C and was held at 
290 °C for 5 minutes.  The total running time was 26 minutes.  The samples were split 
injected with split flow 15 ml/min and split ratio of 10.  
 Carbonyl adduct standards for retention time determination were prepared by 
individually reacting excess AMA (5.1×10-7 mol) with commercially available aldehydes 
or ketones (3.5×10-7 mol) in a 1:1 mixture of acetonitrile:MTBSTFA (v/v) (100 µL).  
MTBSTFA reacted with the AMA-3-hydroxy-2-butanone and AMA-
hydroxyacetaldehyde adducts to form AMA-3-(tert-butyldimethylsilyloxy)-2-butanone 
(AMA-3-TBSO-2-butanone) and AMA-(tert-butyldimethyl-silyloxy)acetaldehyde 
(AMA-TBSO-acetaldehyde), respectively for GC-MS analysis. 
 
5.2.6. Synthesis of AMAH  
 
2-(2-Morpholinoethoxy)isoindoline-1,3-dione.  By analogy to our published method13 
for synthesis of quaternary ammonium aminooxy compounds as well as to a literature 
procedure,14 we prepared AMAH as follows: diisopropyl azodicarboxylate (DIAD) (3.60 
O
N O N
O
O
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mL, 18.3 mmol) was added dropwise to a stirred solution of 2-(4-morpholinyl) ethanol 
(2.00 g, 15.3 mmol), N-hydroxyphthalimide (2.98 g, 18.3 mmol), and triphenylphosphine 
(4.80 g, 18.3 mmol) in dry THF (95 mL) at 0 °C under nitrogen.  The resulting solution 
was allowed to warm to rt and then stirred.  After 16 h, the THF was removed in vacuo 
and the resulting oil was dissolved in EtOAc (150 mL) and washed with sat. NaHCO3 (3 x 
50 mL) and brine (50 mL).  The organic phase was reduced to 50 mL in vacuo followed 
by the addition of cold 5% HCl to pH 3.  The aqueous phase was separated, washed with 
Et2O (3 x 20 mL), and then basified with sat. NaHCO3 to pH 7.5.  The aqueous phase then 
was extracted with CHCl3 (3 x 50 mL).  The combined organic extract was dried 
(Na2SO4), filtered, and the solvent was removed in vacuo to afford 2-(2-
morpholinoethoxy)isoindoline-1,3-dione as a light yellow solid (3.67 g, 87%); mp, 78-79 
°C; TLC, Rf 0.37 (EtOAc); 1H NMR (CDCl3) δ 2.55 (s, 4H), 2.84 (t, J = 4.8 Hz, 2 H), 
3.60 (t, J = 3.8 HZ, 4 H), 4.36 (t, J = 5 Hz, 2 H), 7.74-7.76 (m, 2 H), 7.82-7.84 (m, 2 H); 
13C NMR (CDCl3) δ 53.8, 57.2, 66.9, 74.2, 123.7, 129.2, 134.7, 163.7. 
 
 
AMAH 
4-(2-Aminooxyethyl)-morpholin-4-ium chloride (AMAH).  Hydrazine monohydrate 
(527 µL, 10.9 mmol) was added to a stirred solution of 2-(2-
morpholinoethoxy)isoindoline-1,3-dione (735 mg, 2.66 mmol) in CH2Cl2 (11 mL) at rt.  
After stirring for 20 h, the suspension was filtered through a fritted glass funnel and the 
cake was washed with ample CH2Cl2.  The filtrate and combined CH2Cl2 washes were 
concentrated in vacuo and the residue was distilled using a Kugelrohr apparatus (10 Torr, 
O
N O NH2
H
Cl
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150 °C).  The distillate was dissolved in Et2O (11 mL) and gaseous HCl was bubbled into 
the solution.  The acidic solution was stirred at rt for 1 h, and then dried in vacuo to 
provide 4-(2-aminooxyethyl)-morpholin-4-ium chloride (AMAH, 486 mg, 100% yield) 
as a white solid; mp, 148-151 °C; IR v (cm-1) 902, 1030, 1444, 2022, 2640, 3418; 1H 
NMR (DMSO-d6) δ 3.29 (s, 4 H), 3.47 (t, J = 4.4 Hz, 2 H), 3.89 (t, J = 4.4 Hz, 4 H), 4.47 
(t, J = 4.6 Hz, 2 H), 11.18 (br s, 1H); 13C NMR (DMSO-d6) δ 51.2, 53.5, 63.1, 68.2. 
 
5.2.7. Procedure for Neutralization of AMAH-adducts 
 
A 35 µL aliquot of the methanol AMAH-adduct mixture was transferred to a 200 µL 
insert containing 2 mg of poly(4-vinylpyridine) (PVP) for the neutralization of AMAH-
adducts to AMA-adducts.  After shaking the vial for 30 seconds, the vial was centrifuged 
at 1000 rpm for 5 minutes to settle the PVP.  A 2 µL aliquot was taken from the 
supernatant and directly injected into the GC-MS. 
 
5.2.8. Synthesis of ADMH 
 
2-(2-(Dimethylamino)ethoxy)-2,3-dihydro-1H-isoindole-1,3-dione was synthesized 
following a procedure described by Biswas et al.4 
 
O
N O N R
R' (H)
N O N
O
O
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O-[2-(Dimethylamino)ethyl]hydroxylamine hydrochloride (ADMH).  Methyl 
hydrazine (247 µL, 4.70 mmol) was added to a solution of 2-[2-(dimethylamino)ethoxy]-
2,3-dihydro-1H-isoindole-1,3-dione (1.02 g, 4.35 mmol) in dry CH2Cl2 (14 mL) at 0 °C 
and was stirred for 4.5 h.  At completion, the solvent was removed by distillation and the 
residue was Kugelrohr distilled at atmospheric pressure.  A was a small amount of oxime 
present, so the distilled product was dissolved in 6 M aq. HCl (5 mL) and refluxed for 22 
h.  The majority of the water was removed by distillation and the product was finally 
azeo-dried with hexanes.  Isopropanol was added to the remaining residue and the 
solution was stirred until white crystal formation ceased.  The crystals were collected by 
filtration, washed once with i-PrOH and dried under reduced pressure to yield O-[2-
(dimethylamino)ethyl]hydroxylamine hydrochloride (ADMH, 224 mg, 37%) as a white 
crystal.  1H NMR (DMSO-d6, 700 MHz) δ 2.79 (s, 6H), 3.43 (t, J = 4.6 Hz, 2H), 4.43 (t, J 
= 4.9 Hz, 2H), 11.14, (br s, 3H); 13C NMR (DMSO-d6, 176 MHz) δ 42.3, 53.7, 68.4; FT-
ICR-MS calcd for C4H13N2O+ [M + H]+ m/z 105.1022, found. 
 
5.2.9. Synthesis of AAn 
 
9-Anthracenemethanol.  Sodium borohydride (275 mg, 7.27 mmol) was added to a 
solution of 9-anthracenecarboxaldehyde (1.02 g, 4.93 mmol) in EtOH (30 mL) at 0 °C.  
N O NH2
H
Cl
ADMH
OH
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The reaction was then heated to 55 °C for 3.5 h.  After cooling to rt, the reaction was 
quenched with sat NH4Cl (50 mL) and extracted three times with CH2Cl2.  The combined 
organic phases were dried over Na2SO4, filtered and concentrated in vacuo to give a 
crude material of 9-anthracenemethanol (yellow crystal, 1.07 g) that was used in the next 
step without further purification.  Rf 0.49 (2:23, EtOAc:CH2Cl2). 
 
 
2-(Anthracen-9-ylmethoxy)-2,3-dihydro-1H-isoindole-1,3-dione.  DIAD (1.26 mL, 
6.40 mmol) was added dropwise to a solution of crude 9-anthracenemethanol (1.03 g, 
4.92 mmol), N-hydroxyphthalimide (942 mg, 6.40 mmol), and PPh3 (1.68 g, 6.40 mmol) 
in dry THF (25 mL) at 0 °C and the reaction was stirred overnight.  The solvent was then 
removed and the residue was diluted with CH2Cl2.  The solution was then washed twice 
with sat. NaHCO3 and the aqueous phase was extracted twice with CH2Cl2.  The 
combined organic phases were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo.  The crude material was purified by column chromatography 
(SiO2, CH2Cl2) to give 2-(anthracen-9-ylmethoxy)-2,3-dihydro-1H-isoindole-1,3-dione as 
a yellow solid (1.68 g, 96%).  Rf 0.73 (1:19, EtOAc:CH2Cl2); 1H NMR (400 MHz, 
DMSO-d6) δ 6.18 (s, 2H), 7.59 (t, J = 7.6 Hz, 2H), 7.71 (t, J = 7.6 Hz, 2H), 7.92-7.94 (m, 
4H), 8.17 (d, J = 8.4 Hz, 2H), 8.66 (d, J = 8.8 Hz, 2H), 8.78 (s, 1H); 13C NMR (100 MHz, 
O
N
O
O
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DMSO-d6) δ 71.3, 123.3, 124.0, 124.2, 125.4, 127.1, 128.8, 128.9, 129.8, 130.8, 131.2, 
134.9, 163.4. 
 
 
O-(Anthracen-9-ylmethyl)hydroxylamine (AAn).  Hydrazine monohydrate (343 µL, 
7.08 mmol) was added to a suspension of 2-(anthracen-9-ylmethoxy)-2,3-dihydro-1H-
isoindole-1,3-dione (531 mg, 1.50 mmol) in EtOH (36 mL) at 0 °C.  After the addition 
was complete, the ice bath was removed and 2-(anthracen-9-ylmethoxy)-2,3-dihydro-1H-
isoindole-1,3-dione slowly went into solution before a white precipitate began to drop 
from the solution.  After 5 h the white solids were filtered, washed with CH2Cl2, and the 
filtrate was concentrated in vacuo.  Dilute HCl (30 mL, 10%) was added to the residue 
and stirred for 10 minutes.  The solution was washed once with EtOAc before being 
basified with sat. NaHCO3.  The basic solution was extracted three times with CHCl3, the 
combined organic phase was dried over Na2SO4, filtered and concentrated in vacuo to 
give O-(anthracen-9-ylmethyl)hydroxylamine (AAn, 200 mg, 60%) as yellow crystals.  Rf 
0.35 (1:19, EtOAc:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 5.73 (s, 2H), 7.48 (dd, J = 7.2 
Hz, 2H), 7.57 (dd, J = 6.4, 8.8 Hz, 2H), 8.02 (d, J = 8.0 Hz, 2H), 8.44-8.47 (m, 3H); 13C 
NMR (100 MHz, DMSO-d6) δ 70.0, 124.6, 125.2, 126.4, 127.9, 128.8, 129.2, 131.4, 
131.6. 
  
O
NH2
AAn
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5.3. EXPERIMENTAL PROCEDURES FROM CHAPTER 3 
5.3.1. First Generation 
 
2-(Oct-3-yn-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione.  DIAD (1.84 mL, 9.34 mmol) 
was added to a solution of oct-3-yn-1-ol (907 mg, 7.18 mmol), phthalimide (1.37 g, 9.34 
mmol) and triphenylphosphine (2.45 g, 9.34 mmol) in dry THF (36 mL) at 0 °C and 
stirred overnight.  The solution was then concentrated in vacuo and diluted with EtOAc 
(50 mL).  The solution was washed with NaHCO3 (3 x 40 mL) and the combined aqueous 
layers were extracted with EtOAc (20 mL).  The combined organics were washed with 
brine (45 mL), dried over Na2SO4, filtered and concentrated in vacuo.  The crude material 
was purified by column chromatography (SiO2, 1:19 to 1:4, EtOAc:hexanes gradient) to 
give 2-(oct-3-yn-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione (1.77 g, 97%) as a white solid.  
Rf 0.78 (1:1, EtOAc:hexanes); 1H NMR (500 MHz, CDCl3) δ 0.76 (t, J = 7.3 Hz, 3H), 
1.20-1.25 (m, 2H), 1.29-1.32 (m, 2H), 2.00-2.03 (m, 2H), 2.50-2.53 (m, 2H), 3.78 (t, J = 
7.3 Hz, 2H), 7.66-7.68 (m, 2H), 7.78-7.80 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 13.5, 
18.2, 18.6, 21.8, 30.8, 37.1, 75.8, 82.3, 123.1, 132.0, 133.9, 167.9. 
 
 
Oct-3-yn-1-amine.  Hydrazine monohydrate (1.68 mL, 34.6 mmol) was added to a 
solution of 2-(oct-3-yn-1-yl)-2,3-dihydro-1H-isoindole-1,3-dione (1.77 g, 6.93 mmol) in 
1:1 CH2Cl2:EtOH (5 mL) at 0 °C with stirring.  The reaction was allowed to reach room 
N
O
O
NH2
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temperature and stir overnight.  The white precipitate was removed through filtration and 
the filter cake was washed with ample CH2Cl2 and the filtrate was concentrated in vacuo.  
The crude material was purified by column chromatography (SiO2, 1:1:98 to 10:1:89 
MeOH:NH4OH:CH2Cl2 gradient) to give oct-3-yn-1-amine (555 mg, 64%) as a yellow 
oil.  Rf 0.46 (10:1:89, MeOH:NH4OH:CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 0.82 (t, J = 
7.3 Hz, 3H), 1.29-1.34 (m, 2H), 1.36-1.39 (m, 2H), 1.72 (br s, 2H), 2.06-2.09 (m, 2H), 
2.20-2.23 (m, 2H), 2.71 (t, J = 6.3 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 13.6, 18.4, 
22.0, 23.9, 31.2, 41.5, 77.8, 81.9. 
 
 
Bis(dimethylsilyl)(oct-3-yn-1-yl)amine (4).  n-BuLi (3.15 mL 1.6 M in hexanes, 5.04 
mmol) was added dropwise to a solution of oct-3-yn-1-amine (517 mg, 4.13 mmol) in dry 
THF (21 mL) at –78 °C and stirred for 0.5 h, then warmed to –40 °C and stirred for 
another 0.5 h.  After cooling the solution back to –78 °C, chlorodimethylsilane (504 µL, 
4.54 mmol) was added and the solution was warmed to –40 °C and stirred for 1 h.  The 
solution was cooled back to –78 °C and a second portion of n-BuLi (3.44 mL 1.6 M in 
hexanes, 5.50 mmol) was added dropwise and stirred for 1 h after returning to –40 °C.  
After cooling back to –78 °C the second portion of chlorodimethylsilane (550 µL, 4.95 
mmol) was added and the solution was stirred overnight.  Hexanes (33 mL) was added to 
the reaction to precipitate LiCl, filtered and concentrated in vacuo.  The crude was 
purified by Kugelrohr distillation to provide 4 (731 mg, 73%) as a colorless oil.  1H NMR 
N
Si
Si
H
H
4
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(400 MHz, CDCl3) δ 0.16 (s, 12H), 0.90 (t, J = 7.2 Hz, 3H), 1.38-1.46 (m, 4H), 2.13 (t, J 
= 6.8 Hz, 2H), 2.19 (t, J = 8 Hz, 2H), 2.95 (t, J = 7.8 Hz, 2H), 4.43 (t, J = 3.4 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ -0.3, 13.8, 18.7, 22.2, 24.1, 31.4, 46.1, 78.1, 81.6. 
 
 
2-[(3E)-2,2-Dimethyl-1,2-azasilolidin-3-ylidene]hexan-1-ol (5).  Bis(dimethylsilyl)(oct-
3-yn-1-yl)amine (142 mg, 0.59 mmol) in toluene (10 mL) was added to a solution of cat. 
Rh4(CO)12 (2 mg, 0.0025 mmol) in toluene (5 mL).  The autoclave was then sealed and 
purged with CO before adjusting the pressure to 10 atm with CO gas.  The reactor was 
then heated to 60 °C for 14 h, at which point the pressure was relieved and the reaction 
solution was poured into a solution of NaBH4 (189 mg, 5.0 mmol) in MeOH (5 mL) at 0 
°C and stirred for 10 min.  The reaction was quenched with NH4Cl (20 mL) and extracted 
with Et2O (3 x 10 mL).  The combined organics were dried over K2CO3, filtered and 
concentrated in vacuo.  The crude material was purified by column chromatography 
(SiO2, 1:1:98 to 5:1:94 MeOH:NH4OH:CH2Cl2 gradient) to give 5 (83 mg, 66%).  Rf 0.57 
(10:1:89, MeOH:NH4OH:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.23 (s, 6H), 0.90 (t, J 
= 6.6 Hz, 3H), 1.25-1.36 (m, 4H), 1.56 (br s, 1H), 2.14 (t, J = 7.2 Hz, 2H), 2.34 (t, J = 6.6 
Hz, 2H), 2.76 (br s, 2H), 4.48 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 1.4, 14.1, 23.0, 
27.9, 30.9, 31.9, 42.3, 74.1, 130.3, 155.0. 
 
 
Si
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HO
5
 
 165 
5.3.2. Synthesis of 2-(9-Anthracenyl)ethanol5 (25) 
 
 
(E/Z)-9-(2-Methoxyvinyl)anthracene.  (Methoxymethyl)triphenylphosphonium chloride 
(13.5 g, 39.5 mmol) was suspended in dry THF (105 mL) under nitrogen with stirring to 
which KHMDS (68.5 mL of 0.5 M solution in toluene, 34.2 mmol) was added dropwise 
via syringe at room temperature and stirred for 1 hour.  The addition of KHMDS turned 
the white suspension to a dark red solution.  The solution was then cooled to -78 °C and a 
solution of 9-anthraldehyde (5.43 g, 26.3 mmol) in dry THF (20 mL) was added 
dropwise.  The reaction was allowed to warm to room temperature and was stirred 
overnight.  The reaction solution was then poured into water (75 mL) and EtO2 (50 mL) 
was added.  After separation, the aqueous phase was extracted with EtO2 (75 mL) and 
CH2Cl2 (75 mL).  The combined organics were then dried over Na2SO4, filtered, and 
concentrated in vacuo.  The crude material was purified by column chromatography 
(SiO2, 1:1 CH2Cl2:hexanes) to give a dark orange solid (E/Z)-9-(2-
methoxyvinyl)anthracene (6.05 g, E/Z 1:1, 98%).  Rf 0.6 (1:1, CH2Cl2:hexanes); 1H NMR 
(400 MHz, CDCl3) E isomer δ 3.94 (s, 3H), 6.43 (d, J = 13.2 Hz, 1H), 6.77 (d, J = 13.2 
Hz), 7.45-7.52 (m, 4H), 7.99-8.00 (m, 2H), 8.25 (d, J = 9.2 Hz), 8.37-8.41 (m, 2H); 13C 
NMR (100 MHz, CDCl3) E isomer δ 56.7, 99.1, 125.3, 125.9, 126.5, 126.9, 128.7, 129.9, 
130.8, 131.8, 153.1. 
 
O
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2-(Anthracen-9-yl)acetaldehyde.  (E/Z)-9-(2-methoxyvinyl)anthracene (6.05 g, 25.8 
mmol) was dissolved in THF (129 mL) with stirring.  Aqueous 2 M HCl solution (51.6 
mL, 103.2 mmol) was added and the reaction solution was heated to 60 °C and stirred 
overnight.  The reaction was then quenched with aqueous NaHCO3 (125 mL), extracted 
with EtO2 (3 x 80 mL), and washed with brine (100 mL).  The resulting solution was 
dried over Na2SO4, filtered and concentrated in vacuo to give a crude material 2-
(anthracen-9-yl)acetaldehyde as orange crystals that were used in the next step without 
further purification.  Rf 0.34 (1:1 CH2Cl2:hexanes); 1H NMR (700 MHz, CDCl3) δ 4.70 
(d, J = 2.8 Hz, 2H), 7.50-7.52 (m, 2H), 7.56-7.58 (m, 2H), 8.05 (d, J = 8.4 Hz, 2H), 8.17 
(d, J = 8.4 Hz, 2H), 8.48 (s, 1H); 13C NMR (176 MHz, CDCl3) δ 44.5, 122.0, 122.4, 
123.8, 125.2, 126.4, 127.9, 129.2, 130.0, 195.1. 
 
 
2-(Anthracen-9-yl)ethanol (25).  Crude 2-(anthracen-9-yl)acetaldehyde (5.68 g, 25.8 
mmol) was dissolved in 5:1 THF:MeOH (129 mL) with stirring at room temperature.  
NaBH4 (1.17 g, 31.0 mmol) was added portion-wise to the reaction solution and allowed 
to stir for 12 h.  The reaction was quenched with aqueous NH4Cl (70 mL) and extracted 
O
H
OH
25
 
 167 
with EtO2 (3 x 50 mL).  The combined organics were washed with brine (75 mL), dried 
over Na2SO4, filtered and concentrated in vacuo.  The crude material was purified by 
column chromatography (SiO2, 0:100 to 6:94 EtOAc:CH2Cl2 gradient) to give a yellow 
solid 25 (4.61 g, 80% over two steps).  Rf 0.45 (5:95, EtOAc:CH2Cl2); 1H NMR (400 
MHz, CDCl3) δ 1.56 (s, 1H), 3.94 (t, J = 7.0 Hz, 2H), 4.09 (t, J = 7.0 Hz, 2H), 7.45-7.55 
(m, 4H), 8.01 (d, J = 8.4 Hz, 2H), 8.33 (d, J = 8.8 Hz, 2H), 8.39 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 31.3, 63.6, 124.5, 125.2, 126.0, 126.7, 129.4, 130.4, 130.6, 131.8. 
 
5.3.3. Synthesis of Amino Esters and Amide (Scheme 3.3) 
 
5-((tert-Butoxycarbonyl)amino)pentanoic acid (12.2).  5-aminopentanoic acid (1.99 g, 
17.0 mmol) was dissolved in a 2:1 mixture of 1,4-dioxane:H2O (51 mL) and cooled to 0 
°C.  A 1 M solution of NaOH (0.68 g, 17.1 mmol) was added, followed by the addition of 
di-tert-butyl dicarbonate (4.10g,  18.8 mmol).  After 18 h, the dioxane was removed in 
vacuo and the remaining aqueous layer was washed with EtOAc (19 mL).  The aqueous 
phase was then acidified to pH ~3 with 1 M HCl and extracted with EtOAc (3 x 19 mL).  
The combined organics were dried over MgSO4, filtered, and concentrated in vacuo to 
give a crude material 12.2 (white crystals) which were used in the next step without 
further purification.  1H NMR (400 MHz, CDCl3) δ:  1.43 (s, 9H), 1.52 (dt, J = 7.2 Hz, 
2H), 1.65 (dt, J = 7.4 Hz, 2H), 2.36 (t, J = 7.2 Hz, 2H), 4.61 (br s, 1H).  13C NMR (100 
MHz, CDCl3) δ:  22.0, 28.6, 29.6, 33.7, 40.4, 79.5, 156.3, 178.9. 
HN
Boc
CO2Hn
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6-((tert-Butoxycarbonyl)amino)hexanoic acid (12.1).  1H NMR (400 MHz, CDCl3) δ:  
1.31-1.52 (m, 13H), 1.63 (dt, J = 7.6 Hz, 2H), 2.33 (t, J = 7.4 Hz, 2H), 3.08 (br s, 2H), 
4.60 (br s, 1H), 10.44 (br s, 1H).  13C NMR (100 MHz, CDCl3) δ:  24.5, 26.4, 28.6, 29.9, 
34.1, 40.6, 79.6, 156.1, 179.2. 
4-((tert-Butoxycarbonyl)amino)butanoic acid (12.3).  1H NMR (400 MHz, CDCl3) δ:  
1.43 (s, 9H), 1.80 (dt, J = 7.2 Hz, 2H), 2.38 (t, J = 7.0 Hz, 2H), 3.16 (br s, 2H), 4.72 (br s, 
1H), 9.34 (br s, 1H).  13C NMR (100 MHz, CDCl3) δ:  25.3, 28.6, 31.5, 40.0, 79.8, 156.4, 
178.5. 
 
 
5-(Allyl(tert-butoxycarbonyl)amino)pentanoic acid (13.2). Boc-protected amine 12.2 
(4.65 g, 21.4 mmol) was added to a slurry of 60% NaH (4.28 g, 107 mmol) in dry THF 
(140 mL) at 0 °C.  After one-hour of stirring, allyl bromide (5.56 mL, 64.2 mmol) was 
added dropwise.  After 24 h, the reaction mixture was cooled to 0 °C and quenched with 
water until the reaction became transparent.  The reaction was acidified to pH ~3 by 
addition of 1 M HCl and the layers were separated.  The aqueous phase was extracted 
with EtOAc (2 x 30 mL) and the combined organic phase was washed with brine (50 
mL), dried over Na2SO4, filtered and concentrated in vacuo.  The crude material was 
purified by column chromatography (SiO2, 1:1 EtOAc:hexanes) to give 13.2 as an oil 
(4.77 g, 87%); Rf 0.36 (1:1 EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 
1.51-1.64 (m, 4H), 2.35 (t, J = 7.0 Hz, 2H), 3.17 (br s, 2H), 3.78 (br s, 2H), 5.09 (d, J = 
N
Boc
CO2Hn
13.1:   n = 1
13.2:   n = 2
13.3:    n = 3
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11.6 Hz, 2H), 5.70-5.78 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 22.1, 27.8, 28.6, 33.9, 
46.2, 49.7, 79.9, 116.5, 134.4, 155.8, 179.6; FT-ICR-MS calcd for C13H22NO4– [M – H]– 
m/z 256.1554, found 256.1555. 
4-(Allyl(tert-butoxycarbonyl)amino)butanoic acid (13.1).  1H NMR (400 MHz, CDCl3) 
δ 1.44 (s, 9H), 1.83 (dt, 2H), 2.34 (t, J = 7.2 Hz, 2H), 3.24 (br s, 2H), 3.79 (br s, 2H), 
5.08-5.12 (m, 2H), 5.71-5.80 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 23.5, 28.6, 31.4, 
45.8, 49.7, 80.1, 116.7, 134.1, 155.9, 178.9; FT-ICR-MS calcd for C12H20NO4– [M – H]– 
(m/z) 242.1398, found 242.1398. 
6-(Allyl(tert-butoxycarbonyl)amino)hexanoic acid (13.3).  1H NMR (400 MHz, 
CDCl3) δ 1.30 (dt, J = 7.6 Hz, 2H), 1.43 (s, 9H), 1.83 (dt, J = 7.6 Hz, 2H), 1.63 (dt, J = 
7.6 Hz, 2H), 2.33 (t, J = 7.4 Hz, 2H), 3.15 (t, J = 7.0 Hz, 2H), 3.77 (br s, 2H), 5.07-5.11 
(m, 2H), 5.70-5.80 (m, 1H), 10.02 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.6, 26.4, 
28.1, 28.6, 34.2, 46.6, 49.7, 79.7, 116.3, 134.5, 155.8, 179.7; FT-ICR-MS calcd for 
C14H24NO4– [M – H]– (m/z) 270.1711, found 270.1710. 
 
 
2-(Anthracen-9-yl)ethyl 5-(allyl(tert-butoxycarbonyl)amino)pentanoate (14.2).  To 
amino acid 13.2 (255 mg, 0.99 mmol) and alcohol 25 (197 mg, 0.88 mmol) in dry CH2Cl2 
(8 mL) was added DIC (211 µL, 1.35 mmol) and 4-(N,N-dimethylamino)pyridine 
(DMAP, pinch).  After 3 h, the white solids were filtered and the filter cake was washed 
N
Boc
14.1-3:   Z = O
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with CH2Cl2.  The combined filtrate was condensed in vacuo and the crude material was 
purified by column chromatography (SiO2, 0:100 to 1:19 EtOAc:CH2Cl2 gradient) to give 
14.2 (242 mg, 59%) as an oil; Rf 0.46 (1:19 EtOAc:CH2Cl2); FT-IR 3058, 2981, 1729, 
1685 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 1.50-1.61 (m, 4H), 2.33 (t, J = 7.4 
Hz, 2H), 3.16 (br s, 2H), 3.79 (br s, 2H), 3.97 (t, J = 7.8 Hz, 2H), 4.48 (t, J = 7.8 Hz, 2H), 
5.11 (d, J = 11.6 Hz, 2H), 5.72-5.82 (m, 1H), 7.45-7.49 (m, 2H), 7.51-7.59 (m, 2H), 8.01 
(d, J = 8.4 Hz, 2H), 8.34 (d, J = 9.2 Hz, 2H), 8.39 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 
22.3, 27.5, 27.9, 28.6, 34.2, 46.3, 49.9, 64.3, 79.6, 116.2, 124.3, 125.1, 126.2, 127.0, 
129.2, 129.4, 130.5, 131.7, 134.5, 155.7, 173.8; FT-ICR-MS calcd for C29H35NNaO4+ [M 
+ Na]+ m/z 484.2458, found 484.2459. 
2-(Anthracen-9-yl)ethyl 4-(allyl(tert-butoxycarbonyl)amino)butanoate (14.1).  FT-IR: 
3058, 2981, 1730, 1685 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H), 1.81 (br s, 2H), 
2.31 (br s, 2H), 3.17 (br s, 2H), 3.78 (br s, 2H), 3.98 (t, J = 7.8 Hz, 2H), 4.48 (t, J = 7.8 
Hz, 2H), 5.07-5.12 (m, 2H), 5.71-5.80 (m, 1H), 7.45-7.49 (m, 2H), 7.53-7.56 (m, 2H), 
8.00 (d, J = 8.4 Hz, 2H), 8.34 (d, J = 8.8 Hz, 2H), 8.38 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 23.7, 27.5, 28.6, 31.7, 45.8, 49.9, 64.4, 79.8, 116.7, 124.3, 125.1, 126.2, 127.0, 
129.2, 129.4, 130.5, 131.7, 134.3, 155.7, 173.5; FT-ICR-MS calcd for C28H33NNaO4+ [M 
+ Na]+ (m/z) 470.2302, found 470.2303. 
2-(Anthracen-9-yl)ethyl 6-(allyl(tert-butoxycarbonyl)amino)hexanoate (14.3).  FT-IR: 
3058, 2936, 1730, 1684 cm-1; 1H NMR (400 MHz, CDCl3) δ 1.26 (dt, J = 7.8 Hz, 2H), 
1.42-1.54 (m, 11H), 1.58-1.64 (dt, J = 7.6 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 3.15 (br s, 
2H), 3.80 (br s, 2H), 3.97 (t, J = 7.8 Hz, 2H), 4.47 (t, J = 8.0 Hz, 2H), 5.11 (d, J = 12.0 
Hz, 2H), 5.73-5.83 (m, 1H), 7.45-7.48 (m, 2H), 7.52-7.56 (m, 2H), 8.00 (d, J = 8.4 Hz, 
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2H), 8.34 (d, J = 8.8 Hz, 2H), 8.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.8, 26.5, 
27.5, 28.2, 28.6, 34.4, 46.6, 49.6, 64.2, 79.5, 116.2, 124.3, 125.1, 126.2, 126.8, 126.9, 
129.2, 129.4, 130.5, 131.7, 134.6, 155.7, 173.9; FT-ICR-MS calcd for C30H37NNaO4+ [M 
+ Na]+ (m/z) 498.2615, found 498.2615. 
tert-Butyl allyl(4-((2-(anthracen-9-yl)ethyl)amino)-4-oxobutyl)carbamate (14.4). Rf 
0.59 (EtOAc); FT-IR: 3445, 3058, 2970, 1679, 1520 cm-1; 1H NMR (400 MHz, CDCl3) δ 
1.43 (s, 9H), 1.80 (quin, J = 6.8 Hz, 2H), 2.11 (br s, 2H), 3.19 (br s, 2H), 3.65-3.70 (m, 
2H), 3.76 (br s, 2H), 3.87 (t, J = 7.6 Hz, 2H), 5.08-5.11 (m, 2H), 2H), 5.70-5.79 (m, 1H), 
6.74 (br s, 1H), 7.43-7.46 (m, 2H), 7.49-7.53 (m, 2H), 7.98 (d, J = 8.4 Hz, 2H), 8.34 (br s, 
2H); 13C NMR (100 MHz, CDCl3) δ 24.4, 27.9, 28.6, 33.7, 40.6, 45.7, 49.8, 79.9, 116.5, 
124.5, 125.1, 126.0, 126.5, 129.3, 130.3, 131.3, 131.7, 134.2, 156.3, 173.1; FT-ICR-MS 
calcd for C28H34N2NaO3+ [M + Na]+ (m/z) 469.2462, found 469.2464. 
 
2-(Anthracen-9-yl)ethyl 5-(allylamino)pentanoate (6.2).  Trifluoroacetic acid (0.74 
mL, 9.60 mmol) was added to a solution of 14.2 (68 mg, 0.15 mmol) in dry CH2Cl2 (0.74 
mL) at 0 °C.  After stirring 1h, the volatiles were removed in vacuo and the remaining 
residue was diluted with Et2O (10 mL) and washed with NaHCO3 (3 x 5 mL).  The 
organic phase was washed with brine (5 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to give 6.2 (53 mg, 100% yield) as an oil; Rf 0.20 (1:9 
MeOH:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.49 (dt, J = 7.4 Hz, 2H), 1.64 (dt, J = 
H
N Z
O
n
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7.6 Hz, 2H), 1.84 (br s, 1H), 2.32 (t, J = 7.4 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H), 3.24 (d, J = 
5.6 Hz, 2H), 3.97 (t, J = 7.8 Hz, 2H), 4.48 (t, J = 7.8 Hz, 2H), 5.11 (d, J = 10.4 Hz, 1H), 
5.18 (d, J = 17.2 Hz, 1H), 5.86-5.96 (m, 1H), 7.47 (t, J = 7.4 Hz, 2H), 7.55 (t, J = 7.6 Hz, 
2H), 8.01 (d, J = 8.4 Hz, 2H), 8.34 (d, J = 9.6 Hz, 2H), 8.38 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 22.8, 27.5, 29.5, 34.3, 48.9, 52.5, 64.3, 116.4, 124.3, 124.6, 125.1, 126.2, 126.9, 
129.4, 130.5, 131.7, 136.7, 173.9; FT-ICR-MS calcd for C24H28NO2+ [M + H]+ m/z 
362.2115, found 362.2141. 
2-(Anthracen-9-yl)ethyl 4-(allylamino)butanoate (6.1).  1H NMR (400 MHz, CDCl3) δ 
1.64 (br s, 1H), 1.79 (dt, J = 7.2 Hz, 2H), 2.37 (t, J = 7.2 Hz, 2H), 2.59 (t, J = 7.2 Hz, 
2H), 3.21 (d, J = 6.4 Hz, 2H), 3.97 (t, J = 7.8 Hz, 2H), 4.48 (t, J = 7.8 Hz, 2H), 5.09 (d, J 
= 10.0 Hz, 1H), 5.17 (dd, J = 17.2, 1.4 Hz, 1H), 5.83-5.93 (m, 1H), 7.45-7.49 (m, 2H), 
7.52-7.55 (m, 2H), 8.01 (d, J = 8.4 Hz, 2H), 8.34 (d, J = 8.8 Hz, 2H), 8.38 (s, 1H); 13C 
NMR (100 MHz, CDCl3) δ 25.3, 27.5, 32.3, 48.6, 52.3, 64.3, 116.3, 124.4, 124.9, 125.7, 
126.8, 129.3, 129.5, 130.5, 131.7, 136.7, 173.8; FT-ICR-MS calcd for C23H26NO2+ [M + 
H]+ m/z 348.1958, found 348.1964. 
2-(Anthracen-9-yl)ethyl 6-(allylamino)hexanoate (6.3).  1H NMR (400 MHz, CDCl3) δ 
1.32 (dt, J = 7.8 Hz, 2H), 1.49 (dt, J = 7.4 Hz, 2H), 1.62 (quin, J = 7.6 Hz, 2H), 1.77 (br 
s, 1H), 2.31 (t, J = 7.6 Hz, 2H), 2.60 (t, J = 7.0 Hz, 2H), 3.26 (d, J = 5.6 Hz, 2H), 3.98 (t, 
J = 7.8 Hz, 2H), 4.48 (t, J = 8.0 Hz, 2H), 5.10 (d, J = 10.4 Hz, 1H), 5.19 (d, J = 17.6 Hz, 
1H), 5.87-5.97 (m, 1H), 7.45-7.49 (m, 2H), 7.53-7.57 (m, 2H), 8.01 (d, J = 8.4 Hz, 2H), 
8.34 (d, J = 8.8 Hz, 2H), 8.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.9, 27.0, 27.5, 
29.8, 34.4, 49.2, 52.6, 64.2, 116.3, 124.3, 125.1, 126.2, 126.9, 129.3, 129.4, 130.5, 131.7, 
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136.8, 174.0; FT-ICR-MS calcd for C25H30NO2+ [M + H]+ (m/z) 376.2271, found 
376.2278. 
N-(2-(Anthracen-9-yl)ethyl)-4-(allylamino)butanamide (9, TFA salt).  Trifluoroacetic 
acid (0.50 mL, 6.53 mmol) was added to a solution of 14.4 (20 mg, 0.045 mmol) in dry 
CH2Cl2 (0.50 mL) at 0 °C.  After stirring 1h, the volatiles were removed in vacuo to 
afford the TFA salt of 9 (15 mg, 72%) as an oil; 1H NMR (400 MHz, CDCl3) δ 1.97 (t, J 
= 6.4 Hz, 2H), 2.29 (t, J = 6.4 Hz, 2H), 2.97 (br s, 2H), 3.54 (br s, 2H), 3.60 (q, J = 7.2 
Hz, 2H), 3.81 (t, J = 7.8 Hz, 2H), 5.40-5.46 (m, 2H), 5.84-5.93 (m, 1H), 6.81 (s, 1H), 
7.42-7.52 (m, 4H), 7.97 (d, J = 8.0 Hz, 2H), 8.28 (d, J = 8.8 Hz, 2H), 8.34 (s, 1H), 9.81 
(br s, 2H); 13C NMR (100 MHz, CDCl3) δ 21.9, 27.7, 33.7, 40.7, 46.7, 50.0, 124.0, 124.3, 
125.2, 126.2, 126.7, 127.9, 129.4, 130.3, 130.8, 131.7, 173.0; FT-ICR-MS calcd for 
C23H27N2O+ [M + H]+ (m/z) 347.2118, found 347.2143. 
 
5.3.4. Synthesis of Amino Carbonates (Scheme 3.4) 
 
tert-Butyl (2-hydroxyethyl)carbamate (15.1).  Et3N (2.51 mL, 18.0 mmol) was added to 
a solution of 2-ethanolamine (1.02 g, 16.7 mmol) in dry CH2Cl2 (33 mL) with stirring at 
0 °C.  Boc2O (3.93 g, 18.0 mmol) was then added to the reaction, turning the solution to 
an opaque white color that slowly cleared as the reaction proceeded.  The reaction was 
stirred for 19 h and then was quenched with sat. NH4Cl (30 mL) and the aqueous phase 
was extracted with CH2Cl2 (2 x 20 mL).  The combined organics were washed with brine 
(30 mL), dried over Na2SO4, filtered and concentrated in vacuo to give crude 15.1 as a 
HN
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light yellow oil which was used in the next step without further purification.  Rf 0.38 
(1:19, MeOH:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 2.86 (br s, 1H), 3.23 
(br s, 2H), 3.63 (br s, 2H), 5.03 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 28.6, 43.3, 
62.6, 79.8, 157.0. 
tert-Butyl (3-hydroxypropyl)carbamate (15.2).  1H NMR (400 MHz, CDCl3) δ 1.42 (s, 
9H), 1.64 (dt, J = 5.8 Hz, 2H), 3.18 (br s, 1H), 3.25 (dt, J = 6.4, 5.6 Hz, 2H), 3.63 (br s, 
2H), 4.87 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 28.6, 33.0, 37.1, 59.4, 79.8, 157.3. 
 
 
tert-Butyl (2-((tert-butyldimethylsilyl)oxy)ethyl)carbamate.  TBSCl (3.06 g, 20.3 
mmol) was added to a solution of 1.1 (2.70 g, 16.7 mmol), Et3N (2.85 mL, 20.3 mmol) 
and imidazole (3.14 g, 46.1 mmol) in dry CH2Cl2 (40 mL) with stirring at 0 °C.  After 23 
h, the reaction was quenched with water (25 mL) and the aqueous phase was extracted 
with CH2Cl2 (2 x 10 mL).  The combined organics were washed with sat. NH4Cl, dried 
over Na2SO4, filtered and condensed in vacuo.  The crude material was purified by 
column chromatography (SiO2, 3:7 EtOAc:hexanes) to give tert-butyl (2-((tert-
butyldimethylsilyl)oxy)ethyl)carbamate (4.52 g, 98%) as a colorless oil.  Rf 0.67 (1:1, 
EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 0.06 (s, 6H), 0.89 (s, 9H), 1.44 (s, 9H), 
3.23 (br s, 2H), 3.65 (br s, 2H), 4.84 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ -5.1, 18.5, 
26.1, 28.6, 43.1, 62.5, 79.4, 156.2. 
tert-Butyl (3-((tert-butyldimethylsilyl)oxy)propyl)carbamate.  1H NMR (400 MHz, 
CDCl3) δ 0.05 (s, 6H), 0.89 (s, 9H), 1.42 (s, 9H), 1.68 (dt, J = 6.0 Hz, 2H), 3.23 (br s, 
HN
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2H), 3.70 (t, J = 5.6 Hz, 2H), 5.10 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ -3.4, 18.4, 
26.1, 28.6, 32.2, 39.4, 62.4, 79.0, 156.2. 
 
 
 
 
tert-Butyl allyl(2-((tert-butyldimethylsilyl)oxy)ethyl)carbamate.  tert-Butyl (2-((tert-
butyldimethylsilyl)oxy)ethyl)carbamate (4.52 g, 16.4 mmol) was added to a slurry of 
NaH (1.08 g of 60% in mineral oil, 26.9 mmol) in dry THF (36 mL) at 0 °C and stirred 
for 1 h, and then allyl bromide (3.88 mL, 44.8 mmol) was added dropwise.  The slurry 
was stirred for two days before cooling it to 0 °C and quenching it with water (20 mL).  
The aqueous phase was extracted with EtOAc (2 x 15 mL).  The combined organics were 
washed with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo.  The 
crude material was purified by column chromatography (SiO2, 1:19 Et2O:hexanes) to 
give tert-butyl allyl(2-((tert-butyldimethylsilyl)oxy)ethyl)carbamate (4.36 g, 84%) as a 
light yellow oil.  Rf 0.25 (1:19, Et2O:hexanes); 1H NMR (400 MHz, CDCl3) δ 0.04 (s, 
6H), 0.88 (s, 9H), 1.44 (s, 9H), 3.29 (br s, 2H), 3.71 (br s, 2H), 3.89 (br s, 2H), 5.10 (br s, 
2H), 5.76 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ -5.2, 18.5, 26.1, 28.7, 49.0, 51.6, 
62.0, 79.6, 116.5, 134.6, 155.6. 
tert-Butyl allyl(3-((tert-butyldimethylsilyl)oxy)propyl)carbamate.  1H NMR (400 
MHz, CDCl3) δ 0.04 (s, 6H), 0.88 (s, 9H), 1.44 (s, 9H), 1.72 (dt, J = 6.0 Hz, 2H), 3.23 (br 
s, 2H), 3.61 (t, J = 6.0 Hz, 2H), 3.82 (br s, 2H), 5.10 (d, J = 11.2 Hz, 2H), 5.72-5.80 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ -5.1, 26.1, 28.7, 32.0, 44.0, 49.2, 61.0, 79.5, 116.5, 
134.6, 155.7. 
N
Boc
OTBS
n
 
 176 
 
tert-Butyl allyl(2-hydroxyethyl)carbamate (16.1). TBAF (18.0 mL of a 1 M solution, 
18.0 mmol) was added dropwise to a solution of the corresponding N-allyl silyl ether of 
10.1 (4.36 g, 13.8 mmol) in dry THF (28 mL) with stirring at 0 °C.  After 20 h, the 
reaction solution was diluted with Et2O (50 mL) and washed with sat. NaHCO3 (3 x 40 
mL).  The reaction solution was then washed with brine (40 mL), dried over Na2SO4, 
filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 1:1 EtOAc:hexanes) to give 16.1 (2.65 g, 95%) as a light yellow 
oil.  Rf 0.33 (1:1 EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H), 3.07 (br s, 
1H), 3.37 (br s, 2H), 3.72 (br s, 2H), 3.84 (br s, 2H), 5.10-5.14 (m, 2H), 5.78 (br s, 1H); 
13C NMR (100 MHz, CDCl3) δ 28.5, 50.0, 51.4, 62.5, 80.4, 116.6, 134.2, 157.4; FT-ICR-
MS calcd for C10H20NO3+ [M + H]+ (m/z) 202.1438, found 202.1439. 
tert-Butyl allyl(3-hydroxypropyl)carbamate (16.2).  1H NMR (400 MHz, CDCl3) δ 
1.45 (s, 9H), 1.66 (br s, 2H), 3.37 (br s, 2H), 3.55 (br s, 2H), 3.75 (br s, 2H), 5.12 (d, J = 
11.2 Hz, 2H), 5.71-5.81 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 28.5, 30.7, 42.6, 50.0, 
58.5, 80.4, 116.7, 134.1, 157.1. 
 
 
3-(Allyl(tert-butoxycarbonyl)amino)propyl 1H-imidazole-1-carboxylate (17.2). N,N-
Diiso-propylethylamine (566 µL, 3.25 mmol) was added to a solution of alcohol 16.2 
N
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(399 mg, 1.85 mmol) in dry CH2Cl2 (46 mL) at 0 °C.  1,1’-Carbonyldiimidazole (527 mg, 
3.25 mmol) was then added to the cooled solution and the cooling bath was removed to 
allow the reaction to slowly warm to room temperature.  After 24 h, the reaction was 
washed with water (2 x 20 mL), brine (20 mL), and then dried (Na2SO4).  After filtration 
and concentration in vacuo, the residue was purified by column chromatography (SiO2, 
EtOAc) to give 17.2 (543 mg, 95%) as a colorless oil; Rf 0.50 (EtOAc); 1H NMR (400 
MHz, CDCl3) δ 1.43 (s, 9H), 2.01 (dt, J = 6.6 Hz, 2H), 3.34 (br s, 2H), 3.82 (br s, 2H), 
4.43 (t, J = 6.4 Hz, 2H), 5.09-5.14 (m, 2H), 5.74-5.81 (m, 1H), 7.06 (s, 1H), 7.41 (s, 1H), 
8.12 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 27.7, 28.6, 43.5, 50.3, 66.4, 80.2, 116.7, 
117.3, 130.9, 134.2, 137.3, 148.8, 155.6; FT-ICR-MS calcd for C15H24N3O4+ [M + H]+ 
m/z 310.1761, found 310.1765. 
2-(Allyl(tert-butoxycarbonyl)amino)ethyl 1H-imidazole-1-carboxylate (17.1).  Rf 0.50 
(EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 3.59 (br s, 2H), 3.87 (br s, 2H), 
4.48 (t, J = 5.2 Hz, 2H), 5.11 (d, J = 10.8 Hz, 2H), 5.76 (br s, 1H), 7.05 (s, 1H), 7.41 (s, 
1H), 8.12 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 28.5, 45.4, 51.0, 66.0, 80.5, 116.7, 
117.3, 130.9, 133.9, 137.3, 148.8, 155.7; FT-ICR-MS calcd for C14H21N3NaO4+ [M + 
Na]+ (m/z) 318.1424, found 318.1428. 
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2-(Anthracen-9-yl)ethyl 3-((allyl)amino)propyl carbonate (7.2, TFA salt).  Alcohol 
25 (131 mg, 0.59 mmol) was added to a mixture of 17.2 (210 mg, 0.65 mmol) and KOH 
(s, 1 pellet) in dry toluene (3 mL) at 60 °C.  After 5 h the reaction was concentrated in 
vacuo and the residue was diluted with CH2Cl2 (5 mL).  The solution was washed with 
water (3 x 5 mL), dried over Na2SO4, filtered and concentrated in vacuo.  The crude 
material was purified by column chromatography (SiO2, 1:19 EtOAc:CH2Cl2) to give 
Boc-protected 7.2 as an orange oil (93 mg, 34%).  Rf 0.63 (1:19 EtOAc:hexanes); FT-IR: 
3017, 2971, 1739, 1229 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.47 (s, 9H), 1.92 (br s, 2H), 
3.30 (br s, 2H), 3.83 (br s, 2H), 4.05 (t, J = 8.0 Hz, 2H), 4.19 (t, J = 6.2 Hz, 2H), 4.49 (t, J 
= 8.2 Hz, 2H), 5.13 (d, J = 11.2 Hz, 2H), 5.74-5.84 (m, 1H), 7.46-7.50 (m, 2H), 7.54-7.58 
(m, 2H), 8.02 (d, J = 8.0 Hz, 2H), 8.34 (d, J = 8.8 Hz, 2H), 8.40 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 27.6, 28.0, 28.6, 43.9, 49.8, 66.0, 67.3, 79.9, 116.8, 124.1, 125.2, 126.4, 
127.2, 128.3, 129.5, 130.5, 131.7, 134.3, 155.5, 155.6; FT-ICR-MS calcd for 
C28H33NNaO5+ [M + Na]+ m/z 486.2251, found 486.2251. 
 Trifluoroacetic acid (0.50 mL, 6.53 mmol) was added to a solution of Boc-protected 
7.2 (12 mg, 0.026 mmol) in dry CH2Cl2 (0.50 mL) at 0 °C.  After stirring 1h, the volatiles 
were removed in vacuo to afford the TFA salt of 7.2 (12 mg, 96%) as an oil; 1H NMR 
(400 MHz, CDCl3) δ 2.10 (t, J = 6.8 Hz, 2H), 3.00 (br s, 2H), 3.53 (br s, 2H), 4.02 (t, J = 
8.4 Hz, 2H), 4.23 (t, J = 6.0 Hz, 2H), 4.50 (t, J = 8.4 Hz, 2H), 5.12-5.48 (m, 2H), 5.83-
N
H
O
n
7.1: n = 1
7.2: n = 2
O
O
 
 179 
5.96 (m, 1H), 7.45-7.56 (m, 4H), 8.00 (d, J = 8.4 Hz, 2H), 8.30 (d, J = 8.8 Hz, 2H), 8.39 
(s, 1H), 9.64 (br s, 2H); 13C NMR (100 MHz, CDCl3) δ 25.7, 27.4, 43.9, 50.1, 64.6, 67.7, 
124.1, 124.3, 125.2, 126.4, 127.2, 127.6, 128.3, 129.5, 130.5, 131.7, 155.3; FT-ICR-MS 
calcd for C23H26NO3+ [M + H]+ m/z 364.1907, found 364.1911. 
tert-Butyl allyl(2-(((2-(anthracen-9-yl)ethoxy)carbonyl)oxy)ethyl)carbamate (7.1, 
Boc-protected).  Rf 0.64 (1:19 EtOAc:hexanes); FT-IR: 3017, 2971, 1740, 1230 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 1.47 (s, 9H), 3.46 (br s, 2H), 3.95 (br s, 2H), 4.04 (t, J = 8.0 
Hz, 2H), 4.27 (br s, 2H), 4.50 (t, J = 8.2 Hz, 2H), 5.13 (br s, 2H), 5.77 (br s, 1H), 7.44-
7.50 (m, 2H), 7.51-7.58 (m, 2H), 8.02 (d, J = 8.0 Hz, 2H), 8.34 (d, J = 8.8 Hz, 2H), 8.40 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 27.5, 28.6, 45.5, 50.4, 66.2, 67.5, 79.4, 117.1, 
124.1, 125.2, 126.4, 127.2, 128.3, 129.5, 130.5, 131.7, 134.1, 155.0, 155.4; FT-ICR-MS 
calcd for C27H31NNaO5+ [M + Na]+ (m/z) 472.2094, found 472.2096. 
 
2-(Anthracen-9-yl)ethyl 3-((allyl)amino)ethyl carbonate (7.1, TFA salt).  
Trifluoroacetic acid (0.50 mL, 6.53 mmol) was added to a solution of Boc-protected 7.1 
(13 mg, 0.030 mmol) in dry CH2Cl2 (0.50 mL) at 0 °C.  After stirring 1h, the volatiles 
were removed in vacuo to afford the TFA salt of 2.1 (14 mg, 100%) as an oil; 1H NMR 
(400 MHz, CDCl3) δ 3.24 (t, J = 4.8 Hz, 2H), 3.62-3.64 (m, 2H), 4.00 (t, J = 8.0 Hz, 2H), 
4.44-4.48 (m, 4H), 5.42-5.46 (m, 2H), 5.85-5.96 (m, 1H), 7.43-7.54 (m, 4H), 7.99 (d J = 
8.0 Hz, 2H), 8.26 (d, J = 8.8 Hz, 2H), 8.37 (s, 1H); 13C NMR (100 MHz, CDCl3) δ  27.2, 
45.3, 50.2, 63.0, 68.0, 124.0, 124.6, 125.2, 126.4, 127.2, 127.6, 129.5, 130.5, 131.7, 
134.3, 154.9; FT-ICR-MS calcd for C22H24NO3+ [M + H]+ (m/z) 350.1751, found 
350.1758. 
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5.3.5. Synthesis of Carbamate (Scheme 3.5) 
 
 
 
tert-Butyl (2-aminoethyl)carbamate (18).  Ethylene diamine (9.2 mL, 138 mmol) was 
added dropwise via syringe to dry CH2Cl2 (82 mL) at 0 °C with stirring.  A solution of 
Boc2O (5.60 g, 25.7 mmol) in dry CH2Cl2 (76 mL) was added dropwise over 8 h with 
continued chilling.  The reaction was allowed to stir overnight to form a colorless 
solution with clumps of white solids.  The solids were filtered off and the filter cake was 
washed with CH2Cl2.  The filtrate was condensed in vacuo, and then poured into 
NaHCO3 solution (75 mL), which produced an exotherm, and shaken.  The aqueous 
solution was extracted with CH2Cl2 (3 x 50 mL), and then the combined organics were 
dried over Na2SO4, filtered and condensed in vacuo to give crude 18 (turbid oil, 4.50 g) 
which was used in the next step without further purification.  Rf 0.24 (10:2:88, 
MeOH:NH4OH:CH2Cl2; 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 2.76 (br s, 2H), 3.14 
(br s, 2H), 5.05 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 28.5, 41.9, 43.4, 79.3, 156.4. 
 
 
 
tert-Butyl N-(2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethyl)carbamate.  Phthalic 
anhydride (4.18 g, 28.2 mmol) was added to a solution of crude 18 (4.11 g, 25.7 mmol) in 
toluene (86 mL) with stirring and the reaction flask was fitted with a Dean-Stark 
apparatus.  The mixture was heated to reflux for 6.5 h with the phthalic anhydride slowly 
HN
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going into solution.  After the heat was removed, the solution was allowed to stir 
overnight where a precipitate dropped out of solution.  The mixture was washed with 
water (3 x 50 mL) and the combined aqueous phases were extracted with EtOAc (2 x 30 
mL).  The combined organics were washed with brine (50 mL), dried over Na2SO4, 
filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 1:19 to 1:1, EtOAc:CH2Cl2 gradient) to give tert-butyl N-(2-(1,3-
dioxo-2,3-dihydro-1H-isoindol-2-yl)ethyl)carbamate (5.76 g, 77%) as a white solid.  Rf 
0.27 (1:19, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.33 (s, 9H), 3.42 (br s, 2H), 
3.82 (t, J = 5.6 Hz, 2H), 4.83 (br s, 1H), 7.70-7.72 (m, 2H), 7.82-7.86 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 28.4, 38.3, 39.8, 79.7, 123.5, 132.3, 134.2, 156.2, 168.7. 
 
 
tert-Butyl allyl(2-(1,3-dioxoisoindolin-2-yl)ethyl)carbamate  (19).  tert-Butyl N-(2-
(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethyl)carbamate phthalimide (5.76 g, 19.8 
mmol) was added to a slurry of NaH (1.59 g of 60% in mineral oil, 39.7 mmol) in dry 
THF (83 mL) at 0 °C.  After stirring 1h, allyl bromide (2.23 mL, 25.8 mmol) was added 
dropwise.  The slurry was stirred for three days and then quenched by addition into water 
(50 mL).  The layers were separated and the aqueous phase was extracted with Et2O (2 x 
35 mL).  The combined organic phase was washed with brine (50 mL), dried over 
Na2SO4, filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 1:19 EtOAc:CH2Cl2) to give 19 (3.77 g, 58%) as a white solid; Rf 
N
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0.55 (1:19 EtOAc:hexanes); mp = 73-76 °C; 1H NMR (400 MHz, CDCl3) δ 1.27 (s, 9H), 
3.46 (br s, 2H), 3.81 (br s, 2H), 3.87 (br s, 2H), 5.01-5.13 (m, 2H), 5.71-5.77 (m, 1H), 
7.70 (br s, 2H), 7.82 (br s, 2H); 13C NMR (100 MHz, CDCl3) δ 28.2, 44.5, 49.3, 50.2, 
80.1, 117.2, 123.4, 132.3, 133.9, 134.2, 155.3, 168.3. 
 
 
2-(Anthracen-9-yl)ethyl N-(2-(allylamino)ethyl)carbamate (8, TFA salt).  Hydrazine 
monohydrate (147 µL, 3.03 mmol) was added to a solution of 19 (217 mg, 0.66 mmol) in 
2:1 CH2Cl2:EtOH (6 mL) with stirring at 0 °C.  The reaction was stirred for 18 h, 
allowing it to warm slowly to room temperature.  The white precipitate was then filtered 
and the filter cake was washed with CH2Cl2 and concentrated in vacuo.  The concentrate 
was diluted with CH2Cl2 and the precipitate was filtered, the cake washed with CH2Cl2 
and concentrated in vacuo again to give the crude amine (light yellow oil, 122 mg, 92%) 
which was used in the next step without further purification.  Rf 0.47 (10:2:88 
MeOH:NH4OH:CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 1.40 (s, 2H), 1.43 (s, 9H), 2.79 
(t, J = 5.0 Hz, 2H), 3.22 (br s, 2H), 3.81 (br s, 2H), 5.09-5.12 (m, 2H), 5.74-5.79 (m, 1H); 
13C NMR (100 MHz, CDCl3) δ 28.6, 40.8, 50.1, 79.8, 116.4, 134.3, 156.0; FT-ICR-MS 
calcd for C10H21N2O2+ [M + H]+ (m/z) 201.1598, found 201.1599. 
 The amine (188 mg, 0.94 mmol) was added dropwise with stirring to a solution of 
ClC(O)OCH2CH2(9-anthracenyl) (303 mg, 1.06 mmol) in dry CH2Cl2 (3.5 mL) at 0 °C.  
After 10 minutes, Et3N (148 µL, 1.06 mmol) was added dropwise to the reaction, causing 
N
H
8
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the solution to darken.  After stirring 17h, the reaction mixture was quenched by addition 
of sat. NH4Cl (5 mL) and the aqueous phase was extracted with CH2Cl2 (5 mL).  
Combined organic phase was dried over Na2SO4, filtered and concentrated in vacuo.  The 
crude material was purified by column chromatography (SiO2, 5:1:4 
CH2Cl2:hexanes:EtOAc) to give  Boc-protected 3 (171 mg, 41%) as a yellow gum;  Rf 
0.33 (1:19 EtOAc:CH2Cl2); FT-IR: 3449, 3058, 2971, 1724, 1514 cm-1; 1H NMR (400 
MHz, CDCl3) δ 1.46 (s, 9H), 3.13 (br s, 2H), 3.36 (br s, 2H), 3.83 (br s, 2H), 3.97 (t, J = 
8.0 Hz, 2H), 4.43 (br s, 2H), 5.10-5.15 (m, 2H), 5.75-5.81 (m, 1H), 7.44-7.48 (m, 2H), 
7.52-7.56 (m, 2H), 8.00 (d, J = 8.4 Hz, 2H), 8.35-8.37 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 28.1, 28.5, 40.5, 46.2, 50.6, 64.6, 80.3, 116.6, 124.4, 125.1, 126.1, 126.8, 129.3, 
130.5, 131.7, 134.0, 155.3, 157.0; FT-ICR-MS calcd for C27H32N2NaO4+ [M + Na]+ m/z 
471.2254, found 471.2256. 
 Trifluoroacetic acid (0.50 mL, 6.53 mmol) was added to a solution of Boc-protected 
8 (20 mg, 0.045 mmol) in dry CH2Cl2 (0.50 mL) at 0 °C.  After stirring 1h, the volatiles 
were removed in vacuo to afford the TFA salt of 3 (18 mg, 88%) as an oil; 1H NMR (400 
MHz, CDCl3) δ 3.09 (br s, 2H), 3.48-3.56 (m, 4H), 3.90 (t, J = 8.0 Hz, 2H), 4.36 (t, J = 
8.0 Hz, 2H), 5.35-5.47 (m, 2H), 5.81-5.88 (m, 1H), 7.41-7.51 (m, 4H), 7.97 (d, J = 8.4 
Hz, 2H), 8.27 (d, J = 8.8 Hz, 2H), 8.34 (s, 1H), 9.47 (br s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 27.8, 37.8, 47.2, 50.2, 65.1, 124.3, 124.6, 125.2, 126.2, 126.9, 127.5, 129.4, 
130.5, 131.7, 134.3, 157.5; FT-ICR-MS calcd for C22H25N2O2+ [M + H]+ m/z 349.1910, 
found 349.1913 
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5.3.6. Synthesis of gem-Dimethylester (Scheme 3.6) 
 
 
 
4,4-Dimethylcyclohexanone.  10 % Palladium on carbon (10 mg, 0.0094 mmol) was 
added to a solution of 4,4-dimethyl-2-cyclohexen-1-one (1.52 g, 12.2 mmol) in hexanes 
(15 mL).  The atmosphere was purged with H2 and sealed with a H2 balloon attached.  
After 48 h the reaction was filtered through Celite and the filter cake was rinsed with 
hexanes.  The filtrate was concentrated in vacuo to give 4,4-dimethylcyclohexanone (1.29 
g white crystals, 83%) that was used in the next step without further purification.  Rf 0.46 
(1:3, EtOAc:Hexanes); 1H NMR (400 MHz, CDCl3) δ 1.09 (s, 6H), 1.66 (t, J = 6.0 Hz, 
4H), 2.33 (t, J = 6.0 Hz, 4H); 13C NMR (100 MHz, CDCl3) δ 27.7, 30.1, 38.2, 39.3, 
212.8. 
 
 
 
5,5-Dimethylazepan-2-one.  A solution of 4,4-dimethylcyclohexanone (1.29 g, 10.2 
mmol) in formic acid (10 mL) was added dropwise to a solution of hydroxylamine-O-
sulfonic acid (1.73 g, 15.3 mmol) in formic acid (7 mL) and allowed to stir at rt for 15 
min.  The reaction flask was then heated to reflux.  After 24 h, the reaction solution was 
cooled to rt and quenched with 10 N NaOH (40 mL).  The aqueous mixture was extracted 
with chloroform (4 x 20 mL) and the combined organics were washed with water (2 x 10 
O
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mL) and brine (10 mL).  The solution was dried over MgSO4, filtered and concentrated in 
vacuo to give 5,5-dimethylazepan-2-one (1.06 g brown crystals, 73%) that was used in 
the next step without further purification.  Rf 0.13 (EtOAc); 1H NMR (400 MHz, CDCl3) 
δ 0.97 (s, 6H), 1.42-1.44 (m, 2H), 1.48-1.50 (m, 2H), 2.39-2.42 (m, 2H), 3.15 (q, J = 5.2 
Hz, 2H), 6.50 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 29.0, 32.0, 33.0, 36.0, 38.3, 
42.4, 179.1. 
 
 
tert-Butyl 5,5-dimethyl-2-oxoazepane-1-carboxylate.  Di-tert-butyl dicarbonate (1.54 
g, 7.01 mmol) and DMAP (856 mg, 7.01 mmol) were added to a solution of 5,5-
dimethylazepan-2-one (899 mg, 6.37 mmol) in dry THF (16 mL) at rt.  After purging the 
head-space with N2, the reaction was heated to reflux.  After 2.5 h the reaction was 
cooled to rt and the volatiles were removed in vacuo and the crude material was purified 
by column chromatography (SiO2, 1:9 to 3:7, EtOAc:hexanes gradient) to give tert-butyl 
5,5-dimethyl-2-oxoazepane-1-carboxylate as yellow crystals (1.05 g, 68%).  Rf 0.68 
(EtOAc); 1H NMR (400 MHz, CDCl3) δ 0.94 (s, 6H), 1.46-1.49 (m, 11H), 1.52-1.55 (m, 
2H), 2.54-2.57 (m, 2H), 3.67-3.70 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 28.2, 28.8, 
32.2, 35.2, 36.5, 41.8, 41.9, 83.0, 153.0, 175.8. 
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6-((tert-Butoxycarbonyl)amino)-4,4-dimethylhexanoic acid (20).  Lithium hydroxide 
monohydrate (340 mg, 8.10 mmol) was added to a solution of tert-butyl 5,5-dimethyl-2-
oxoazepane-1-carboxylate (888 mg, 3.68 mmol) in 2:1 THF:H2O (18 mL) and the 
reaction was heated to 60 oC.  After 4 h the reaction was cooled to rt and partitioned 
between Et2O and H2O and the organic layer separated.  The aqueous phase was acidified 
to pH ~4 with 10 % HCl and extracted with EtOAc (3 x 15 mL).  The combined organics 
were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated in vacuo 
to give 20 (912 mg yellow crystals, 96%) that was used in the next step without further 
purification.  Rf 0.29 (1:1, EtOAc:Hexanes with 0.5 % AcOH); 1H NMR (400 MHz, 
CDCl3) δ 1.37-1.43 (m, 11H), 1.58 (t, J = 8.4 Hz, 2H), 2.30 (t, J = 8.4 Hz, 2H), 3.11 (br s, 
2H), 4.49 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 26.9, 28.6, 29.5, 32.1, 36.6, 36.9, 
41.6, 79.5, 156.2, 179.7. 
 
 
6-(Allyl(tert-butoxycarbonyl)amino)-4,4-dimethylhexanoic acid (21).  Amino acid 20 
(912 mg, 3.52 mmol) was added to a slurry of 60% NaH (703 mg, 17.6 mmol) in dry 
THF (18 mL) at 0 °C.  After stirring 1 h, allyl bromide (913 µL, 10.5 mmol) was added 
dropwise.  After 24 h, the reaction mixture was cooled to 0 °C and quenched with water 
until the reaction became transparent.  The reaction was acidified to pH ~3 by addition of 
HN
Boc
OH
O
20
N
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1 M HCl and the layers were separated.  The aqueous phase was extracted with EtOAc (3 
x 10 mL) and the combined organic phase was washed with brine (15 mL), dried over 
Na2SO4, filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 1:1 EtOAc:hexanes with 0.5% AcOH) to give 21 (712 mg, 68%) 
as a light yellow oil; Rf 0.43 (1:1 EtOAc:hexanes with 0.5% AcOH); 1H NMR (400 MHz, 
CDCl3) δ 0.88 (s, 6H), 1.39-1.44 (m, 11H), 1.56 (t, J = 8.0 Hz, 2H), 2.31 (t, J = 8.2 Hz, 
2H), 3.14 (br s, 2H), 3.80 (br s, 2H), 5.11 (d, J = 11.6 Hz, 2H), 5.71-5.81 (m, 1H); 13C 
NMR (100 MHz, CDCl3) δ 26.8, 28.7, 29.5, 32.0, 36.4, 39.5, 42.8, 49.6, 79.8, 116.8, 
134.6, 155.6, 180.2; FT-ICR-MS calcd for C16H28NO4– [M – H]– m/z 298.2024, found 
298.2024. 
 
 
2-(Anthracen-9-yl)ethyl 4,4-dimethyl-6-(allylamino)-hexanoate (10, TFA salt).  To a 
mixture of carboxylic acid 21 (370 mg, 1.24 mmol) and 25 (249 mg, 1.12 mmol) in dry 
CH2Cl2 (10 mL) at 0 °C was added DIC (264 µL, 1.69 mmol) and DMAP (pinch).  After 
16 h, the precipitated white solids were filtered and the filter cake was washed with 
CH2Cl2.  The combined filtrate was condensed in vacuo and the crude material was 
purified by column chromatography (SiO2, 0:100 to 1:19 EtOAc:CH2Cl2 gradient) to give 
Boc-protected gem-dimethyl ester 10 as a yellow oil (494 mg, 87%); Rf 0.58 (1:19 
EtOAc:CH2Cl2); FT-IR 3058, 2963, 1728, 1684 cm-1; 1H NMR (400 MHz, CDCl3) δ 0.87 
(s, 6H), 1.39 (br s, 2H), 1.46 (s, 9H), 1.51 (t, J = 8.4 Hz, 2H), 2.28 (t, J = 8.2 Hz, 2H), 
N
H
O
O
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3.12 (br s, 2H), 3.81 (br s, 2H), 3.98 (t, J = 7.8 Hz, 2H), 4.48 (t, J = 7.8 Hz, 2H), 5.12 (d, 
J = 11.6 Hz, 2H), 5.73-5.82 (m, 1H), 7.46-7.49 (m, 2H), 7.53-7.57 (m, 2H), 8.02 (d, J = 
8.4 Hz, 2H), 8.34 (d, J = 9.2 Hz, 2H), 8.39 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 26.8, 
27.5, 28.7, 29.8, 32.0, 36.6, 39.2, 42.8, 49.6, 53.6, 64.3, 79.6, 116.6, 124.3, 125.2, 126.2, 
127.0, 129.5, 130.5, 131.7, 134.7, 155.5, 174.5; FT-ICR-MS calcd for C32H41NNaO4+ [M 
+ Na]+ m/z 526.2928, found 526.2927. 
 Trifluoroacetic acid (0.50 mL, 6.53 mmol) was added to a solution of Boc-protected 
10 (11 mg, 0.022 mmol) in dry CH2Cl2 (0.50 mL) at 0 °C.  After stirring 1h, the volatiles 
were removed in vacuo to afford the TFA salt of 10 (10 mg, 85%) as an oil; 1H NMR 
(400 MHz, CDCl3) δ 0.86 (s, 6H), 1.47 (t, J = 8.4 Hz, 2H), 1.58 (t, J = 8.6 Hz, 2H), 2.24 
(t, J = 8.4 Hz, 2H), 2.88 (br s, 2H), 3.54 (br s, 2H), 3.96 (t, J = 7.6 Hz, 2H), 4.46 (t, J = 
8.0 Hz, 2H), 5.40-5.47 (m, 2H), 5.84-5.94 (m, 1H), 7.44-7.56 (m, 4H), 8.00 (d, J = 8.8 
Hz, 2H), 8.32 (d, J = 9.2 Hz, 2H), 8.38 (s, 1H), 9.47 (br s, 2H); 13C NMR (100 MHz, 
CDCl3) δ 26.5, 27.4, 29.4, 32.1, 36.1, 37.1, 43.2, 49.9, 64.4, 124.1, 124.3, 125.2, 126.2, 
127.0, 127.9, 129.2, 129.5, 130.5, 131.7, 174.1; FT-ICR-MS calcd for C27H34NO2+ [M + 
H]+ m/z 404.2584, found 404.2588. 
 
5.3.7. Synthesis of gem-Dimethylcarbonate (Scheme 3.7) 
 
 
Methyl 4-(allyl(tert-butoxycarbonyl)amino)-2,2-dimethylbutanoate (22).  DIC (837 
µL, 5.34 mmol) and DMAP (pinch) were added to a mixture of amino acid 16.2 (631 mg, 
N
Boc
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2.59 mmol) and dry MeOH (173 µL, 4.28 mmol) in CH2Cl2 (32 mL) at rt.  After 12 h the 
precipitated solids were filtered and the filter cake was washed with CH2Cl2.  The 
combined filtrate was concentrated in vacuo and the resulting residue was purified by 
column chromatography (SiO2, 1:1:8, EtOAc:THF:hexanes) to give methyl 4-(allyl(tert-
butoxycarbonyl)amino)butanoate as a pale yellow oil (532 mg, 80%); Rf 0.65 (1:1:8, 
EtOAc:THF:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H), 1.82 (dt, J = 7.0 Hz, 
2H), 2.30 (t, J = 7.4 Hz, 2H), 3.20 (br s, 2H), 3.65 (s, 3H), 3.79 (br s, 2H), 5.10 (d, J = 
12.8 Hz, 2H), 5.72-5.80 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 23.7, 28.6, 31.4, 45.9, 
49.7, 51.8, 79.8, 116.7, 134.3, 155.7, 173.8. 
The methyl ester (532 mg, 2.06 mmol) was dissolved in dry THF (10 mL) and 
cooled to –78 °C with stirring.  A solution of lithium bis(trimethylsilyl)amide (LiHMDS) 
in THF (6.20 mL of 1 M solution, 6.20 mmol) was added dropwise to the reaction 
solution.  After stirring 1h, methyl iodide (772 µL, 12.4 mmol) was added dropwise and 
the reaction was stirred overnight while slowly warming to rt.  After 22 h, the reaction 
was cooled to 0 °C and quenched with water (5 mL), followed by 1 M HCl (5 mL).  The 
phases were separated and the aqueous phase was extracted with Et2O (3 x 15 mL).  The 
combined organic phase was washed with NaHCO3 (10 mL) and brine (10 mL) and then 
dried over Na2SO4, filtered and concentrated in vacuo.  The crude material was purified 
by column chromatography (SiO2, 1:4 EtOAc:hexanes) to give 22 (397 mg, 67%) as a 
yellow oil; Rf 0.48 (1:4, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.18 (s, 6H), 
1.44 (s, 9H), 1.74 (br s, 2H), 3.11 (br s, 2H), 3.65 (s, 3H), 3.79 (br s, 2H), 5.10 (d, J = 
10.8 Hz, 2H), 5.70-5.79 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 25.3, 28.6, 38.1, 41.1, 
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43.1, 49.4, 51.9, 79.7, 116.1, 134.2, 155.5, 178.0; FT-ICR-MS calcd for C15H27NNaO4+ 
[M + Na]+ m/z 308.1832, found 308.1836.  
 
 
tert-Butyl allyl(4-hydroxy-3,3-dimethylbutyl)carbamate (23).  LiBH4 (45 mg, 2.08 
mmol) was added to a solution of 22 (265 mg, 0.93 mmol) in dry THF (21 mL) at 0 °C.  
After 5 minutes of stirring the reaction was warmed to rt and stirred overnight.  The 
reaction was then carefully quenched with NH4Cl (25 mL) and extracted with Et2O (3 x 
10 mL).  The combined organic phase was washed with brine (15 mL), dried over 
Na2SO4, filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 1:1 EtOAc:hexanes) to give 23 (175 mg, 73%) as a colorless oil; 
Rf 0.47 (1:1, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 0.86 (s, 6H), 1.43-1.49 (m, 
11H), 2.89 (br s, 1H), 3.13-3.17 (m, 2H), 3.32 (s, 2H), 3.78 (br s, 2H), 5.09-5.13 (m, 2H), 
5.71-5.81 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 24.4, 28.6, 34.7, 36.5, 42.9, 50.4, 
70.8, 79.8, 116.4, 134.6, 155.8; FT-ICR-MS calcd for C14H27NNaO3+ [M + Na]+ m/z 
280.1883, found 280.1886. 
 
 
 
N
Boc
23
OH
 
 191 
 
2-(Anthracen-9-yl)ethyl 2,2-dimethyl-4-(allylamino)butyl carbonate (11, TFA salt).  
N,N-Diisopropylethylamine (304 µL, 1.74 mmol) was added to a solution of alcohol 23 
(251 mg, 0.98 mmol) in dry CH2Cl2 (25 mL) at 0 °C.  1,1’-Carbonyldiimidazole (283 mg, 
1.74 mmol) was then added to the solution followed by warming to rt.  After 24 h, the 
reaction was washed with water (2 x 10 mL), brine (10 mL) and then dried over Na2SO4.  
After filtration and concentration in vacuo, the crude residue was purified by column 
chromatography (SiO2, EtOAc) to give the imidazole carbamate as a colorless oil (316 
mg, 92%); Rf 0.61 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.01 (s, 6H), 1.42 (s, 9H), 
1.56 (t, J = 7.8 Hz, 2H), 3.21 (br s, 2H), 3.76 (br s, 2H), 4.12 (s, 2H), 5.07-5.09 (m, 2H), 
5.70-5.79 (m, 1H), 7.07 (s, 1H), 7.42 (s, 1H), 8.13 (s, 1H); 13C NMR (100 MHz, CDCl3) 
δ 24.2, 28.6, 33.7, 36.7, 42.5, 50.0, 75.9, 79.8, 116.4, 117.2, 130.9, 134.5, 137.2, 148.9, 
155.4. 
 A solution of alcohol 25 (191 mg, 0.86 mmol) in dry THF (1 mL) was added 
dropwise to a slurry of NaH (103 mg of 60% in mineral oil, 2.57 mmol) in dry THF (5 
mL) at –5 °C and stirred for 30 minutes.  A solution of the above imidazole carbamate 
(316 mg, 0.90 mmol) in dry THF (1 mL) was then added dropwise to the reaction 
mixture.  The reaction was stirred overnight, then the mixture was filtered through Celite 
and the filter cake was washed with Et2O.  The filtrate was washed with water (2 x 10 
mL) and the combined aqueous layers were extracted with Et2O (3 x 10 mL).  The 
combined organic phase was washed with brine, dried over Na2SO4, filtered and 
N
H
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concentrated in vacuo.  The crude material was purified by column chromatography 
(SiO2, 1:19 EtOAc:CH2Cl2) to give Boc-protected 11 (207 mg, 48%) as a yellow oil; Rf 
0.64 (1:19, EtOAc:CH2Cl2); FT-IR 3008, 2974, 1743, 1685, 1256 cm-1; 1H NMR (400 
MHz, CDCl3) δ 0.98 (s, 6H), 1.46 (s, 9H), 1.53 (t, J = 7.8 Hz, 2H), 3.19 (br s, 2H), 3.77-
3.82 (m, 2H), 3.90 (s, 2H), 4.05 (t, J = 8.0 Hz, 2H), 4.50 (t, J = 8.4 Hz, 2H), 5.10-5.13 
(m, 2H), 5.74-5.80 (m, 1H), 7.45-7.49 (m, 2H), 7.53-7.57 (m, 2H), 8.01 (d, J = 8.4 Hz, 
2H), 8.34 (d, J = 9.2 Hz, 2H), 8.40 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.1, 27.6, 
28.7, 33.5, 37.1, 42.5, 49.7, 67.3, 76.2, 79.7, 116.2, 124.1, 125.2, 126.4, 127.2, 128.3, 
129.5, 130.5, 131.7, 134.5, 155.5, 155.7; FT-ICR-MS calcd for C26H32NO3+ [M + Na]+ 
m/z 528.2928, found 528.2720. 
 Trifluoroacetic acid (0.50 mL, 6.53 mmol) was added to a solution of Boc-protected 
11 (12 mg, 0.024 mmol) in dry CH2Cl2 (0.50 mL) at 0 °C.  After stirring 1h, the volatiles 
were removed in vacuo to afford the TFA salt of 11 (11 mg, 92%) as an oil; 1H NMR 
(400 MHz, CDCl3) δ 0.96 (s, 6H), 1.70 (t, J = 8.4 Hz, 2H), 2.99 (br s, 2H), 3.86 (br s, 
2H), 4.03 (t, J = 8.0 Hz, 2H), 4.49 (t, J = 8.0 Hz, 2H), 5.40-5.48 (m, 2H), 5.81-5.91 (m, 
1H), 7.45-7.60 (m, 4H), 8.00 (d, J = 8.4 Hz, 2H), 8.32 (d, J = 8.4 Hz, 2H), 8.39 (s, 1H), 
9.06 (br s, 2H); 13C NMR (100 MHz, CDCl3) δ 24.0, 27.4, 33.6, 34.8, 43.3, 50.0, 67.5, 
75.3, 124.1, 124.3, 125.2, 126.4, 127.2, 127.5, 128.3, 129.5, 130.5, 131.7, 155.5; FT-
ICR-MS calcd for C26H32NO3+ [M + H]+ m/z 406.2377, found 406.2379. 
 
5.3.8. Experimental Procedures for Determination of Release Rate of 25 and 26. 
 
 The Boc protecting group was removed from each linker as described for 6.2 and 
immediately placed into a 0.01 M solution in MeOH and heated at 55 °C for 24 h.  200 
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µL aliquots were pulled at t = 0, 0.25, 0.5, 0.75, 1, 2, 3 and 24 h and were stored at -20 
°C to prevent further release.  The solvent was removed under vacuum for 3.5 h at rt and 
was then returned to -20 °C until analyzed by HPLC.  The remaining residue was diluted 
to 500 µL with HPLC grade CH2Cl2 and a 50 µL aliquot was injected into the HPLC 
fitted with a Waters Nova-Pak HR Silica 6 µm 60 Å 3.9x300 mm Prep Column using 1% 
MeOH:CH2Cl2 with 0.1% triethylamine as the eluent.  The percent release was 
determined by the ratio of the starting linker to the release of 25 or 26. 
 To test thermal stability of 11 at 37 °C, three samples were incubated at 37 °C for 
24 h.  The solvent was then evaporated and analyzed as described above.   
 
5.3.9. Experimental Procedure for 1H NMR Verification of Cyclization 
Samples of 6.1 and 7.1 (10 mg) were placed into separate screw-cap NMR tubes.  Each 
sample was diluted with toluene-d8 (0.5 mL) and a 1H NMR was taken.  This NMR 
measurement was considered t = 0 h.  The samples were then heated to 55 °C and held 
for 3 h (6.1) and 5 h (7.1), at which time another 1H NMR spectrum of each sample was 
obtained.  The samples were then heated to ≥90 °C and held at that temperature overnight 
to complete the cyclization.  1H NMR spectra were once again obtained.  To verify the 
formation of the respective lactam and oxazolidinone, the toluene-d8 was removed in 
vacuo and the samples were diluted with CDCl3 and the spectral results were found to be 
in agreement with published literature.6 
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5.3.10. Synthesis of Ester 27 (Scheme 3.9) 
 
 
2-((5-(Allyl(tert-butoxycarbonyl)amino)pentanoyl)oxy)-N-(2-((1,3-dioxoisoindolin-2-
yl)oxy)ethyl)-N,N-dimethylethanaminium iodide (27).  Amino acid 13.2 (98 mg, 0.38 
mmol) and the 2-(2-((2-hydroxyethyl)(methyl)amino)ethoxy)-2,3-dihydro-1H-isoindole-
1,3-dione mono-O-phthalimide of N-methyl-diethanolamine4 were dissolved in dry 
CH2Cl2 (1.7 mL) with stirring.  DIC (82 µL, 0.52 mmol) was added to the reaction 
solution followed by cat. DMAP.  After 2 h, the white solids were filtered out and the 
filter cake was washed with CH2Cl2.  The filtrate was condensed in vacuo and the crude 
material was purified by column chromatography (SiO2, 3:1 to 1:0, EtOAc:hexanes 
gradient) to give the corresponding ester as a light yellow oil (96 mg, 55%). Rf 0.55 
(EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 1.49-1.62 (m, 4H), 2.33 (t, J = 7.4 
Hz, 2H), 2.39 (s, 3H), 2.77 (t, J = 6.0 Hz, 2H), 2.91 (t, J = 5.6 Hz, 2H), 3.16 (br s, 2H), 
3.78 (br s, 2H), 4.16 (t, J = 5.8 Hz, 2H), 4.30 (t, J = 5.4 Hz, 2H), 5.09 (d, J = 11.2 Hz, 
2H), 5.72-5.78 (m, 1H), 7.72-7.75 (m, 2H), 7.76-7.84 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 22.4, 28.0, 28.6, 34.1, 42.9, 46.3, 55.9, 60.6, 62.3, 76.1, 79.6, 116.5, 123.7, 
129.2, 134.6, 155.7, 163.6, 173.6. 
 To the ester (96 mg, 0.19 mmol) in dry CH2Cl2 (1 mL) in a pressure tube was added 
iodomethane (24 µL, 0.38 mmol).  The tube was sealed and heated to 60 °C for 18 h.  
The solution was then concentrated in vacuo to give a crude ammonium salt (yellow 
gum, 122 mg, 100%) that was used in the next step without further purification.  Rf 0.20 
N O N ONH2
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(1:9, MeOH:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.39 (s, 9H), 1.50-1.56 (m, 4H), 
2.40 (t, J = 6.6 Hz, 2H), 3.12 (t, J = 7.0 Hz, 2H), 3.66 (s, 6H), 3.73 (br s, 2H), 4.26 (br s, 
2H), 4.39 (br s, 2H), 4.64 (br s, 2H), 4.77 (br s, 2H), 5.06 (d, J = 12.0 Hz, 2H), 5.68-5.74 
(m, 1H), 7.76-7.81 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 21.9, 27.5, 28.5, 46.2, 49.9, 
53.2, 57.8, 63.2, 64.9, 72.4, 79.5, 116.2, 124.1, 128.6, 134.3, 135.2, 155.6, 163.2, 172.5. 
 Methyl hydrazine (24 µL, 0.46 mmol) was added to a stirred solution of the crude 
ammonium salt (49 mg, 0.076 mmol) in 1:1 CH2Cl2:EtOH (2 mL) at –40 °C.  After 1.5h, 
the solution was concentrated in vacuo and diluted with CH2Cl2, causing a white 
precipitate to form.  The solid was filtered and the filter cake was washed with CH2Cl2.  
The filtrate was concentrated in vacuo to give 27 (yellow gum, 39 mg, 100%) that was 
used in the next step without further purification; Rf 0.14 (1:9, MeOH:CH2Cl2); 1H NMR 
(400 MHz, CDCl3) δ 1.41 (s, 9H), 1.51-1.59 (m, 4H), 2.39 (t, J = 7.0 Hz, 2H), 3.14 (t, J = 
6.4 Hz, 2H), 3.48 (s, 6H), 3.74 (br s, 2H), 4.02 (br s, 2H), 4.08 (br s, 2H), 4.19 (br s, 2H), 
4.57 (br s, 2H), 5.07 (d, J = 15.6 Hz, 2H), 5.70-5.74 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ 22.0, 27.6, 28.6, 33.8, 46.2, 49.9, 53.1, 57.8, 63.9, 64.2, 69.2, 79.7, 116.3, 
134.3, 155.7, 172.6; FT-ICR-MS calcd for C19H38N3O5+ [M]+ m/z 388.2806, found 
388.2807. 
 
5.3.11. Experimental Procedures for Manufacture of PDMS Microchannel 
 
The device design and detailed fabrication protocol was based on a previous device by 
Sethu et al. 7   Briefly, the device was fabricated using standard soft lithographic 
techniques.  A silicon wafer was first treated with oxygen plasma in an asher (March 
Instruments, Concord, MA) and then spin coated with SU-8, a negative photoresist (SU-8 
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50, MicroChem, Newton, MA). Standard photolithography using a transparency mask 
(CAD ART Services Inc., Poway, CA) was generated using AutoCAD layout software 
(Autodesk, Inc., San Rafael, CA), and used to create negative replicas of the channel 
structures.  A silicone elastomer, polydimethylsiloxane (PDMS) (Dow Corning, Midland, 
MI) was mixed 10:1 with a cross linking agent and poured on top of the silicon wafer, 
and cured at 60 ºC for 12 hours in a petri dish.  The cured elastomer with the replicated 
channel structure was released and access holes to the channels were punched using a 22-
gauge syringe needle.  The PDMS piece with the channels was bonded irreversibly to a 
glass slide after treatment with oxygen plasma in the asher.  Access tubing (Tygon, Small 
Parts Inc. Miami Lakes, FL) with a slightly larger diameter than the holes was 
subsequently press fitted into the punched holes. 
 
5.3.12. Procedure for Loading 27 onto PDMS Microchannel 
Ester 27 (39 mg, 0.076 mmol) was placed into a pressure tube with a stir-bar and the 
headspace was purged with nitrogen.  Catalytic PtO2 was then added, followed by 
triethoxysilane (14 µL, 0.076 mmol).  The headspace was purged with nitrogen and the 
pressure tube was sealed and heated to 80 °C.  After two days, the reaction was cooled to 
room temperature and the solution was filtered under nitrogen through Celite and the 
filter cake was washed with dry CH2Cl2.  The filtrate was concentrated in vacuo to give a 
moisture-sensitive residue, triethoxylsilane intermediate 28, which was immediately 
loaded onto the PDMS microchannel without further purification by first dissolving in 
CH3CN (0.8 M) and then injecting the solution (10 µL, 80 µmol) into the microchannel.  
After 1h, the microchannel was washed with CH3CN (5 x 10 µL) and placed in 110 °C 
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oven for 15 minutes.  On cooling, the loaded microchannel was stored at room 
temperature in a sealed bag until needed. 
 
5.3.13. Experimental Procedures for PDMS Microchannel Reaction and Release 
FITC-CHO Attachment 
A solution of FITC-CHO (10 µL of 0.02 M, 0.2 µmol) was injected into the aminooxy-
functionalized microchannel and allowed to react for 1 h.  The remaining FITC-CHO 
solution was then removed and the microchannel was washed with MeCN (5 x 10 µL).  
The microchannel was then observed with a fluorescence microscope 
(excitation/emission, 495 nm/521 nm) and the microchannel was fluorescent. 
Boc Deprotection 
The linker was activated by removing the Boc protecting group by injecting a 1:4 
solution of TFA:MeCN (10 µL) into the microchannel and allowing it to react for 1 h.  
The microchannel was then evacuated and washed with MeCN (3 x 10 µL).  The 
basification of the ammonium salt was achieved by injecting a 1:1 solution of 
TEOA:MeCN into the microchannel (2 x 10 µL) and allowing each aliquot to sit for 5 
minutes.  The microchannel was then washed with MeCN (5 x 10 µL). 
Thermally induced cyclization/substrate release 
The microchannel with the activated linker was placed on a hot plate at ~60 °C for 30 
minutes to induce an intramolecular cyclization and release of the FITC-CHO substrate.  
After cooling the microchannel to rt, it was washed with MeCN (5 x 10 µL) and the 
washings were collected.  The microchannel was then observed with a fluorescence 
microscope (excitation/emission, 495 nm/521 nm) and it was no longer fluorescent.  To 
 
 198 
ensure that release of the FITC-CHO moiety occurred upon heating, a fluorescent 
measurement was taken of the collected washings and fluorescence was observed. 
 
5.4. EXPERIMENTAL PROCEDURES OF CHAPTER 4 
5.4.1. Synthesis of Non-Nucleophilic Ester Linker 
 
Anthracen-9-ylmethyl dec-9-enoate (10).  9-Decenoic acid (343 mg, 2.02 mmol) and 9-
anthracenemethanol (361 mg, 1.73 mmol) were dissolved in dry CH2Cl2 (15 mL) with 
stirring.  DIC (395 µL, 2.52 mmol) was added to the reaction solution followed by cat. 
DMAP.  After 2 h, the white solids were filtered out and the filter cake was washed with 
CH2Cl2.  The filtrate was condensed in vacuo and the crude material was purified by 
column chromatography (SiO2, 0:100 to 1:9 EtOAc:CH2Cl2 gradient) to give 10 (506 mg, 
81%) as a yellow oil.  Rf 0.67 (CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.24-1.33 (m, 
8H), 1.62 (quin, J = 5.6 Hz, 2H), 2.00 (q, J = 5.6 Hz, 2H), 2.33 (t, J = 5.8 Hz, 2H), 4.96 
(dd, J = 8.0 and 13.6 Hz, 2H), 5.76-5.82 (m, 1H), 6.16 (s, 2H), 7.48-7.51 (m, 2H), 7.56-
7.59 (m, 2H), 8.03 (d, J = 6.8 Hz, 2H), 8.34 (d, J = 7.2 Hz, 2H), 8.50 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 25.2, 29.0, 29.1, 29.2, 33.9, 34.5, 58.8, 114.3, 124.1, 125.3, 126.6, 
126.8, 129.3, 131.2, 131.6, 139.3, 174.3. 
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5.4.2. Synthesis of 11 
 
 
tert-Butyl allylcarbamate.  Allyl amine (997 mg, 17.5 mmol) was dissolved in dry 
CH2Cl2 (35 mL) and cooled to 0 °C with stirring.  Boc2O was added to the reaction 
solution and stirred for 18 h, allowing the reaction to slowly warm to room temperature.  
Upon completion, the solution was washed with HCl (2 x 13 mL of 1 M solution), dried 
over Na2SO4, filtered and concentrated in vacuo to give tert-butyl allylcarbamate (2.55 g, 
93%) as white crystals which were used in the next step without further purification.  Rf 
0.65 (1:1, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H), 3.73 (br s, 2H), 
4.60 (br s, 1H), 5.08-5.19 (m, 2H), 5.78-5.88 (m, 1H); 13C NMR (100 MHz, CDCl3) δ  
28.6, 43.3, 79.6, 115.9, 135.1, 156.0. 
 
 
tert-Butyl allyl(methyl)carbamate (11).  A suspension of NaH (579 mg, 24.1 mmol) in 
dry THF (100 mL) was cooled to 0 °C with stirring.  A solution of tert-butyl 
allylcarbamate (2.53 g, 16.1 mmol) in dry THF (10 mL) was added to the reaction flask 
dropwise and stirred for 20 min at 0 °C.  Methyl iodide (1.5 mL, 24.1 mmol) was added 
and the reaction was stirred for 16 h allowing it to slowly come to room temperature.  
The reaction was quenched with sat. NH4Cl (150 mL) and the aqueous phase was 
extracted with EtO2 (3 x 90 mL) and wash with brine (100 mL).  The combined organics 
NH
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were dried over Na2SO4, filtered and concentrated in vacuo.  The crude material was 
purified by column chromatography (SiO2, 1:3, EtOAc:hexanes) to give 11 (1.03 g, 38%) 
as a light yellow oil.  Rf 0.53 (1:3, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.45 
(s, 9H), 2.81 (s, 3H), 3.80 (br s, 2H), 5.08-5.13 (m, 2H), 5.70-5.80 (m, 1H); 13C NMR 
(100 MHz, CDCl3) δ 28.6, 33.9, 51.5, 79.6, 116.5, 133.9, 155.9. 
 
 
tert-Butyl methyl(3-(triethoxysilyl)propyl)carbamate.  11 (518 mg, 3.02 mmol) and 
cat. PtO2 were placed into a pressure vial with a stir bar and the vial was purged with 
nitrogen.  Triethoxysilane (600 µL, 3.25 mmol) was then added and the vial was purged 
with nitrogen and then sealed.  The reaction vial was heated to 85-95 °C and stirred for 
one week.  Upon completion, the reaction mixture was filtered through Celite and the 
filter cake was washed with dry CH2Cl2.  The solution was then concentrated in vacuo to 
give crude tert-butyl methyl(3-(triethoxysilyl)propyl)carbamate as a brown oil that was 
used in the next step without further purification.  1H NMR (400 MHz, CDCl3) δ 0.55 (t, 
J = 8.4 Hz, 2H), 1.20-1.25 (m, 9H), 1.44 (s, 9H), 1.58-1.61 (m, 2H), 2.82 (s, 3H), 3.16 (br 
s, 2H), 3.78-3.87 (quin, J = 6.8 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 7.6, 18.5, 21.5, 
28.7, 34.4, 58.6, 59.3, 79.2, 156.0. 
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5.4.3. Anhydrous NP Loading Procedure (with heat) 
 
The functionalization of the iron oxide NPs was done following a modified procedure as 
described by Galeotti et al.8  Briefly, Fe3O4 NPs (150 mg) were placed in a round bottom 
flask and purged with nitrogen.  CHCl3 (20 mL) was then added via syringe and the NPs 
were suspended with sonication (3 x 10 min with 5 min pause between sonication).  
While maintaining sonication, a solution of the alkoxysilane linker (819 mg, 2.44 mmol) 
in CHCl3 (5 mL) was added dropwise via a syringe.  Sonication was continued for 10 min 
after completion of the addition of the silylated linker and was then mechanically stirred 
for 2.5 h at room temperature.  Then, the reaction flask was heated to 60-65 °C and 
stirred for 48 h.  After cooling, the coated NPs were magnetically separated and the 
supernatant was removed followed by washing with CHCl3 (5 x 10 mL).  The coated NPs 
were then dried with an oil vacuum pump for 30 min.  The vial was then purged with 
nitrogen and heated to 100-110 °C for 24 h to yield 12 (197 mg, 10.8 molecules/nm2). 
 
5.4.4. Acidic Boc-Deprotection of Functionalized NPs to Afford 2° Amine 
 
A suspension of 12 (13.2 mg) in CH2Cl2 was sonicated for 15 seconds to break any 
aggregation and was then cooled to 0 °C.  Trifluoroacetic acid was then added and the 
vial was allowed to stand for 1 h.  Upon completion, the NPs were magnetically 
Fe3O4 O Si N
Boc
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separated, washed with CH2Cl2 (5 x 5 mL) and dried with an oil vacuum pump for 2 h to 
afford 13 (5.5 molecules/nm2). 
 
 
 
Excess fluorescein isothiocyanate was added to 13 (12 mg) suspended in dry THF (2 mL) 
and sonicated for 30 seconds.  The suspension was allowed to stand for 4.5 h before the 
NPs were magnetically separated and the supernatant was removed.  The NPs were 
washed with sat. NaHCO3 (3 x 5 mL), MeOH (5 x 5 mL), and EtO2 (2 x 5 mL).  The 
washed NPs were dried with an oil vacuum pump to yield the fluorescent NPs. 
 
5.4.5. Synthesis of Non-Nucleophilic Olefinic Ester 
 
2-(Anthracen-9-yl)ethyl pent-4-enoate (17.1).  4-Pentenoic acid (159 µL, 1.56 mmol) 
and 2-(anthracen-9-yl)ethanol (281 mg, 1.26 mmol) were dissolved in dry CH2Cl2 (15 
mL) with stirring.  DIC (305 µL, 1.95 mmol) was added to the reaction solution followed 
by cat. DMAP.  After 2 h, the white solids were filtered out and the filter cake was 
Fe3O4 O Si N
NHS
OO OH
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washed with CH2Cl2.  The filtrate was condensed in vacuo and the crude material was 
purified by column chromatography (SiO2, 1:1 hexanes:CH2Cl2) to give 17.1 (359 mg, 
93%) as a yellow oil.  Rf 0.36 (1:1 hexanes:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 2.35-
2.46 (m, 4H), 3.99 (t, J = 8.0 Hz, 2H), 4.50 (t, J = 7.8 Hz, 2H), 5.00-5.08 (m, 2H), 5.79-
5.88 (m, 1H), 7.46-7.50 (m, 2H), 7.54-7.58 (m, 2H), 8.02 (d, J = 8.4 Hz, 2H), 8.38 (d, J = 
8.8 Hz, 2H), 8.40 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 27.5, 29.0, 33.8, 64.3, 115.7, 
124.3, 125.1, 126.2, 127.0, 129.2, 129.4, 130.5, 131.7, 136.8, 173.4. 
 
5.4.6. Synthesis of Non-Nucleophilic Olefinic Carbonate 
 
 
Allyl 1H-imidazole-1-carboxylate.  N,N-diisopropylethylamine (5.37 mL, 30.8 mmol) 
was added to a solution of allyl alcohol (1.21 g, 20.8 mmol) in dry CH2Cl2 (69 mL).  The 
solution was cooled to 0 °C and 1,1’-carbonyldiimidazole (5.07 g, 31.2 mmol) was added 
and the reaction was stirred overnight.  The reaction was washed with water (2 x 40 mL), 
brine (40 mL) and dried over Na2SO4, filtered and concentrated in vacuo.  The crude 
material was purified by column chromatography (SiO2, EtOAc) to give allyl 1H-
imidazole-1-carboxylate (2.24 g, 71%) as a light yellow oil.  Rf 0.51 (EtOAc); 1H NMR 
(400 MHz, CDCl3) δ 4.87 (d, J = 5.6 Hz, 2H), 5.37 (d, J = 10.0 Hz, 1H), 5.44 (d, J = 16.8 
Hz, 1H), 5.95-6.03 (m, 1H), 7.05 (s, 1H), 7.42 (s, 1H), 8.13 (s, 1H); 13C NMR (100 MHz, 
CDCl3) δ 68.8, 117.3, 120.6, 130.6, 130.9, 137.3, 148.6. 
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Allyl (2-(anthracen-9-yl)ethyl) carbonate (17.2).  1,8-Diazabicyclo[5.4.0]undec-7-ene 
(1.68 mL, 11.2 mmol) was added to a solution of allyl 1H-imidazole-1-carboxylate (1.71 
g, 11.2 mmol) in dry CH3CN (56 mL).  The reaction solution was stirred for 10 minutes 
before adding 2-(anthracen-9-yl)ethanol (2.50 g, 11.2 mmol).  The reaction was stirred 
overnight before quenching with sat. NH4Cl (40 mL).  The aqueous phase was extracted 
with EtOAc (2 x 40 mL) and the combined organic phases were washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo.  The crude material was purified by 
column chromatography (SiO2, 3:1, CH2Cl2:hexanes) to give 17.2 (2.33 g, 68%) as 
yellow crystals.  Rf 0.63 (3:1, CH2Cl2:hexanes); 1H NMR (400 MHz, CDCl3) δ 4.06 (t, J 
= 8.0 Hz, 2H), 4.52 (t, J = 8.4 Hz, 2H), 4.69 (d, J = 5.6 Hz, 2H), 5.31 (dd, J = 10.8, 1.8 
Hz, 1H), 5.40 (dd, J = 17.6, 1.2 Hz, 1H), 5.93-6.03 (m, 1H), 7.47-7.50 (m, 2H), 7.55-7.59 
(m, 2H), 8.02 (d J = 8.4 Hz, 2H), 8.35 (d, J = 8.8 Hz, 2H), 8.40 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 27.6, 67.4, 68.7, 119.1, 124.1, 125.2, 126.4, 127.2, 128.3, 129.5, 130.5, 
131.7, 131.8, 155.3. 
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5.4.7. Synthesis of Non-Nucleophilic Olefinic Carbamate 
 
 
2-(Anthracen-9-yl)ethyl 1H-imidazole-1-carboxylate.  N,N-Diisopropylethylamine 
(408 µL, 2.34 mmol) was added to a solution of 2-(anthracen-9-yl)ethanol (346 mg, 1.55 
mmol) in dry CH2Cl2 (8 mL), the solution was cooled to 0 °C and 1,1’-
carbonyldiimidazole (380 mg, 2.34 mmol) was added.  After stirring overnight, the 
reaction solution was washed with water (2 x 5 mL), brine, dried over Na2SO4, filtered 
and concentrated in vacuo.  The crude material was purified by column chromatography 
(SiO2, CH2Cl2 to 3:2, EtOAc:CH2Cl2 gradient) to give 2-(anthracen-9-yl)ethyl 1H-
imidazole-1-carboxylate (436 mg, 89%) as a pale yellow solid.  Rf 0.23 (1:19, 
EtOAc:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 4.16 (t, J = 7.4 Hz, 2H), 4.80 (t, J = 7.6 
Hz, 2H), 7.02 (s, 1H), 7.31 (s, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.58 (t, J = 7.4 Hz, 2H), 8.00 
(s, 1H), 8.04 (d, J = 8.0 Hz, 2H), 8.33 (d, J = 8.8 Hz, 2H), 8.44 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 27.0, 68.0, 117.3, 123.8, 125.3, 126.6, 127.5, 127.9, 129.7, 130.5, 130.8, 
131.7, 137.3, 149.0. 
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2-(Anthracen-9-yl)ethyl allylcarbamate (17.3).  1,8-Diazabicyclo[5.4.0]undec-7-ene 
(206 µL, 1.38 mmol) was added to a solution of 2-(anthracen-9-yl)ethyl 1H-imidazole-1-
carboxylate (436 mg, 1.38 mmol) in dry CH3CN (7 mL).  The reaction solution was 
stirred for 10 minutes before adding allylamine (114 µL, 1.51 mmol).  The reaction was 
stirred overnight before quenching with sat. NH4Cl (40 mL).  The aqueous phase was 
extracted with EtOAc (2 x 5 mL) and the combined organic phases were washed with 
brine, dried over Na2SO4, filtered and concentrated in vacuo.  The crude material was 
purified by column chromatography (SiO2, CH2Cl2 to 2:3, EtOAc:CH2Cl2 gradient) to 
give 17.3 (356 mg, 85%) as pale yellow crystals.  Rf 0.72 (1:19, EtOAc:CH2Cl2); 1H 
NMR (400 MHz, CDCl3) δ 3.85 (br s, 2H), 4.00 (t, J = 7.8 Hz, 2H), 4.47 (t, J = 7.6 Hz, 
2H), 4.74 (br s, 1H), 5.13-5.22 (m, 2H), 5.84-5.90 (m, 1H), 7.45-7.49 (m, 2H), 7.53-7.56 
(m, 2H), 8.01 (d, J = 8.4 Hz, 2H), 8.36 (d, J = 8.8 Hz, 2H), 8.39 (s, 1H); 13C NMR (100 
MHz, CDCl3) δ 28.1, 43.7, 64.9, 116.3, 124.4, 125.1, 126.2, 126.9, 129.4, 130.6, 131.7, 
134.7, 156.7. 
 
5.4.8. Procedure for the Addition of Polysaccharides to Functionalized NPs 
Fe3O4 NPs functionalized with linker 17.2 (11 mg) were suspended in DMSO (1 mL).  
Then, excess polysaccharide (D-lactose or 6 kDa dextran) was added to the suspension 
and the mixture was stirred overnight.  The coated NPs were magnetically separated and 
H
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the supernatant was decanted.  The resulting NPs were washed once with DMSO and 
twice with MeOH before being dried using high vacuum to afford polysaccharide coated 
NPs (12 mg). 
 
5.4.9. Synthesis of Monodispersed SiO2@Fe3O4 NPs 
The Fe3O4 NPs were coated with a thin silica shell using the modified procedure of Pinho 
et al.9  Briefly, the EMG 304 ferrofluid (1 mL, 233 mg NPs, 8.55 x 1016 NPs) was added 
to Millipore water (98 mL) and was then added to a solution of EtOH (312 mL) and 
NH4OH (6.2 mL, 28-30%) with rapid mechanical stirring.  Tetraethyl orthosilicate 
(TEOS) (2.13 mL) was then added to the colloidal suspension and was stirred for 12 h.  
An aliquot was removed to allow for characterization.  The NPs were magnetically 
separated and the remaining colloidal supernatant was centrifuged at 13,200 RPM for 20 
min.  The NPs were then washed 5x with EtOH with magnetic separation and 
centrifugation after each wash.  The excess EtOH was then removed by rotary 
evaporation and the NPs were dried under vacuum for 3 h.  The resulting SiO2@Fe3O4 
NPs were characterized by IR, TGA, DLS, ζ-potential, SQUID and TEM. 
 
5.4.10. Synthesis of Carbamate Linker for AMF-Induced Hydrolytic Release 
 
2-((tert-Butyldimethylsilyl)oxy)ethan-1-ol.  A solution of TBSCl (2.34 g, 15.5 mmol) in 
dry CH2Cl2 (20 mL) was added dropwise over 1 h to a solution of ethylene glycol (8 mL, 
143 mmol) and Et3N (2.80 mL, 19.9 mmol) in dry CH2Cl2 (25 mL) at 0 °C and was 
stirred overnight.  The solvent was removed in vacuo and the remaining oil was extracted 
HO OTBS
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with hexanes (4x) and the combined extractions were washed twice with sat. NH4Cl, 
once with brine and was dried over Na2SO4, filtered and concentrated in vacuo to afford 
the mono-TBS protected diol 2-((tert-butyldimethylsilyl)oxy)ethan-1-ol (2.52 g, 92%) as 
a colorless oil and was used without further purification.  Rf 0.59 (1:3, EtOAc:hexanes). 
 
 
2-((tert-Butyldimethylsilyl)oxy)ethyl 1H-imidazole-1-carboxylate.  1,1’-
Carbonyldiimidazole (3.47 g, 21.4 mmol) was added to a solution of the mono-TBS 
protected diol (2.52 g, 14.3 mmol) and N,N-diisopropylethylamine (3.70 mL, 21.4 mmol) 
in dry CH2Cl2 (48 mL) at 0 °C and was stirred for 6 h.  The reaction was washed twice 
with water and the combined aqueous phases were extracted once with CH2Cl2.  The 
combined organic layers were then washed twice with sat. NH4Cl, once with brine and 
were dried over Na2SO4, filtered and concentrated in vacuo to afford crude 2-((tert-
butyldimethylsilyl)oxy)ethyl 1H-imidazole-1-carboxylate as a colorless oil and was used 
without further purification.  Rf 0.36 (1:3, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) 
δ 0.06 (s, 6H), 0.88, (s, 9H), 3.93 (t, J = 4.8 Hz, 2H), 4.71 (t, J = 4.8 Hz, 2H), 7.06 (s, 
1H), 7.42 (s, 1H), 8.13 (s, 1H); 13C NMR (100 MHz, CDCl3) δ -5.2, 18.4, 25.9, 61.0, 
69.4, 117.3, 130.9, 137.3, 149.0. 
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Methyl N-(hex-5-en-1-yl)carbamate. Triethylamine (12.8 mL, 91.0 mmol) was slowly 
added to a solution of hex-5-en-1-amine hydrochloride (4.11 g, 30.334 mmol) in dry 
CH2Cl2 (300 mL) at 0 °C, then methyl chloroformate (3.52 mL, 45.5 mmol) was added 
dropwise and the reaction was stirred overnight.  The remaining white solids were 
removed by filtration and the filter cake was washed with CH2Cl2.  The filtrate was then 
washed with 1 M HCl (2 x 100 mL) and the combined aqueous phases were extracted 
once with CH2Cl2.  The combined organic phases were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo to afford the crude methyl N-(hex-5-en-1-
yl)carbamate as a yellow oil which was used without further purification.  Rf 0.42 (1:3, 
EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.40 (quin, J = 7.2 Hz, 2H), 1.50 (quin, J 
= 7.2 Hz, 2H), 2.05 (q, J = 7.2 Hz, 2H), 3.15-3.16 (m, 2H), 3.64 (s, 3H), 4.68 (br s, 1H), 
4.92-5.01 (m, 2H), 5.72-5.82 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 26.2, 29.7, 33.5, 
41.2, 52.1, 114.9, 138.6, 157.3. 
 
 
N-methyl-1-aminohex-5-ene.  Lithium aluminum hydride (2.30 g, 60.7 mmol) was 
slowly added to a solution of crude N-(hex-5-en-1-yl)carbamate (30.334 mmol) in dry 
Et2O (75 mL) at 0 °C, then the cooling bath was removed and the reaction was heated at 
reflux overnight.  The reaction was then cooled to 0 °C and carfully quenched with aq. 
Rochelle’s Salt (50%, 40 mL) and stirred for 0.5 h.  The layers were separated and the 
aqueous phase was extracted twice with Et2O.  The combined organic phases were 
N
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washed with brine, dried over Na2SO4, filtered and the solvent was removed by 
distillation followed by distillation of the product to afford N-methyl-1-aminohex-5-ene 
(3.26  g ,95%) as a colorless oil.  Rf 0.38 (1:9, MeOH:CH2Cl2 with 1% NH4OH); 1H 
NMR (400 MHz, CDCl3) δ 1.39-1.55 (m, 4H), 2.05 (q, J = 6.8 Hz, 2H), 2.41 (s, 3H), 2.56 
(t, J = 6.6 Hz, 2H), 4.91-5.01 (m, 2H), 5.72-5.84 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 
26.9, 29.6, 33.8, 36.7, 52.2, 114.6, 139.0. 
 
 
2-((tert-Butyldimethylsilyl)oxy)ethyl N-(hex-5-en-1-yl)-N-methylcarbamate. The 
carbamate was synthesized as described by Heller, et.al.10  DBU (2.13 mL, 14.3 mmol) 
was added to a solution of crude 2-((tert-butyldimethylsilyl)oxy)ethyl 1H-imidazole-1-
carboxylate (14.3 mmol) in dry MeCN (70 mL) and was stirred for 10 min, then N-
methyl-1-aminohex-5-ene (1.60 g, 14.3 mmol) was added and the reaction was stirred 
overnight.  The reaction was then washed twice with sat. NH4Cl and the combined 
aqueous layers were extracted three times with EtOAc.  The combined organic phases 
were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo.  The 
crude material was purified by column chromatography (SiO2, 1:3, EtOAc:hexanes) to 
give a colorless oil 2-((tert-Butyldimethylsilyl)oxy)ethyl N-(hex-5-en-1-yl)-N-
methylcarbamate (3.56 g, 79%).  Rf 0.40 (1:3, EtOAc:hexanes); 1H NMR (400 MHz, 
CDCl3) δ 0.06 (s, 6H), 0.89 (s, 9H), 1.38 (quin, J = 7.4 Hz, 2H), 1.52, (quin, J = 7.6 Hz, 
2H), 2.07 (q, J = 7.2 Hz, 2H), 2.88 (s, 3H), 3.25 (t, J = 7.2 Hz, 2H), 3.80 (t, J = 5.0 Hz, 
2H), 4.13 (t, J = 5.0 Hz, 2H), 4.93-5.02 (m, 2H), 5.73-5.84 (m, 1H); 13C NMR (100 MHz, 
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CDCl3) δ -5.1, 18.5, 26.1, 27.6, 33.6, 34.1, 49.0, 62.0, 66.8, 114.9, 138.7, 156.7; FT-ICR-
MS calcd for C16H34NO3Si+ [M+H]+ m/z 316.2302, found 316.2307. 
 
 
2-Hydroxyethyl N-(hex-5-en-1-yl)-N-methylcarbamate.  TBAF (1 M in THF, 10.6 mL, 
10.6 mmol) was added dropwise to a solution of 2-((tert-Butyldimethylsilyl)oxy)ethyl N-
(hex-5-en-1-yl)-N-methylcarbamate (2.58 g, 8.17 mmol) in dry THF (16 mL) at 0 °C and 
was stirred overnight.  The reaction solution was washed twice with sat. NaHCO3 and the 
combined aqueous layers were extracted three times with Et2O.  The combined organic 
phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to 
afford crude 2-hydroxyethyl N-(hex-5-en-1-yl)-N-methylcarbamate as a yellow oil and 
was used without further purification.  Rf 0.12 (1:3, EtOAc:hexanes); 1H NMR (400 
MHz, CDCl3) δ 1.40 (quin, J = 7.8 Hz, 2H), 1.55 (quin, J = 7.6 Hz, 2H), 2.08 (q, J = 6.8 
Hz, 2H), 2.90 (s, 3H), 3.26 (t, J = 7.2 Hz, 2H), 3.78-3.82 (q, J = 4.4 Hz, 2H), 4.23 (t, J = 
4.4 Hz, 2H), 4.94-5.02 (m, 2H), 5.74-5.84 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 25.9, 
27.4, 33.6, 34.7, 48.9, 62.6, 67.7, 115.0, 138.6, 157.4. 
 
 
2-(Methanesulfonyloxy)ethyl N-(hex-5-en-yl)-N-methylcarbamate.  Methanesulfonyl 
chloride (728 mL, 9.40 mmol) was added dropwise to a solution of the crude 2-
hydroxyethyl N-(hex-5-en-1-yl)-N-methylcarbamate (8.17 mmol) and triethylamine (1.72 
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mL, 12.3 mmol) in CH2Cl2 (27 mL) at 0 °C and stirred overnight.  The reaction was then 
washed twice with sat. NH4Cl and the combined aqueous layers were extracted twice 
with CH2Cl2.  The combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo to give crude 2-(methanesulfonyloxy)ethyl N-(hex-5-
en-yl)-N-methylcarbamate as a light yellow oil (2.15 g).  Rf 0.36 (major product) & 0.68 
(1:1, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3, Rf 0.36) δ 1.37 (quin, J = 7.6 Hz, 
2H), 1.54 (quin, J = 7.6 Hz, 2H), 2.07 (q, J = 7.2 Hz, 2H), 2.89 (s, 3H), 3.01 (s, 3H), 3.26 
(t, J = 7.2 Hz, 2H), 4.32-4.34 (m, 2H), 4.39-4.41 (m, 2H), 4.93-5.02 (m, 2H), 5.74-5.81 
(m, 1H); 13C NMR (100 MHz, CDCl3, Rf 0.36) δ 26.1, 27.0, 33.5, 34.1, 37.9, 49.2, 62.8, 
68.1, 114.9, 138.6, 155.9. 
 
 
2-((1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)oxy)ethyl N-(hex-5-en-1-yl)-N-
methylcarbamate.  K2CO3 (1.17 g, 8.47 mmol) was added to a solution of the combined 
2-(methanesulfonyloxy)ethyl N-(hex-5-en-yl)-N-methylcarbamate products (Rf 0.36 & 
0.68) (2.15 g, 7.70 mmol) in DMSO (26 mL), followed by the addition of N-
hydroxyphthalimide (2.39 g, 14.6 mmol) and the dark red solution was heated at 75 °C 
overnight.  The yellow solution was cooled to rt and slowly quenched with water and 
extracted four times with EtOAc.  The combined organic phase was washed three times 
with water, once with brine, dried over Na2SO4, filtered and concentrated in vacuo.  The 
crude material was purified by column chromatography (SiO2, 1:1, EtOAc:hexanes) to 
give 2-((1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)oxy)ethyl N-(hex-5-en-1-yl)-N-
N O
O
O N
O
O
 
 213 
methylcarbamate (2.02 g, 71% over 3 steps) as a yellow oil.  Rf 0.55 (1:1, 
EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.35 (quin, J = 7.6 Hz, 2H), 1.52 (quin, J 
= 7.6 Hz, 2H), 2.05 (q, J = 7.2 Hz, 2H), 2.85 (br s, 3H), 3.24 (t, J = 7.2 Hz, 2H), 4.41 (s, 
4H), 4.91-5.00 (m, 2H), 5.72-5.82 (m, 1H), 7.72-7.75 (m, 2H), 7.80-7.82 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 26.1, 27.2, 33.5, 34.6, 49.1, 62.8, 76.7, 114.8, 123.7, 129.2, 
134.7, 138.7, 156.1, 163.5; FT-ICR-MS calcd for C18H23N2O5+ [M+H]+ m/z 347.1601, 
found 347.1606. 
 
 
2-(Aminooxy)ethyl N-(hex-5-en-1-yl)-N-methylcarbamate (23).  Hydrazine 
monohydrate (34 mL, 0.70 mmol) was added to a solution of 2-((1,3-Dioxo-2,3-dihydro-
1H-isoindol-2-yl)oxy)ethyl N-(hex-5-en-1-yl)-N-methylcarbamate (258 mg, 0.74 mmol) 
in CH2Cl2 (4 mL) at 0 °C and was stirred for 1 h.  The solids were then filtered off and 
the filter cake was washed with ample CH2Cl2.  The filtrate was then concentrated in 
vacuo to afford 23 (154 mg, 96%) as a colorless oil without further purification.  Rf 0.24 
(1:1, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.36 (quin, J = 7.6 Hz, 2H), 1.52 
(quin, J = 7.6 Hz, 2H), 2.05 (q, J = 7.2 Hz, 2H), 2.86 (s, 3H), 3.24 (t, J = 7.2 Hz, 2H), 
3.80 (t, J = 3.6 Hz, 2H), 4.26 (t, J = 4.4 Hz, 2H), 4.91-5.00 (m, 2H), 5.42 (br s, 2H), 5.71-
5.82 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 26.0, 27.3, 33.5, 34.6, 48.8, 62.9, 74.3, 
114.8, 138.7, 156.7; FT-ICR-MS calcd for C10H21N2O3+ [M+H]+ m/z 217.1547, found 
217.1548. 
N O
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2-(((E/Z)-(2-(Anthracen-9-yl)ethylidene)amino)oxy)ethyl N-(hex-5-en-1-yl)-N-
methylcarbamate (26). 2-(Anthracen-9-yl)acetaldehyde11 (175 mg, 0.79 mmol) was 
added to a solution of 23 (156 mg, 0.72 mmol) in CH2Cl2 (4 mL) and stirred for 1 h.  The 
reaction solution was concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 0:1 to 3:17, EtOAc:CH2Cl2 gradient) to give 26 (291 mg, 96%) as 
a yellow oil.  Rf 0.55 (1:19, EtOAc:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 0.78 (br s, 
0.25H), 0.87 (br s, 0.25H), 1.26 (br s, 1.44H), 1.35-1.41 (m, 2H), 1.55-1.63 (m, 2H), 
1.92-2.07 (m, 2H), 2.78 (br s, 0.68H), 2.95 (s, 1.91H), 3.14 (br s, 0.46H), 3.22 (br s, 
0.46H), 3.30-3.34 (m, 1.33H), 4.26 (dd, J = 16.8, 5.4 Hz, 1.78H), 4.49-4.52 (m, 3.48H), 
4.68 (d, J = 4.4 Hz, 1.31H), 4.88-5.02 (m, 2H), 5.69-5.79 (m, 1H), 6.74 (t, J = 5.0 Hz, 
0.60H), 7.47-7.57 (m, 4.48H), 8.01-8.05 (m, 2H), 8.19 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 
8.8 Hz, 1H), 8.43 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 25.3, 26.6, 28.7, 33.6, 34.8, 
48.8, 64.1, 72.9, 114.9, 124.2, 125.3, 126.3, 127.1, 128.7, 129.4, 130.3, 131.7, 138.7, 
150.3, 156.6; FT-ICR-MS calcd for C26H31N2O3+ [M+H]+ m/z 419.2329, found 419.2333. 
 
 
2-(Aminooxy)ethyl N-methyl-N-(6-(triethoxysilyl)hexyl)carbamate or 2-(((E/Z)-(2-
(anthracen-9-yl)ethylidene)amino)oxy)ethyl N-methyl-N-(6-(triethoxysilyl)hexyl) 
carbamate.  Following a procedure outlined by Sabourault et al.,12 catalytic PtO2 and 
N O
O
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H
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triethoxysilane (131 mL, 0.71 mmol) was added to 23 or 26 (153 mg, 0.71 mmol) in a 
pressure tube.  The tube was flushed with N2, sealed and heated to 90 °C for 48 h.  The 
reaction solution was cooled to rt and filtered through Celite into a flask flushed with N2 
and the filter cake was washed with ample dry CH2Cl2.  The filtrate was concentrated in 
vacuo to afford the crude material as a light brown oil which was used without further 
characterization or purification due to its sensitivity to moisture. 
 
5.4.11. SQUID Measurements 
The magnetic properties of the magnetic NPs were measured using a Quantum Design 
MPMS-5S superconducting quantum interference device (SQUID) magnetometer (in the 
temperature range from 2 to 400 K) courtesy of Professor Lance DeLong (University of 
Kentucky).    The samples were loaded in a gel capsule and secured inside a standard 
drinking straw with small holes punched in both the straw and capsule for equalization of 
pressure and temperature.    M(H) data was taken by starting the sample at saturation, 5 
T, and then cycling to -5 T and back to 5 T in different step ranges to see the details of 
the hysteresis.  The data was taken using DC magnetization to disturb the magnetic NPs 
as little as possible during the measurement. 
 
5.4.12. Synthesis of AO@SiO2@Fe3O4 and FL@SiO2@Fe3O4 NPs 
The suspension of SiO2@Fe3O4 NPs was placed under mild vacuum and heated to 60 °C 
for 8 h.  This process was used to remove the catalytic ammonia thus increasing the 
chances of obtaining a thin organic monolayer on the surface of the NPs.  The removal of 
the ammonia decreased the pH of the solution from 11.7 to 8.8.  Then, EtOH (5 mL) was 
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added to 2-(aminooxy)ethyl N-methyl-N-(6-(triethoxysilyl)hexyl)carbamate or 2-(((E/Z)-
(2-(anthracen-9-yl)ethylidene)amino)oxy)ethyl N-methyl-N-(6-(triethoxysilyl)hexyl) 
carbamate (1.454 mmol) and the solution was added to the NP suspension with rapid 
mechanical stirring.  The mixture was stirred for 20 h.  The majority of the 
AO@SiO2@Fe3O4 or FL@SiO2@Fe3O4 NPs were then magnetically separated and the 
remaining colloidal supernatant was centrifuged at 13,200 RPM for 20 min.  The NPs 
were then washed 5x with EtOH with magnetic separation and centrifugation after each 
wash.  The excess EtOH was then removed by rotary evaporation and the NPs were dried 
under vacuum for 3 h.  The resulting NPs were characterized by IR, TGA, DLS, ζ-
potential and TEM. 
 
5.4.13. AMF-Induced Heating of Bulk Solution 
Temperature measurements were taken with a Neoptix Nomad fitted with a fiber optic 
temperature sensor.  All data was recorded using Neoptix NeoLink software.  AMF 
conditions were set to 501.6 amps and a frequency of 204 kHz.  Each AMF pulse lasted 
for 2 or 5 min followed by 2 or  5 min of without an AMF for a combined total of 40 min 
of AMF exposure.  All samples were started at room temperature and were allowed to 
cool at room temperature; all heating was induced using only an AMF.  The control was 
0.75 mL of 2:1 PBS:acetonitrile without SiO2@Fe3O4 NPs, which gave a ΔT of 4.8 ± 0.1 
°C with a 5 min AMF pulse.  The ΔT of a 5 min AMF pulse with 7.0 mg of SiO2@Fe3O4 
NPs in 0.75 mL 2:1 PBS:acetonitrile was +16.4 ± 0.3 °C.  The ΔT from the start of the 
first AMF pulse to the start of the sixth AMF pulse was +4 °C. 
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5.4.14. Assay of Percent 27 Released from NPs 
 To determine the percent of 27 released from FL@SiO2@Fe3O4 NPs, it is necessary 
to determine the residual amount of 2-(((E/Z)-(2-(anthracen-9-
yl)ethylidene)amino)oxy)ethyl N-methyl-N-(6-(triethoxysilyl)hexyl)carbamate remaining 
on the FL@SiO2@Fe3O4 NPs post AMF exposure.  After recording the fluorescence 
intensity of the last (eighth) AMF pulse, the NPs were magnetically separated and the 
AMF supernatant was removed.  The isolated NPs then were washed 5x with MeCN 
followed by magnetic separation to remove any hydrogen bound 27.  To the washed NPs 
was added 1 mL of 5% HF in EtOH.  The suspension was stirred until all NPs had 
dissolved resulting in a light yellow solution.  The acidic solution was added to a 
separatory funnel and then basified using sat. aq. NaHCO3.  The basic solution was 
extracted 3 x with Et2O and the combined extracts were concentrated by rotary 
evaporation and dried under vacuum.  The resulting residue was dissolved in a 2:1 
mixture of PBS:MeCN (0.75 mL) at pH 7.4 and the fluorescence was measured.  This 
measured fluorescence intensity was then added to the total fluorescence intensity 
measured in the supernatant after the final AMF pulse, and the combined intensity was 
set to 100%.  The results from all three experiments were normalized by dividing the 
fluorescent intensity by the milligrams of FL@SiO2@Fe3O4 NPs used for the experiment. 
 
 
 
 
 
 
 218 
5.4.15. Synthesis of Thiol Linker for Loading onto Au@Fe3O4 NPs 
 
 
4-((tert-Butyldimethylsilyl)oxy)butan-1-ol.  A solution of TBSCl (5.20 g, 34.5 mmol) in 
dry CH2Cl2 (60 mL) was added dropwise over 1 h to a solution of 1,4-butanediol (14.7 
mL, 166 mmol) and Et3N (6.99 mL, 49.8 mmol) in dry CH2Cl2 (50 mL) at 0 °C and was 
stirred overnight.  The solvent was removed in vacuo and the remaining oil was extracted 
with hexanes (4x) and the combined extractions were washed twice with sat. NH4Cl, 
once with brine and was dried over Na2SO4, filtered and concentrated in vacuo to afford 
crude 4-((tert-butyldimethylsilyl)oxy)butan-1-ol (6.58 g, 93%) as a colorless oil and was 
used without further purification.  Rf 0.44 (1:3, EtOAc:hexanes). 
 
 
4-((tert-Butyldimethylsilyl)oxy)butyl methanesulfonate.  Methanesulfonyl chloride 
(2.87 mL, 37.0 mmol) was added to a solution of crude 4-((tert-
butyldimethylsilyl)oxy)butan-1-ol (6.58 g, 32.2 mmol) and Et3N (6.79 mL, 48.3 mmol) in 
dry CH2Cl2 (107 mL) at 0 °C and was stirred for 2 h.  The reaction solution was washed 
twice with sat. NH4Cl and the combined aqueous layers were extracted twice with 
CH2Cl2.  The combined organic phases were washed once with brine and was dried over 
Na2SO4, filtered and concentrated in vacuo to afford 4-((tert-butyldimethylsilyl)oxy)butyl 
methanesulfonate (9.03 g, 99%) as an orange oil and was used without further 
purification.  Rf 0.52 (1:3, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 
0.88 (s, 9H), 1.62 (quin, J = 6.0 Hz, 2H), 1.83 (quin, J = 7.2 Hz, 2H), 2.99 (s, 3H), 3.64 
OTBSHO
TBSO OMs
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(t, J = 6.0 Hz, 2H), 4.26 (t, J = 6.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ -5.2, 18.5, 
26.1, 28.8, 37.6, 62.4, 70.3. 
 
 
2-(4-((tert-Butyldimethylsilyl)oxy)butyl)-2,3-dihydro-1H-isoindole-1,3-dione.  
Phthalimide (8.55 g, 58.1 mmol) was added to a solution of 4-((tert-
butyldimethylsilyl)oxy)butyl methanesulfonate (8.64 g, 30.6 mmol) and K2CO3 (5.07 g, 
36.7 mmol) in DMSO (180 mL) and the solution was heated to 75 °C for 17 h.  The 
reaction was then cooled to rt and was quenched with water.  The aqueous solution was 
extracted with EtOAc (4x) and the combined organic phases were washed with water 
(3x).  The organic phase was then washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo to afford 2-(4-((tert-butyldimethylsilyl)oxy)butyl)-2,3-dihydro-1H-
isoindole-1,3-dione (9.27 g, 91%) as white crystals and was used without further 
purification.  Rf 0.59 (1:3, EtOAc:hexanes); 1H NMR (400 MHz, CDCl3) δ 0.03 (s, 6H), 
0.87 (s, 9H), 1.55 (quin, J = 6.4 Hz, 2H), 1.74 (quin, J = 7.4 Hz, 2H), 3.63 (t, J = 6.4 Hz, 
2H), 3.70 (t, J = 7.2 Hz, 2H), 7.65 (dd, J = 2.4, 2.8 Hz, 2H), 7.83 (dd, J = 1.6, 3.4 Hz, 
2H); 13C NMR (100 MHz, CDCl3) δ -5.1, 18.5, 25.3, 26.1, 30.2, 38.1, 62.7, 123.4, 132.4, 
134.0, 168.6. 
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(4-Aminobutoxy)(tert-butyl)dimethylsilane.  Hydrazine monohydrate (6.74 mL, 139 
mmol) was added to a solution of crude 2-(4-((tert-butyldimethylsilyl)oxy)butyl)-2,3-
dihydro-1H-isoindole-1,3-dione (9.27 g, 27.8 mmol) in CH2Cl2 (140 mL) at 0 °C and was 
stirred overnight, allowing the reaction to come to rt.  The white precipitate was filtered 
and the filter cake was washed with ample CH2Cl2.  The crude solution was concentrated 
in vacuo to afford (4-aminobutoxy)(tert-butyl)dimethylsilane (3.99 g, 71%) as a light 
yellow oil and was used without further purification.  Rf 0.26 (1:9, MeOH:CH2Cl2 with 
1% NH4OH); 1H NMR (400 MHz, CDCl3) δ 0.03 (s, 6H), 0.87 (s, 9H), 1.44-1.55 (m, 
4H), 1.61 (br s, 2H), 2.68 (t, J = 6.8 Hz, 2H), 3.60 (t, J = 6.2 Hz); 13C NMR (100 MHz, 
CDCl3) δ -5.1, 18.5, 26.1, 30.4, 30.5, 42.3, 63.3. 
 
 
(((3-Bromopropyl)sulfanyl)diphenylmethyl)benzene.  K2CO3 (2.28 g, 16.5 mmol) 
followed by 1,3-dibromopropane (7.61 mL, 75 mmol) was added to a solution of 
triphenylmethanethiol (4.22 g, 15.3 mmol) in dry THF (75 mL) under N2.  The reaction 
was refluxed for 24 h before cooling to rt.  The reaction solution was washed twice with 
water, extracted twice with Et2O, washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo.  The excess 1,3-dibromopropane was distilled off to afford (((3-
bromopropyl)sulfanyl)diphenylmethyl)benzene (5.94 g, 98%) as white crystals.  Rf 0.54 
(1:3, CH2Cl2:hexanes); 1H NMR (400 MHz, CDCl3) δ 1.81 (quin, J = 6.8 Hz, 2H), 2.32 
TBSO NH2
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(t, J = 6.8 Hz, 2H), 3.32 (t, J = 6.8 Hz, 2H), 7.19-7.30 (m, 9H), 7.40-7.44 (m, 6H); 13C 
NMR (100 MHz, CDCl3) δ 30.5, 31.8, 32.5, 66.9, 126.9, 128.1, 129.8, 144.9. 
 
 
12,12,13,13-Tetramethyl-1,1,1-triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane.  
(((3-bromopropyl)sulfanyl)diphenylmethyl)benzene (800 mg, 2.01 mmol) was added to a 
solution of (4-aminobutoxy)(tert-butyl)dimethylsilane (1.02 g, 5.03 mmol) in MeCN (20 
mL) and the reaction was heated to 55 °C for 24 h.  After cooling to rt, the reaction was 
quenched with sat. NaHCO3 and extracted three times with EtOAc.  The combined 
organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo.  The crude material was purified by column chromatography (SiO2, 0:1 to 1:4, 
MeOH:CH2Cl2 with 1% NH4OH gradient) to give 12,12,13,13-tetramethyl-1,1,1-
triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane (852 mg, 82%) as an orange oil.  Rf 0.33 
(1:4, MeOH:CH2Cl2 with 1% NH4OH); 1H NMR (400 MHz, CDCl3) δ 0.04 (s, 6H), 0.88 
(s, 9H), 1.51-1.52 (m, 4H), 1.60 (quin, J = 7.4 Hz, 2H), 2.17 (t, J = 7.0 Hz, 2H), 2.57 (t, J 
= 7.2 Hz, 4H), 3.59 (t, J = 6.0 Hz, 2H), 7.17-7.28 (m, 9H), 7.39-7.41 (m, 6H); 13C NMR 
(100 MHz, CDCl3) δ -5.1, 18.6, 25.9, 26.2, 28.5, 29.9, 30.7, 48.6, 49.5, 63.2, 66.8, 126.8, 
128.1, 129.8, 145.1. 
 
 
tert-Butyl N-(4((tert-butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl) 
propyl)carbamate.  Boc2O (348 mg, 1.60 mmol) was added to a solution of 12,12,13,13-
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tetramethyl-1,1,1-triphenyl-11-oxa-2-thia-6-aza-12-silatetradecane (754 mg, 1.45 mmol) 
and Et3N (224 µL, 1.60 mmol) in CH2Cl2 (5 mL) at 0 °C.  After 3 h, the reaction solution 
was washed twice with sat. NH4Cl and the aqueous phase was extracted twice with 
CH2Cl2.  The combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo to afford crude tert-butyl N-(4((tert-
butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl)propyl)carbamate as an 
orange oil and was used without further purification.  Rf 0.81 (1:19, EtOAc:CH2Cl2); 1H 
NMR (400 MHz, CDCl3) δ 0.03 (s, 6H), 0.88 (s, 9H), 1.39 (br s, 4H), 1.45 (br s, 2H), 
1.52 (s, 9H), 2.13 (t, J = 7.4 Hz, 2H), 3.05 (br s, 4H), 3.58 (t, J = 6.0 Hz, 2H), 7.18-7.29 
(m, 9H), 7.39-7.41 (m, 6H); 13C NMR (100 MHz, CDCl3) δ -5.1, 18.5, 25.9, 26.2, 27.6, 
28.6, 29.6, 30.3, 46.5, 47.1, 63.1, 66.8, 79.3, 126.8, 128.1, 129.8, 145.1, 155.6. 
 
 
tert-Butyl N-(4-hydroxybutyl)-N-(3-((triphenylmethyl)sulfanyl)propyl)carbamate. 
TBAF (1.89 mL of 1 M solution in THF, 1.89 mmol) was added to a solution of crude 
tert-butyl N-(4((tert-butyldimethylsiyl)oxy)butyl)-N-(3-((triphenylmethyl)sufanyl) 
propyl)carbamate (1.45 mmol) in dry THF (3 mL) at 0 °C and the reaction was stirred 
overnight, allowing the reaction to warm to rt.  Upon completion, the reaction was 
washed twice with sat. NaHCO3 and the combined aqueous phases were extracted three 
times with Et2O.  The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo.  The crude material was purified by column 
chromatography (SiO2, 3:7, EtOAc:CH2Cl2) to give tert-butyl N-(4-hydroxybutyl)-N-(3-
TrS N
Boc
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((triphenylmethyl)sulfanyl)propyl)carbamate (453 mg, 62% over 2 steps) as a light 
yellow oil.  Rf 0.52 (3:7, EtOAc:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 
1.47-1.51 (m, 4H), 1.58 (quin, J = 7.6 Hz, 2H), 3.08 (br s, 4H), 3.63 (t, J = 6.0 Hz, 2H), 
7.19-7.30 (m, 9H), 7.41-7.43 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 24.8, 28.2, 28.6, 
29.5, 29.7, 46.6, 46.9, 62.6, 66.8, 79.5, 126.8, 128.0, 129.7, 145.0, 155.7. 
 
 
4-(((tert-Butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)propyl))amino) butyl 1H-
imidazole-1-carboxylate.  1,1’-Carbonyldiimidazole (214 mg, 1.32 mmol) was added to 
a solution of tert-butyl N-(4-hydroxybutyl)-N-(3-((triphenylmethyl)sulfanyl)propyl) 
carbamate (444 mg, 0.88 mmol) and (i-Pr)2NEt (228 µL, 1.32 mmol) in dry CH2Cl2 (3 
mL) at 0 °C and was stirred overnight.  The reaction solution was washed twice with 
water and extracted once with CH2Cl2.  The combined organic layers were washed twice 
with sat. NH4Cl, once with brine, were dried over Na2SO4, filtered and concentrated in 
vacuo to afford crude 4-(((tert-butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)propyl)) 
amino) butyl 1H-imidazole-1-carboxylate (517 mg, 98%) as a light yellow oil and was 
used without further purification.  Rf 0.50 (3:7, EtOAc:CH2Cl2); 1H NMR (400 MHz, 
CDCl3) δ 1.42 (s, 9H), 1.59 (br s, 4H), 1.76 (quin, J = 6.8 Hz, 2H), 2.18 (t, J = 7.4 Hz, 
2H), 3.11 (br s, 4H), 4.42 (t, J = 6.6 Hz, 2H), 7.08 (s, 1H), 7.20-7.31 (m, 9H), 7.42-7.44 
(m, 7H), 8.15 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.6, 25.9, 28.2, 28.5, 29.4, 46.5 (2 
C’s), 66.8, 68.1, 79.6, 117.2, 126.7, 128.0, 129.7, 130.8, 137.2, 144.9, 148.8, 155.5. 
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2-(2-(((4-(((tert-Butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl)propyl))amino) 
butoxy)carbonyl)oxy)ethoxy)-2,3-dihydro-1H-isoindole-1,3-dione.  DBU (129 µL, 
0.86 mmol) was added to a solution of crude tert-butyl N-(4-hydroxybutyl)-N-(3-
((triphenylmethyl)sulfanyl)propyl)carbamate (517 mg, 0.86 mmol) in dry MeCN (4 mL).  
After stirring for 10 min, 2-(2-hydroxyethoxy)-2,3-dihydro-1H-isoindole-1,3-dione (178 
mg, 0.86 mmol) was added and the reaction was stirred overnight.  Upon completion, the 
reaction was washed twice with sat. NH4Cl and the combined aqueous layers were 
extracted three times with EtOAc.  The combined organic layers were washed with brine, 
dried over Na2SO4, filtered and concentrated in vacuo.  The crude material was purified 
by column chromatography (SiO2, 3:17, EtOAc:CH2Cl2) to give 2-(2-(((4-(((tert-
butoxy)carbonyl)((3-((triphenylmethyl)sulfanyl) propyl))amino)butoxy)carbonyl)oxy) 
ethoxy)-2,3-dihydro-1H-isoindole-1,3-dione (350 mg, 55% over 2 steps) as a colorless 
oil.  Rf 0.75 (3:17, EtOAc:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 1.46-1.64 
(m, 6H), 2.15 (t, J = 7.4 Hz, 2H), 3.06 (br s, 4H), 4.14 (t, J = 6.4 Hz, 2H), 4.43-4.48 (m, 
4H), 7.18-7.29 (m, 9H), 7.39-7.42 (m, 6H), 7.73-7.76 (m, 2H), 7.81-7.85 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ 24.6, 26.1, 28.2, 28.6, 29.5, 46.5, 46.6, 65.2, 68.1, 75.6, 79.5, 
123.8, 126.8, 128.0, 129.0, 129.7, 134.7, 145.0, 155.1, 155.5, 163.5. 
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N-(4-(((2-(aminooxy)ethoxy)carbonyl)oxy)butyl)-N-((tert-butoxy)carbonyl)-3-
((triphenylmethyl)sulfanyl)propan-1-amine.  Hydrazine monohydrate (51 µL, 1.04 
mmol) was added to a solution of 2-(2-(((4-(((tert-butoxy)carbonyl)((3-
((triphenylmethyl)sulfanyl)propyl))amino)butoxy)carbonyl) oxy)ethoxy)-2,3-dihydro-
1H-isoindole-1,3-dione (154 mg, 0.21 mmol) in CH2Cl2 at 0 °C and stirred for 2 h.  
When complete, the white precipitate was removed by filtration and the filter cake was 
washed with ample CH2Cl2.  The filtrate was concentrated in vacuo to afford 28 (127 mg, 
100%) as a colorless oil and did not require further purification.  Rf 0.52 (1:3, 
EtOAc:CH2Cl2); 1H NMR (400 MHz, CDCl3) δ 1.38 (s, 9H), 1.48-1.62 (m, 6H), 2.14 (t, J 
= 7.4 Hz, 2H), 3.05 (br s, 4H), 3.85 (t, J = 4.6 Hz, 2H), 4.12 (t, J = 6.4 Hz, 2H), 4.33 (t, J 
= 4.4 Hz, 2H), 5.51 (br s, 2H), 7.18-7.21 (m, 3H), 7.25-7.29 (m, 6H), 7.39-7.41 (m, 6H); 
13C NMR (100 MHz, CDCl3) δ 24.7, 26.2, 27.5, 28.6, 29.5, 46.7 (2 C’s), 65.5, 66.8, 68.0, 
73.4, 79.5, 126.8, 128.0, 129.7, 145.0, 155.5, 155.6. 
 
 
TrS N
Boc
O O
O
O NH2
28
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A Versatile Probe for Chemoselective Capture and 
Analysis of 
Carbonyl Compounds in Exhaled Breath 
 
 
Ralph J. Knipp,† Mingxiao Li,‡ Xiao-An Fu*,‡ and Michael H. Nantz*,† 
 
†Department of Chemistry, ‡Department of Chemical Engineering, University of Louisville,  
Louisville, Kentucky 40292, United States 
 
 
 
 
 
ABSTRACT:  We describe an aminooxy reagent for the capture of trace aldehyde and 
ketone volatile organic compounds (VOCs) in exhaled breath.  The reagent, 4-(2-
aminooxyethyl)-morpholin-4-ium chloride (AMAH), when coated onto micropillars 
within a silicon microreactor, chemoselectively and covalently retains carbonyl VOCs 
from exhaled breath.  The AMAH-carbonyl adducts are then rinsed from the microreactor 
with methanol and directly analyzed by Fourier transform-ion cyclotron resonance (FT-
ICR) mass spectrometry (MS), where the aminium ion of the reagent enhances the 
sensitivity for high mass accuracy.  We also outline a protocol for treatment of the 
AMAH-carbonyl adducts with poly(4-vinylpyridine) to afford the corresponding volatile 
carbonyl adducts that now can be analyzed by gas chromatography-mass spectrometry 
(GC-MS).  This convenient protocol imparts flexibility for the identification and 
quantification of isomeric VOCs using both FT-ICR-MS and GC-MS.  Representative 
breath analyses are given to illustrate this applicability of AMAH. 
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Quantitative Analysis of Carbonyl Compounds in Exhaled Breath 
 
Mingxiao Li1, Ralph Knipp2, Michael H. Nantz2, Michael Bousamra3,4, Xiao-An Fu*1 
1Department of Chemical Engineering, 2Department of Chemistry, 3Department of 
3Department of Cardiovascular and Thoracic Surgery, 4James Graham Brown Cancer 
Center, University of Louisville, Louisville, Kentucky 40292, United States 
 
ABSTRACT 
Quantitative analysis of trace volatile carbonyl compounds in human breath is reported. 
The approach is based on microreactor chips fabricated from silicon wafers. The 
microreactors have thousands of micropillars in microfluidic channels for uniformly 
distributing a gaseous breath sample flowing through the channels. The surfaces of the 
micropillars are functionalized with a quaternary ammonium aminooxy salt, [2-
(aminooxy)ethyl]-N,N,N-trimethylammonium iodide (ATM), for chemoselective trapping 
of trace carbonyl compounds by means of oximation reactions. ATM adducts and 
unreacted ATM are eluted from the microreactor with 50 µL of methanol and directly 
analyzed by nanospray Fourier transform ion cyclotron resonance (FTICR) mass 
spectrometry (MS). The capture efficiencies of formaldehyde, acetaldehyde, acetone and 
2-butanone have been determined to be above 95%. The levels of these and other 
carbonyl compounds in exhaled breath samples from 45 non-smokers and 45 current 
smokers were compared. Formaldehyde, acetaldehyde and acetone were present in 
significantly higher concentrations in the current smokers group, while 2-butanone and 3-
hydroxy-2-butanone were not affected by smoking cigarettes.  
  
INTRODUCTION 
   Analysis of volatile organic compounds (VOCs) at trace levels has attracted 
much interest because of demanding applications in non-invasive disease diagnosis and 
monitoring environment air quality. Human exhaled breath primarily consists of 
atmospheric gases, water vapor, and trace level metabolic VOCs.1,2 Breath analysis could 
potentially provide a non-invasive and painless means to detect disease, and the sampling 
of breath does not require skilled medical staff.3-7 Breath analysis challenges existing 
analytical methods because VOC concentrations in breath are beyond instrument limits of 
detection.3,7 This problem is further exacerbated by other interfering gases that are mixed 
in large concentration with the VOCs. Gas chromatography coupled with a mass 
spectrometer detector (GC-MS) is currently the dominant technique for analysis of trace 
VOCs. A complex preconcentration process consisting of cryogenic adsorption and 
thermal desorption is typically required before trace VOC samples can enter into a GC 
column.8-14 Solid-phase microextraction (SPME) is a popular preconcentration method 
and a rapid extraction technique for analysis of VOCs from a variety of matrixes by GC-
MS.15-18 However, SPME is only semiquantitative due to the inefficiency inherent with 
physical adsorption on the SPME fiber. Other methods including selected ion flow tube 
mass spectrometry (SIFT-MS),19-20 proton transfer reaction mass spectrometry (PTR- 
MS)21-23 and electronic nose methods24-25 also have been used for analysis of breath.    
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NANOPARTICLES FOR DRUG DELIVERY 
 
Cross Reference to Related Applications 
 This patent application claims the benefit of priority of U.S. application serial No. 
61/762,832 filed February 8, 2013 and U.S. application serial No. 61/773,663 filed March 
6, 2013, which applications are hereby incorporated by reference.  
 
Statement of Government Support 
 This invention was made with state government support under Grant number 
2190-RDE-013 awarded by the Kentucky Science and Engineering Foundation.  The 
Commonwealth of Kentucky has certain rights in the invention. 
 
Background 
 An important attribute of a drug delivery system is its ability to allow for spatial 
and temporal regulated drug release, thereby minimizing side effects and improving 
therapeutic efficacy of conventional pharmaceuticals.  Iron oxide nanoparticles (NPs), 
specifically Fe3O4 nanoparticles, possess many appropriate qualities that make them a 
viable choice for drug delivery.  Fe3O4 NPs are biocompatible (Kievit, F. M., et al.,  
Accounts of Chemical Research 2011, 44 (10), 853-862), have low cytotoxicity (Bulte, J. 
W. M., et al., NMR in Biomedicine 2004, 17, 484-499), and provide multiple means for 
surface modification.  Though these attributes are needed in a drug delivery vehicle, there 
are multiple different NPs that possess similar qualities including gold and silica.  Fe3O4 
is set apart from these NPs due to its paramagnetic or superparamagnetic (SPM) qualities 
(Yang, C., et al., Chemical Communications 2011, 47, 5130-5141).  The SPM properties 
of Fe3O4 NPs have been used for a variety of applications.  A basic utilization of SPM 
capability is to induce non-invasive hyperthermia within cancer cells.  Alternating 
electromagnetic field (AMF)-induced Fe3O4 NPs heat body tissue to temperatures as high 
as 45 °C, and this causes cell death.  In addition, when functionalized either by ionic 
interactions or through entrapment via a polymer gel coating, drugs can be guided to 
tumor regions through the use of a magnet, as first demonstrated by Meyers in 1963 
(Meyers, P.H., et al., American Journal of Roentgenology, Radium Therapy, and Nuclear 
Medicine 1963, 90, 1068–1077).  Through more advanced methods, Fe3O4 NPs are now 
extensively functionalized with complex delivery mechanisms and can be directed by 
taking advantage of tumor folate receptors (Kim, J., et al., Advanced Materials 2008, 20, 
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DOI: 10.1002/ ((please add manuscript number))  
Article type: Full Paper 
 
 
Magnetic-Field Induced Hydrolysis as a Mechanism for  
Rapid Release of Nanoparticle-Bound Substrates 
 
Ralph J. Knipp, Stephanie J. Mattingly and Michael H. Nantz* 
 
 
R. J. Knipp, S. J. Mattingly, Professor M. H. Nantz, Department of Chemistry, University 
of Louisville, 2320 S. Brook St., Louisville, Kentucky 40292, United States 
E-mail: michael.nantz@louisville.edu  
 
Keywords: AMF, carbamates, covalent, hydrolysis, nanoparticles  
 
Abstract: Application of an alternating magnetic field (AMF) to magnetic core–shell 
iron oxide–silica nanoparticles fitted with short carbonate- or carbamate-functionalized 
chains that covalently link a fluorophore results in rapid functional group hydrolysis with 
attendant release of the fluorophore.  This first example of AMF-induced carbamate 
hydrolysis resulted in ca. 10-fold greater release of fluorophore substrate in comparison 
to the control at 37 °C in the absence of an AMF.  
 
1. Introduction 
An important attribute of a drug delivery system is regulated spatial and temporal drug 
release to minimize side effects as well as to improve the therapeutic efficacy of 
conventional pharmaceuticals.  Iron oxide nanoparticles (NPs) possess many features that 
make them a viable choice for drug delivery formulations.  Magnetite (Fe3O4) NPs are 
biocompatible,[1] have low cytotoxicity,[2] can be readily surface-modified and have 
inherent paramagnetic or superparamagnetic properties.[3]  As a result of their magnetism, 
one highly-studied feature of Fe3O4 NPs is their ability to heat a surrounding environment  
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